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Amyotrophic Lateral Sclerosis (ALS) is a degenerative disease predominantly affecting 
motor neurons in the brain and spinal cord. ALS has a clear genetic component, with 
mutations in four genes accounting for ~50% of familial and ~10% of sporadic cases. 
Several other rarer ALS genes have been identified but their mechanistic role in causing 
TDP-43 proteinopathy is unknown. Exome sequencing of 699 index familial ALS cases 
identified mutations in three recently discovered ALS genes: 16 in Tank Binding Kinase 1 
(TBK1), a kinase involved in inflammation and autophagy; five in Matrin 3 (MATR3), a 
DNA/RNA binding protein; and one in Optineurin (OPTN) in a consanguineous 
Palestinian family with an aggressive form of ALS. The experiments described in this 
thesis sought to explore the functional impact of these novel ALS-associated variants 
with the aim of determining their potential pathogenicity and providing insights into 
disease mechanisms. 
Here I show that missense and nonsense TBK1 mutations can disrupt its kinase activity 
by interfering with homodimer formation and phosphorylation of its targets IRF3, OPTN 
and itself, pointing towards a common loss of kinase function mechanism. Furthermore, I 
show that the novel OPTN p.S174X truncation mutation causes a complete loss of 
OPTN protein expression in homozygous, and haploinsufficiency in heterozygous patient 
fibroblasts due to nonsense mediated decay. Heterozygotes show a minor increase in 
the mitochondrial markers TOM20 and COXIV and increased cellular respiration under a 
stress test but do not present any striking mitophagy or autophagy defects and 
homozygous fibroblasts are apparently unaffected. Lastly I explore the effects of MATR3 
mutations on protein solubility which was decreased for the p.S85C mutant and that 
p.R841C forms cytoplasmic inclusions, however no phenotype was elicited for two other 
mutations.  
The findings in this thesis have made a modest contribution to our knowledge of the 
molecular mechanisms underlying the pathogenesis of ALS, the understanding of which 
is pivotal in order to develop more effective therapies for this dreadful disease. 
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 – Introduction  
1.1 Overview of Amyotrophic Lateral Sclerosis  
Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND), also known as 
Lou Gherig’s disease, is an adult onset neurodegenerative disorder that predominantly 
targets the upper and lower motor neurons, which causes progressive muscle wasting 
and weakness and stiffness due to spasticity. This condition was considered a muscular 
dysfunction until 1869, when Jean-Martin Charcot (1825–1893) correctly identified that 
degeneration of spinal cord motor neurons caused muscular ‘amyotrophy’ and ‘lateral 
sclerosis’ (scarring) of the corticospinal tracts from degeneration of upper motor neurons, 
and gave it the name amyotrophic lateral sclerosis (Katz, Dimachkie and Barohn, 2015).  
ALS patients can initially present with symptoms in either limb or bulbar (throat) 
territories. Around 65% of the cases can be classified as being of spinal onset affecting 
the limbs, whereas 30% of the cases have a bulbar onset causing dysarthria, dysphagia 
or both, and 5% present with breathless due to diaphragm weakness (Kiernan et al. 
2011; Zufiría et al. 2016). Classically ALS patients show similar symptoms such as: 
muscle wasting, weakness and fasciculation, caused by the degeneration of lower motor 
neurons, and spasticity, hyper-reflexia and an extensor plantar response (Babinski sign), 
caused by the upper motor neuron degeneration (Taylor, Brown and Cleveland, 2016). 
Survival rate is generally 3-5 years from diagnosis, typically by respiratory failure (Shaw, 
Al-Chalabi and Leigh, 2001). 
The prevalence of ALS is around 5 cases per 100,000 people with a lifetime risk for men 
of 1 in 350, compared to 1 in 400 for women. These statistics are derived from analysing 
populations of European origin as these communities have been the focus of most 
epidemiological studies (Al-Chalabi and Hardiman, 2013). The average age of onset is 
55 years old (Taylor et al. 2016), however, in rare cases the disease onset can be 
considered early onset (<45 years old) or juvenile (<25 years old) (Turner et al., 2012).  
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Despite this disease being recognised for almost 150 years and a considerable amount 
of progress in terms of research, there is still no effective treatment for ALS. The only 
compound currently used for treatment in Europe and USA is Riluzole, a glutamate 
release inhibitor, that has been shown to increase survival by only a few months (Jardin 
et al. 2010; Lacomblez et al. 1996; Riviere et al. 1998).  
In ~10% of ALS cases other family members have been affected by ALS or a linked form 
of frontotemporal dementia (FTD) and are, therefore, described as ‘familial ALS’ (fALS). 
The majority of these cases show a Mendelian inheritance pattern of the defective gene 
(Byrne et al., 2011), most often with a dominant trait and high penetrance (Taylor et al. 
2016). To date more than 50 genes have been found to be involved in the aetiology of 
fALS. Among these, four genes account for ~60% of the fALS cases: C9orf72 (~25%), 
SOD1 (~20%), FUS (~4%), TARDBP (~5%). C9ORF72 expansion tends to cause 
disease late in life, representing 50% of cases with an age of onset > 40 years old while 
FUS mutations accounts for 30% of the cases with age of onset < 40 years old 
(Millecamps et al., 2012).  
The remaining ~90% of ALS cases that do not have a family history of ALS or FTD are 
described as being sporadic ALS (sALS) cases. The lack of family history does not 
exclude a genetic contribution as most genes are incompletely penetrant and of late 
onset (particularly C9ORF72) and fast progression, making the task of tracking familial 
history particularly challenging. In some cases, it is possible to see an overlap between 
genes identified in fALS and genes linked to sALS. For instance: 4% of sALS are 
associated with missense mutations in SOD1 (Gamez et al., 2006) and over 5% of the 
cases are linked to C9ORF72 expansion (Cooper-Knock et al., 2012). 
ALS is associated, clinically and pathologically, with another adult-onset 
neurodegenerative disease, frontotemporal dementia (FTD), the second most common 
cause of dementia presenting under age of 65 (McKhann et al., 2001; Forman et al., 
2006). Many of the pathological processes that lead to a loss of motor neurons in ALS 
are also implicated as causing the loss of cortical neurons in the frontal and temporal 
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lobes, which are a feature of FTD. This corresponds, clinically, with the cognitive 
impairment that 50% of ALS patients experience during the course of their disease. 
Around 20% of the ALS cases meet the criteria for a diagnosis of FTD (Taylor et al. 
2016).  
1.2 Clinical features  
ALS presents a very heterogeneous spectrum of clinical features. The diagnosis of ALS 
is based on a history of progressive muscle weakness and a combination of signs 
indicating the degeneration of upper motor neurons (UMN, originating in the frontal 
cortex and projecting to neurons in the spinal cord) and lower motor neurons (LMN, 
originating in the spinal cord and innervating skeletal muscle fibres) (Talbot, 2009) 
(Figure 1.1). Typical ALS can be divided into two main groups:  
1. Limb-onset ALS (~65%): This presents with fasciculation in the initial phase of 
the disease, impairment of the limb movement and muscle wasting and 
weakness (Talbot, 2009).  
2. Bulbar-onset ALS (~30%): This typically presents with difficulties in speaking and 
swallowing with signs of tongue atrophy. These patients often develop limb 
symptoms later in the disease (Kiernan et al., 2011) and usually have a worse 
prognosis compared to limb-onset ALS patients (Mortara et al., 1981).  
There are two more phenotype that are, sometimes, associated with ALS and can 
develop into classic ALS but have, generally, a better prognosis. It is, however, important 
to distinguish these phenotypes from classic ALS (Talbot, 2009):  
1. Primary Lateral Sclerosis (PLS): This is predominantly an upper motor neuron 
disease usually presenting with stiffness and modest weakness in the legs as 
primary symptoms, with a spastic increase in tone, exaggerated reflexes and an 
extensor plantar response. This group have the better prognosis with survival 
usually ≥5 years and may be much longer (Gordon et al., 2006).  
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2.  Progressive Muscular Atrophy (PMA): This presents with progressive muscle 
wasting due to lower motor neuron degeneration (Gordon et al., 2006). Only 4% 
of MND patients show this form of MND (Wijesekera et al., 2009) with survival 
rate as high as decades (Talbot, 2009). However, 40% of PMA patients will 
develop UMN symptoms within 18 months and therefore reclassified as having 
ALS (Jeldican et al., 2007).  
ALS is an aggressive disease and it displays a short survival time in most of the cases. 
Approximately 50% of patients will die within 30 months from symptoms onset, around 
15-20% will survive 5 years and only a small percentage will live more than 10 years 
from diagnosis (Talbot, 2009). Death usually occurs due to respiratory failure due to 
weakness of thoracic and diaphragmatic muscles.  
Interestingly, there is no strict association between specific gene mutations and 
particular clinical features. However, mutations in the Fused in Sarcoma (FUS) gene are 
associated with an early onset of ALS upper limb and rapid progression (Kwiatkowski et 
al., 2009; Vance et al., 2009; Bäumer et al., 2010; MacKenzie et al., 2011; Mackenzie et 
al., 2012). Even patients who are carriers of the same gene, may display differences in 
the manifestation of the disease, for example: mutations in Cu/Zn Superoxide Dismutase 
1 (SOD1), the first gene to be associated with ALS (Rosen et al., 1993), can have 
different phenotypes: p.A4V in the heterozygous state shows an aggressive and very 
rapid disease progression (Yim et al., 1997) whereas people heterozygous for p.D90A 
SOD1 mutation are usually asymptomatic and even homozygous patients develop slowly 
progressive disease (Juneja et al., 1997).  
Around 20-50% of ALS patients show cognitive impairment symptoms such as 
personality change, decreased verbal fluency, irritability and failure to perform tasks that 
require frontal executive functions. These symptoms are recognised as a mild 
manifestation of FTD. The clinical and pathological overlap between ALS and FTD is 
such that it is now accepted that the two conditions represent phenotypic ends of a 
common spectrum (Taylor et al. 2016). 95% of ALS cases have TDP-43 positive 
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ubiquitinated inclusions in their spinal motor neurons, which are also present in cortical 
neurons of the frontal and temporal lobes of 95% of tau-negative FTD cases (Neumann 
et al., 2010).The remaining 5% of FTD patients have cytoplasmic FUS even in the 
absence of FUS mutations, associated with FUS inclusions in spinal motor neuron in 
ALS. Interestingly, this feature has also been shown by patients with familial ALS (Vance 
et al., 2009; Neumann et al., 2010; King et al., 2015). Pathological overlap between ALS 
and FTD has also been observed in the hexanucleotide repeat GGGGCC (G4C2) 
expansion in chromosome 9 open reading frame 72 (C9ORF72), which is responsible for 
20-50% of fALS and 10% of sALS and FTD cases (Dejesus-hernandez et al., 2011; 
Renton et al., 2011), where the classical pathology involves TDP-43 negative p62 
positive inclusions in the cerebellum, frontal and temporal lobes (Al-Sarraj et al., 2011). 
This overlap has been confirmed by voxel-based morphometry Magnetic Resonance 
Imaging (MRI), where a bilateral atrophy of the motor and premotor cortex can be 
observed in patients with ALS and FTD, although patients with FTD-ALS show a greater 
frontotemporal atrophy than those with ALS alone (Morita et al. 2006; Neumann et al. 
2010).   
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Figure 1.1 – Anatomical representation of the motor system. (Adapted from Taylor et al. 2016). 
1.3 Diagnosis 
There is no existing diagnostic test for ALS. Therefore, the diagnosis is dependent on 
clinical evaluation together with negative laboratory tests for diseases with similar 
symptoms. Electro diagnostic studies are, currently, the most reliable way to confirm a 
loss of lower motor neurons (fasciculation or spontaneous denervation discharges) and 
exclude peripheral neuropathy or myopathy (Daube, 2000). Magnetic Resonance 
Imaging (MRI) of brain and spinal cord is also used to rule out structural disorders such 
as spinal cord and/or nerve root compression due to bone and/or disc degeneration, 
inflammation, syringommyelia and tumours (Traynor and Ghasemi, 2000; Turner et al., 
2009). Lastly, DNA tests for an expansion mutation in the androgen receptor can be 
used to diagnose Kennedy’s disease, which can mimic ALS (Shaw, Al-Chalabi and 
Leigh, 2001). 
35 
Clinicians base their diagnosis mainly on the combination of UMN and LMN signs in one 
or more region in the absence of an alternative diagnosis being identified by the tests 
described above. In 1991 the World Federation of Neurology developed The El Escorial 
criteria (Brooks et al., 1994), which was later revised in 1998 and in 2008 to 
acknowledge advances in laboratory testing (de Carvalho et al., 2008; Schrooten et al., 
2011). The criteria are listed below: 
1. Definite ALS: UMN and LMN signs in three areas of the body (bulbar, arm, leg). 
2. Probable ALS: UMN and LMN involvement in two regions with at least some 
UMN signs rostral to LMN signs. 
3. Probable ALS—laboratory supported: UMN signs in one or more regions and 
LMN degeneration evidence defined by electromyography in at least two regions. 
4. Possible ALS: UMN and LMN involvement in one region. UMN signs in two or 
more regions. UMN signs and LMN signs in two regions with no UMN 
involvement rostral to LMN signs. 
1.4 Aetiology  
The aetiology of all ALS cases is yet to be fully determined but a combination of 
environmental and genetics factors have been implicated: male gender, advanced age 
and genetic history of ALS (Ingre et al., 2015). Hereditability research has reported that 
about 60% of the risk of ALS is determined by genetic factors and 40% is caused by 
environmental factors (Al-Chalabi et al. 2010). Nonetheless, the correlation between 
genetic and environmental risk with phenotype remains unexplained (Al-Chalabi and 
Hardiman 2013). 
1.4.1 Environmental factors 
A number of epidemiological and population based studies have suggested that 
environmental factors might interact with genetic factors and modify the aetiopathogenic 
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process of ALS. In 2014 a population-based study suggested that ALS could be a multi-
step process, more specifically a mathematical model revealed that a total of 6 
environmental and/or genetic factors are needed in order for ALS to occur (Al-Chalabi et 
al. 2014). The first association of ALS with environmental factors was found in Guam, 
when indigenous people showed a particularly high incidence of ALS in the population. 
This was attributed to the accumulation in the CNS of a neurotoxin: the beta-N-
methylamino-L-alanine (BMAA) (Banack and Cox, 2003; Bradley and Mash, 2009). 
Another environmental factor related to ALS is heavy metal exposure (Ingre et al., 2015), 
indeed higher levels of lead were found in the blood and bones of ALS patients 
compared to controls (Kamel et al., 2002; Fang et al., 2010). Manganese is known to 
have neurotoxic effects with manifestation of motor impairment (Sjögren et al., 1996) and 
was also found to be abundant in the cerebral spinal fluid (CSF) of ALS patients (Roos et 
al., 2012). Involvement of pesticides has also been suggested (Gunnarsson et al., 1992; 
McGuire et al., 1997) and confirmed more recently by meta-analysis studies (Kamel et 
al., 2012; Malek et al., 2012). However, environmental risk factors are very complicated 
to identify as the exposure to any environmental factor is rarely quantifiable and highly 
variable.  
1.4.2 Genetics 
Approximately 10% of ALS cases show familiar history (fALS), with at least one other 
affected member in the family, the remaining 90% of cases are apparent sporadic ALS 
(sALS) (Rowland, Hneider and Shneider, 2001). The past 30 years of research in ALS 
have seen an exponential growth in the number of ALS associated genes, discovered 
initially through classical linkage and association studies and more recently through 
whole exome sequencing (WES) and whole genome sequencing (WGS). However, 
linkage analysis in ALS kindreds is problematic as it is a late onset disorder with short 
survival and incomplete penetrance and large DNA collections from suitable pedigrees 
are rare. WES and WGS are novel and promising techniques that have already identified 
important genes in ALS. To date, over 50 genes have been reported to be linked to ALS 
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pathogenesis accounting for ~60% of familial ALS cases (Figure 1.2) and ~ 10% of 
sporadic ALS cases (van Es et al., 2017), with 50% of the fALS being caused by the four 
main genes: SOD1, C9ORF72, TARDBP and FUS/TLS (Ling, Polymenidou and 
Cleveland, 2013). Considering that the genes discovered in fALS are often the same as 
the ones implicated in sALS, a strict classification of ALS cases into sporadic and familial 
ALS is an oversimplification (Al-Chalabi et al., 2010). Most of the studies published until 
now suggest an overlap between the genetic architecture of these two categories (van 
Es et al., 2017). The ALS risk for a first order family member of a sALS patient is eight-
fold higher compared to the population risk at age 85, raising their risk to 2.4% (Hanby et 
al., 2011).  
 
Figure 1.2 – Percentage of mutated genes in familial ALS. 
To unravel the complex genetics of this disease, a large scale GWAS project has been 
launched in 2012 called Project MinE (https://www.projectmine.com/), aiming to genome 
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sequence 15000 ALS cases and 7500 controls. This project is predicted to be finished by 
2018. Here will follow a description of all the major genes discovered in ALS to date.  
1.4.2.1 Principal genes  
This section will focus on the four main genes that together represents 20% of all ALS 
cases (Al-Chalabi et al., 2012; White and Sreedharan, 2016). 
1.4.2.1.1 Superoxide Dismutase 1 (SOD1) 
SOD1 was the first gene to be linked to ALS. Disease associated mutations in this gene 
were discovered through linkage studies in 1993 when Rosen and colleagues identified 
11 missense mutations implicated in ALS (Rosen et al., 1993). To date over 190, mostly 
missense, mutations were found spread along the 153 codons of SOD1 and account for 
~20% of fALS (ALS data base (ALSdb, http://alsdb.org); van Es et al. 2017) and 5% of 
apparently sporadic cases (Kiernan et al., 2011). Mutations are almost exclusively found 
within the exons, suggesting that they might gain their toxicity through the disruption of 
the protein structure or function (Sangwan and Eisenberg, 2016). SOD1 encodes for a 
protein (SOD1) that catalyses the conversion of superoxide radicals in hydrogen 
peroxide, through cyclical reduction and oxidation of copper (Zelko, Mariani and Folz, 
2002; Pasinelli and Brown, 2006). This protein is ubiquitous among human cells and 
mostly cytoplasmic. In order to operate its function, SOD1 needs to homodimerise, with 
each subunit binding one atom of zinc and one of copper. Many mutations found in ALS 
cases do not affect its catalytic activity, so loss of catalytic function is not a requirement 
for pathogenicity (Pasinelli and Brown, 2006).  The mechanism of pathogenicity seems 
to be due to a toxic gain of function caused by a change in the amino acid sequence, 
which causes SOD1 misfolding and aggregation in the cell (Pasinelli and Brown, 2006).  
Interestingly, from a clinical point of view, patients who carry different SOD1 mutations, 
can present in different ways. Most mutations are heterozygous and are passed down 
generations in an autosomal dominant pattern of inheritance. However, exceptions do 
exist, for example the p.D90A mutation causes ALS only when both alleles are mutated. 
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This mutation is heterozygous in 2-3% of the Scandinavian population, showing high 
penetrance when homozygous (Andersen et al., 1996; Robberecht et al., 1996). 
Symptoms caused by this mutation are very distinctive and show a slowly progressive 
form of ALS, with corticospinal signs and average survival of about 10 years. SOD1 
pathology is rarely associated with dementia, however, patients homozygous for the 
mutation p.D90A show cognitive impairment in the later stages of the disease, probably 
due to the prolonged duration of the illness (Turner et al. 2005). Interestingly, some 
individuals that carry this mutation in heterozygosity outside the Scandinavian population 
develop classic ALS with survival of three to five years (Pasinelli and Brown, 2006). It 
has been proposed that the North Scandinavian population might carry some 
neuroprotective allele that would, somehow, weaken the toxicity of the mutation (Soares 
et al., 2004). The p.A4V SOD1 mutation is the most abundant in North America, 
representing 50% of the familial ALS cases. It presents with a predominantly lower 
motor neuron involvement and is rapidly progressive with mean survival of one year 
(Cudkowicz et al., 1997).  
Many transgenic mouse models have been created in order to better understand the 
molecular mechanisms whereby mutated SOD1 causes motor neuron degeneration in 
ALS (Pasinelli et al., 2004). These models have also been used to test compounds that 
could be used in clinical trials, however, this approach has been criticised by many 
(Ludolph et al., 2007). Mouse models have confirmed that knock down of wild-type 
SOD1 causes no phenotype in mice (Bruijn et al., 1998) whereas the expression of many 
SOD1 mutants leads to motor neuron degeneration. Collectively the evidence indicates 
that SOD1 might cause the disease through a toxic gain of function (Sangwan and 
Eisenberg, 2016).   
Although there is no evidence of the transmission of ALS between individuals, a prion-
like behaviour has been hypothesised for mutant SOD1. This theory was supported by 
some evidence showing that SOD1 is secreted extracellularly in vitro (Münch, O’Brien, 
and Bertolotti 2011; Sundaramoorthy et al. 2013; Turner et al. 2005). Furthermore, 
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homogenates of mouse spinal cord has been found to cause SOD1 aggregation in vitro 
(Chia et al., 2010) and, if injected in mice, to induce the pathology, which spreads along 
the spinal cord (Grad et al., 2011, 2014, Ayers et al., 2014, 2016). This theory could also 
explain the spread of clinical symptoms between anatomically connected areas to the 
region of onset (Sangwan and Eisenberg, 2016). 
Over 25 years of investigation of SOD1 ALS have revealed that mutant SOD1 
aggregation is toxic to multiple cellular systems including mitochondria function, axonal 
transport and proteostasis (Al-Chalabi et al., 2012). Therapies targeting the mutant RNA 
and protein are showing promise. Gene silencing through antisense oligonucleotide has 
been shown to reduce the level of mutant SOD1 and to be well tolerated in phase 1 
clinical trials (Miller et al., 2013; Nizzardo et al., 2016). Furthermore, an immunisation 
approach has also been explored and it has shown to be marginally effective in mouse 
models (Urushitani, Ezzi and Julien, 2007; Gros-Louis et al., 2010; Liu et al., 2012). 
Mutant SOD1 cases, however, account for only ~3% of all ALS and they do not show the 
classical pathology of TDP-43 cytoplasmic inclusions, present in the vast majority of 
sporadic and familial ALS cases (Mackenzie et al., 2007). Therefore, therapies shown to 
be effective in mutant SOD1 cellular and animal models of ALS may not be effective in 
most ALS cases.  
1.4.2.1.2 TAR DNA-binding protein (TARDBP)  
A major breakthrough in ALS research was the discovery that TDP-43 (encoded by 
TARDBP), an RNA binding protein, represented a major component of the ubiquitin-
positive inclusions found in the spinal cord of almost all ALS and tau-negative FTD 
patients (Neumann et al., 2006). TDP-43 is a protein composed by 414 amino acids, 
carrying two RNA recognition motifs (RRM) and a low complexity glycine-rich domain at 
the C-terminus end of the protein (Kato et al., 2012; King, Gitler and Shorter, 2012). To 
date over 50 TARDP, predominantly missense mutations, have been associated with 
ALS, and account for 5% of fALS and 1% of sALS (www.alsdb.org; Sreedharan et al. 
2008), and represent 1-2% of total ALS cases (Sreedharan et al., 2008; Renton, Chiò 
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and Traynor, 2013). The distribution of mutations among different populations is mostly 
even with some exceptions. For instance, the p.A382T variant is enriched in the 
Sardinian population (Chiò et al., 2011).  Most of the mutations cause single amino acid 
substitutions in the glycine-rich domain, at the C-terminal region, which is involved in the 
binding of TDP-43 to the other ribonucleoprotein (Renton, Chiò and Traynor, 2013) as 
well as in protein-protein interaction (Buratti et al., 2005).  
TDP-43 was originally identified as a transcriptional repressor of the trans-activation 
response (TAR) element of the HIV virus (Ou et al., 1995). It is predominantly nuclear, 
where it binds and regulates RNA transcription, splicing and transport (Buratti and 
Baralle, 2012). Furthermore, it shuttles between the nucleus and the cytosol where it 
delivers RNA to the ribosomal machinery in the cytoplasm and in the axodendritic 
arborisation. TDP-43 binds particularly to UGUG RNA motifs dictating the inclusions or 
exclusion of specific exons (Buratti and Baralle, 2001; Tollervey et al., 2011). A great 
deal of attention has focussed on the role TDP-43 plays in alternative splicing, a function 
that is disturbed when TDP-43 is sequestered into cytoplasmic aggregates and unable to 
enter the nucleus (Freibaum et al., 2010; Polymenidou et al., 2011; Tollervey et al., 
2011). TDP-43 has also been found in RNA granules, promoting anterograde axonal 
transport and regulating the translation of a subgroup of mRNAs (Wang et al., 2008; 
Alami et al., 2014). TDP-43 is also recruited to stress granules, membrane-less cytosolic 
RNA-protein clusters that arise in response to oxidative, osmotic and heat stressors (Li 
et al., 2013). It is hypothesised that TDP-43 is present in high concentrations in stress 
granules where it misfolds to form toxic oligomer ‘seeds’, which initiate further 
aggregation and inclusion formation. Thus the stress granule has been labelled “the 
crucible of aggregation” (Li et al., 2013). 
The most common feature of TDP-43 associated pathology is the presence of TDP-43 in 
insoluble inclusions in the cytosol, which entails a loss of nuclear TDP-43 and the 
formation of TDP-43 C-terminal fragments (20-25 and 30 kDa). Furthermore, aberrant 
phosphorylation and ubiquitination of TDP-43 inclusions are evident in upper and lower 
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motor neurons as well as in the prefrontal cortex in ALS-FTD cases (Geser, Lee and 
Trojanowski, 2010; Mackenzie, Rademakers and Neumann, 2010). Interestingly, 95% of 
all ALS patients present TDP-43 pathology with the exception of mutant SOD1 and FUS 
cases (Mackenzie et al., 2007; Tan et al., 2007), with indistinguishable features between 
patients positive or negative for mutation in TDP-43 itself (Pamphlett et al., 2009).  
The underlying mechanism driving neurodegeneration due to TDP-43 aggregation is still 
to be determined. In addition to the loss of splicing function described above, TDP-43 
mutations cause the protein to be unstable and aggregate in the cytoplasm, which may 
be directly toxic to motor neurons (Johnson et al., 2009; Kabashi et al., 2009). Recent 
research has shown that mutant TDP-43 can disrupt the axonal transport of RNA (Alami 
et al., 2014) and cause mitochondria dysfunction (Wang et al., 2016), which is common 
to the effects of mutant SOD1.   
Overexpression of TDP-43 to 2.5 fold in mice showed an aggressive phenotype with 
early onset and short survival (2 months from symptom onset) with evidence of TDP-43 
pathology (Y. Xu et al., 2011). However, these mice are not  a very good model as they 
die prematurely because of intestinal complication (Esmaeili et al., 2013; Hatzipetros et 
al., 2014). Mouse models that express p.A315T and p.G348C mutations, show age 
related motor deficit symptoms but no paralysis or early death (Picher-Martel et al., 
2016). In 2015 a study reported that double transgenic mice for humanTDP-43WT and 
humanTDP-43Q331K display a very early onset limb paralysis with death occurring at 8-10 
weeks of age (Mitchell et al., 2015). Single p.Q331K transgenic mice, on the other hand, 
presented with mild motor dysfunction at three months of age which progressed slowly 
over 24 months when they showed reduced endurance on the rotaroad, a device used to 
test mice locomotion. These mice show classic TDP-43 pathology presenting most of 
ALS related features (Mitchell et al., 2015). However, the overexpression of human TDP-
43 in mice entails a reduction in the endogenous level of mouse TDP-43 (Arnold et al., 
2013), making it hard to differentiate between a loss of endogenous mouse TDP-43 
function or a gain of function caused by overabundant human TDP-43.  
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Overexpression of wild type and mutant TDP-43 has also been shown to cause 
aggregation in Caenorhabditis Elegans (C. Elegans) with motility impairment and 
degeneration pattern that was aggravated in mutants compared to wild type (Ash et al., 
2010; Liachko, Guthrie and Kraemer, 2010). Furthermore, injections of mutant TDP43 in 
zebrafish embryo show evidence of motor axonopathy (Kabashi et al., 2009; Laird et al., 
2010). 
The discovery of TDP-43 has highlighted the importance of RNA processing in ALS 
pathogenesis, which was confirmed by the discovery of another RNA binding protein, 
FUS described below, prompting further investigation on how mutations in these genes 
might affect RNA metabolism (Lagier-Tourenne et al., 2012).  
1.4.2.1.3 Fused in Sarcoma (FUS) 
Fused in Sarcoma or Translated in Liposarcoma (FUS/TLS) was initially reported as an 
oncofusion protein involved in liposarcoma (Crozat et al., 1993; Rabbitts et al., 1993). 
Mutations in FUS were later identified in familial ALS by two independent studies 
(Kwiatkowski et al., 2009; Vance et al., 2009). Since then, over 70 FUS variants have 
been reported in ALS patients, accounting for 4% of the fALS and 1% of the 
apparently sporadic ALS cases (Picher-Martel et al., 2016). Similar to TDP-43, mutations 
discovered in FUS are mainly missense variants, although a few truncation, deletion and 
insertion variants have also been reported. These cluster in two sites at the extreme 
carboxylate terminus of the protein and in the low complexity domain (Lagier-Tourenne, 
Polymenidou and Cleveland, 2010; Andersen and Al-Chalabi, 2011).  
Many studies have shown that mutations in FUS cause an early onset (age <40 years 
old), sometimes even juvenile (<25 years), and rapid disease progression (Waibel et al., 
2013). ALS patients with FUS mutations have a predominantly LMN onset with rare 
cognitive symptoms (Lattante, Rouleau and Kabashi, 2013) and truncation mutations 
show a more aggressive phenotype compared to missense mutations (Picher-Martel et 
al., 2016). 
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FUS pathology is varied across the mutation spectrum and even within patients carrier 
for the same mutation (Kapeli, Martinez and Yeo, 2017). A common pathological feature 
of FUS is the mislocalisation of the protein, usually nuclear, to the cytosol either as 
inclusions or diffused smaller aggregates. FUS in ALS has also been reported to 
aggregate in stress granules and form ubiquitin-negative inclusions (Kwiatkowski et al., 
2009; Vance et al., 2009). Interestingly, cytoplasmic FUS inclusions have also been 
described in TDP-43 and tau negative FTD (Neumann, Rademakers, et al., 2009) and 
Huntington’s disease (Doi et al., 2008). However, no FUS mutations have been identified 
in any of the FTD-FUS cases (Neumann, Roeber, et al., 2009; Urwin, Josephs, et al., 
2010; Rohrer et al., 2011; Snowden et al., 2011). Furthermore in these cases, FUS 
accumulates with TAF1 and EWS proteins and Transportin1, which are absent from 
mutant FUS inclusions implying a different basis for inclusion formation (Troakes et al., 
2013). 
Physiologically, FUS is involved in almost identical RNA processing roles as TDP-43, 
including: the regulation of transcription, alternative splicing and mRNA trafficking (Fujii 
and Takumi, 2005; Lagier-Tourenne et al., 2012). FUS targets a large spectrum of RNA 
sequences. Among these, FUS has been shown to bind to the intronic regions of pre-
mRNAs, suggesting it might play a role in splicing (Lagier-Tourenne et al., 2012; Rogelj 
et al., 2012).  
The molecular mechanisms underlying the pathogenicity of FUS mislocalisation in ALS 
are unclear. Studies in mice seem to agree that the over-expression of mutant FUS is 
sufficient to cause motor neuron degeneration (Nolan, Talbot and Ansorge, 2016), 
whereas FUS knock out murine models show late neonatal or early postnatal death. 
Furthermore, selective knock out of FUS from the nervous system does not appear to 
cause any neurodegenerative phenotype (Sharma et al., 2016). Evidence seem to agree 
that FUS pathogenicity is associated with its ability to bind RNA and that it might depend 
on FUS-acquired toxic functions, which could impair RNA and protein homeostasis, or 
promote toxic aggregation (Kapeli, Martinez and Yeo, 2017).  An example of this is 
45 
FUS’s property to bind to its own intron seven on FUS mRNA and self-regulate its own 
expression, producing an alternatively spliced form of FUS that will be degraded by 
nonsense mediated decay (Zhou et al., 2013). FUS variants fail to operate this function, 
resulting in an accumulation of the protein that might be toxic for the cell. 
Most of the mutations found in FUS map at the carboxyl terminus of the protein, where 
the Nuclear Localisation Sequence (NLS) localise. At the N terminal FUS presents a 
QGSY-rich and a glycine rich prion like domain, which when mutated gives FUS 
aggregation-prone properties that are exacerbated by some of the FUS mutations 
reported in ALS such as p.R521C and p.P525L (Cushman et al., 2010). Mutations in the 
NLS, on the other end, can impair FUS ability to enter the nucleus, making wild type FUS 
a target for mutant FUS, which might sequester it in stress granules (Vance et al., 2013). 
1.4.2.1.4 C9ORF72 
Another important discovery in the genetics of ALS was the identification of an extensive 
hexanucleotide repeat expansion in intron 1 of the chromosome 9 open reading frame 72 
(C9ORF72) gene. The locus of this expansion on Chromosome 9p21 was linked to 
Familial ALS and FTD in 2006 by two independent studies (Morita et al., 2006; Vance et 
al., 2006) and subsequently in GWAS of sporadic ALS (van Es et al., 2009; Laaksovirta 
et al., 2010; Shatunov et al., 2010) and TDP-43 positive FTD (Van Deerlin et al., 2010). 
In 2011, the hexanuclotide repeat expansion GGGGCC (G4C2) was discovered to be 
causative of ALS (DeJesus-Hernandez et al., 2011; Renton et al., 2011; Gijselinck et al., 
2012). This expansion accounts for ~80% of familial ALS-FTD cases, 20-50% of fALS, 5-
20% of sALS and 10-30% of FTD cases, making it the most prevalent genetic cause of 
ALS and FTD to date (Boeve et al., 2012; Chiò et al., 2012; Cooper-Knock et al., 2012; 
Hsiung et al., 2012; Mahoney et al., 2012; Simón-Sánchez et al., 2012; Snowden et al., 
2012; Smith et al., 2013). Approximately 90% of healthy individuals carry <10 repeat, 
whereas ALS and FTD cases have been found to harbour hundreds or even thousands 
G4C2 repeats in this locus.  
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The role of the G4C2 expansion in the physiopathology of ALS and FTD is still not clear. 
C9OFR72 expansion carriers show higher incidence of bulbar-onset ALS and cognitive 
impairment in 50% of the cases. These patients often show early onset with fast disease 
progression (Byrne et al., 2012; Chiò et al., 2012; Millecamps et al., 2012). This is 
accompanied by upper and lower motor neuron degeneration and TDP-43 positive 
inclusions (Cooper-Knock et al., 2012). These are usually observed in the brain and the 
spinal cord of these patients. Moreover, p62 and Ubiquilin 2 positive nuclear and 
cytoplasmic inclusions are also observed in the granular and molecular layers of the 
cerebellum and these inclusions are TDP-43 negative (Brettschneider et al., 2012). 
Additionally, RNA foci were also identified in the frontal cortex, hippocampus and 
cerebellum of patients carrier for C9ORF72 expansion (Dejesus-hernandez et al., 2011). 
Interestingly, some of these cases have been reported to show other neurodegenerative 
disease symptoms, more typical of Parkinsonism and Huntington’s disease (Cooper-
Knock et al., 2012; Wilke et al., 2016). 
In the last few years of research on C9ORF72 repeat expansions, many pathogenic 
molecular mechanism have been proposed, making the topic particularly controversial. 
The physiologic function of C9ORF72 coded protein is to date unknown, resulting in a 
limited understanding of how this expansion might cause the disease. Three moelcular 
mechanisms have been proposed until now: 
1. Loss of function of C9ORF72 (haploinsufficiency) (Ciura et al., 2013) 
2. Gain of RNA toxicity (Fratta et al., 2013) 
3. Repeat associated non-ATG translation (Zu et al., 2010) 
Haploinsufficiency would derive from the unsuccessful translation of mRNA carrying the 
large expansion. This hypothesis seems unconvincing as no other mutations have been 
identified on the same gene and homozygosity of this variant in human does not 
exacerbate the disease manifestation (Fratta et al., 2013). Furthermore, knock out of the 
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whole gene in mouse does not show any motor neuron degeneration, suggesting that 
haploinsufficiency is unlikely to be a major cause (Koppers et al., 2015).  
RNA foci, localised in the neuronal nucleus and occasionally in the cytoplasm, were 
identified in C9ORF72 post mortem brain and spinal cord tissues as well as in patient 
derived fibroblast and lymphoblast lines (DeJesus-Hernandez et al., 2011; Renton et al., 
2011; Donnelly et al., 2013; Gendron et al., 2013; Lagier-Tourenne et al., 2013; 
Mizielinska et al., 2013; Zu et al., 2013). Furthermore, G4C2 repeats have been reported 
to form highly stable G-quadruplex structure (four stranded helical secondary structures 
that can form in guanine-rich sequences and are stabilised by Hoogsteen hydrogen 
bonding) as well as R-loops (hybrid structures formed by DNA and RNA) in vitro (Fratta 
et al., 2012; Reddy et al., 2013, 2014; Haeusler, Donnelly and Rothstein, 2016). The 
RNA gain of function theory states that RNA foci might be able to sequester important 
proteins involved in RNA metabolism such as hnRNPH, SR2, SC35, ALYREF, ADARB2 
or hnRNP-A1, which have been found to localise with the RNA foci in a number of 
studies (Donnelly et al., 2013; Lee et al., 2013; Mori, Lammich, et al., 2013; Sareen et 
al., 2013; Cooper-Knock et al., 2014, 2015; Haeusler et al., 2014). The G-quadruplex 
and R-loop structure could, on the other hand, interact with nucleolar proteins causing 
nucleolar stress (Haeusler et al., 2014). This hypothesis was confirmed by a number of 
studies using neuronal cell lines, Drosophila Melanogaster and Zebrafish (Lee et al., 
2013; Xu et al., 2013; K. Zhang et al., 2015; Rossi et al., 2015; Jiang et al., 2016; Y. Liu 
et al., 2016). However, there are studies in transgenic fly and mouse models as well as 
induced pluripotent stem cells (iPSCs), which do not confirm this theory (Mizielinska et 
al., 2014; O’Rourke et al., 2015; Peters et al., 2015; Tran et al., 2015), indicating that 
RNA foci alone might not be sufficient to cause neurodegeneration.  
G4C2 repeats were initially reported to go through Repeat Associated Non-ATG 
translation (RAN translation) by two independent studies (Mori et al. 2013; Zu et al. 
2013). The hexanucleotide repeat is translated from the forward and reverse RNA strand 
to generate five different dipeptide proteins (DPRs): poly-Gly-Ala (GA), poly-Gly-Pro 
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(GP), poly- Gly-Arg (GR), poly-Pro-Ala (PA), and poly-Pro-Arg (PR). DPRs have been 
identified to localise in neurons, forming TDP-43-negative, p62-positive pathological 
inclusions in C9ORF72 patients (Al-Sarraj et al., 2011; Murray et al., 2011; Renton et al., 
2011; Gijselinck et al., 2012; Ash et al., 2013; Mann et al., 2013; Mori, Weng, et al., 
2013). Functional studies in yeast, neurons in culture and Drosophila have shown that 
poly-GR and PR are highly toxic, whereas the other dipeptides seem to have a milder 
effect (Kwon et al., 2014; Mizielinska et al., 2014; Wen et al., 2014; Freibaum et al., 
2015; Jovičić et al., 2015; Tao et al., 2015; Yang et al., 2015). It is important to keep in 
mind that these pathogenic mechanisms are not mutually exclusive and that they could 
coexist in order for the disease to manifest. Further research in this field is necessary in 
order to draw any conclusion on C9ORF72 mechanism of action.  
Several studies have focused on the development of a target specific treatment for 
C9ORF72 patients using antisense oligonucleotide (ASO) direct against GGGGCC RNA 
transcripts (Donnelly et al., 2013; Sareen et al., 2013; Jiang et al., 2016). This is a 
promising approach that has been tested on iPS cellular model as well as primary 
fibroblasts and has shown some success, reducing RNA foci without affecting the level 
of total C9ORF72 mRNA (Donnelly et al., 2013; Lagier-Tourenne et al., 2013). However, 
further investigation in animal models and eventually through clinical trials is needed to 
determine whether these ASOs are well tolerated and have a beneficial therapeutic 
effect on disease progression in ALS.  
1.4.2.2 Genes discovered through family-based studies  
Family-based studies have successfully identified genes involved in the pathogenesis of 
ALS (Al-chalabi, Berg and Veldink, 2016). Most of these genes have been found through 
genetic linkage studies, a technique that uses statistical analyses to determine whether a 
set of genetic markers co-segregate with disease in one or more large pedigrees. These 
studies have their limitations because ALS is a rapidly fatal, late onset disease with 
incomplete penetrance, which means that DNA is rarely available from multiple affected 
individuals in large pedigrees that have the power to identify novel loci by linkage. The 
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genes that have been discovered through linkage studies date back to the 1990s and 
early 2000s, and the more advanced techniques of GWAS, WES and WGS are now 
used for gene discovery. Here I describe the genes that have been reported using 
family-based linkage studies in ALS. 
1.4.2.2.1 Ubiquilin 2 (UBQLN2) 
Ubiquilin 2 (UBQLN2) was identified to be associated with ALS in 2011, when five 
mutations were reported in unrelated families of patients with dominant X-linked ALS 
(Deng et al., 2011). Three of these mutations did not always segregate with disease, 
suggesting that UBQLN2 might present incomplete penetrance (Daoud and Rouleau, 
2011). More than 10 mutations have been found in UBQLN2 since then, representing 
~1% of fALS and a very small percentage of sALS. These variants have been reported to 
cluster in the proline rich domain with some exceptions (Deng et al., 2011; Daoud, 
Suhail, et al., 2012; Synofzik et al., 2012; Williams et al., 2012; Gellera et al., 2013). ALS 
patients harbouring mutations in UBQLN2 present an early age of onset and disease 
duration of six months to five years, these characteristics are exacerbated in male 
patients (Deng et al., 2011; Gellera et al., 2013). Clinically UBQLN2 cases show upper 
and lower motor neuron symptoms with a high incidence of dementia, making these 
mutations strongly associated with ALS-FTD (Deng et al., 2011; Gellera et al., 2013). 
Histopathological investigation of post mortem tissue showed UBQLN2 inclusions, which 
often colocalise with other protein involved in ALS pathology such as TDP-43, FUS and 
Optineurin (Deng et al., 2011; Williams et al., 2012). Interestingly, these inclusions were 
also found in ALS patients non carriers of UBQLN2 variants and presenting ALS-
dementia phenotype, suggesting a correlation between UBQLN2 pathology and ALS 
associated dementia (Daoud and Rouleau, 2011). UBQLN2 is involved in protein 
degradation through the Ubiquitin-Proteasome System (UPS) (Ko et al., 2004) and in 
autophagy, a process through which ubiquitinated proteins and dysfunctional organelles 
are degraded in autophagosomes (Ajroud-Driss and Siddique, 2014). This suggests that 
UBQLN2 pathogenesis might involve impaired protein degradation, a hypothesis 
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supported by the identification of ALS associated variants in other autophagy related 
genes such as Optineurin (Maruyama et al., 2010) and VCP (Johnson et al., 2010). 
1.4.2.2.2 Optineurin (OPTN) 
OPTN was eported to be associated with ALS for the first time in 2010 (Maruyama et al., 
2010) by a Japanese group using homozygosity mapping. Mutations in this gene are 
now considered to account for ~3% of familial ALS and ~1% of sporadic ALS (Ling, 
Polymenidou and Cleveland, 2013). Since 2010 ~40 OPTN variants (missense and 
nonsense) have been reported (Maruyama et al., 2010; Del Bo et al., 2011; Iida et al., 
2012; Tümer et al., 2012; Van Blitterswijk, Van Vught, et al., 2012; Weishaupt et al., 
2013; Soong et al., 2014; Li et al., 2015; Özoğuz et al., 2015; Fifita et al., 2016; 
Goldstein et al., 2016), with a higher frequency in non-European populations, in 
particular the Japanese and Chinese. The frequency and penetrance of specific OPTN 
mutations varies with the ethnicity, hinting towards a genetic founder effect 
(Markovinovic et al., 2017). OPTN variants have also been linked to primary open angle 
glaucoma (POAG) (Rezaie et al., 2002; Minegishi et al., 2016) and to Paget’s disease of 
the bone and Chron’s disease of the bowel (Albagha et al., 2010; Obaid et al., 2015; 
Smith et al., 2015). The histopathology of OPTN-linked ALS is not well characterised. 
Some evidence of OPTN inclusions, positive for TDP-43 and p62, have been previously 
observed (Ito et al., 2011; Kamada et al., 2014) however, they do not seem to be a 
feature of OPTN mutant pathology. Interestingly, wild type OPTN has been found to 
colocalise with cytosolic inclusions in other neurodegenerative diseases such as 
Alzheimer’s (AD), Parkinson’s (PD), Huntington’s (HD), Pick’s and Creutzfeldt-Jakob’s 
disease, and sporadic forms of ALS (Maruyama et al., 2010; Hortobágyi et al., 2011; 
Osawa et al., 2011; Ling, Polymenidou and Cleveland, 2013). This can be explained by 
the ability of OPTN to participate in recruiting the autophagy machinery. This protein, in 
fact, is involved in a wide range of pathways from the negative regulation of NF-kB (Zhu 
et al., 2007) to the autophagy receptor function, particularly relevant for ALS and 
neurodegenerative diseases in general, as impaired autophagy has been previously 
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suggested as a possible pathogenic mechanism for these disorders (Wild et al., 2011; 
Wong and Holzbaur, 2014; Heo et al., 2015; Lazarou et al., 2015). OPTN has also been 
reported to be involved in the autophagosome maturation process (Tumbarello et al., 
2015), through interaction with TBK1 (another ALS-associated protein), in the defence 
against pathogens (Pourcelot et al., 2016) and in mitophagy, a mitochondria specific type 
of autophagy (Matsumoto et al., 2015). Although involved in numerous pathways, it is 
still not clear how OPTN mutations might cause ALS and further research is necessary in 
order to elucidate the precise role of OPTN in disease pathogenesis.  
1.4.2.2.3 ALS2 
ALS2 variants have been identified in patients that present a rare form of juvenile onset, 
slowly progressive ALS (ALS2) characterised by autosomal recessive transmission 
(Hadano et al., 2001). Most of the ALS2 variants found to date are predicted to produce 
a truncated form of the protein, with a disease phenotype that seems to be directly 
proportional to how severe the truncation is (Hadano et al., 2001; Yang et al., 2001). 
Given that the disease becomes evident only in the recessive state, where mutations are 
commonly homozygous, ALS2 is clearly due to a ‘loss of function’ mechanism (Pasinelli 
and Brown, 2006). ALS2 codes for a ubiquitously expressed 184 kDa protein, alsin, 
which is particularly abundant in neurons where it localises in the endosomal membrane 
and appears to be involved in endosomal trafficking (Otomo et al., 2003). Mice lacking in 
alsin do not show any signs of neuron degenerations, however, they do present high 
oxidative stress (Cai et al., 2005) as well as age-related neurological impairment and 
compromised vesicle and endosomal trafficking (Hadano et al., 2001).  
1.4.2.2.4 Vesicle-Associated Membrane Protein (VAMP)/synatobrevin-associated 
protein B (VAPB) 
A large Brazilian pedigree affected by atypical ALS as well as SMA was found to carry a 
missense mutation (p.P56S) in VAPB (Nishimura et al., 2004). Later, another missense 
mutation was identified in a cohort of 107 fALS (Chen et al., 2010). However, no further 
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VAPB variants have been found since then. Expression of these variants in mammalian 
cells causes ER fragmentation and cytosolic aggregates, which appear to sequester the 
wild type form of VAPB encoded protein (Nishimura et al., 2004; Kanekura et al., 2006; 
Teuling et al., 2007; Chen et al., 2010). Transgenic mice expressing p.P56S VAPB 
variant in the nervous system do not show reduced survival, however, they do display 
cytosolic aggregation of TDP-43, SQSTM1 and ubiquitin at 18 months of age (Tudor et 
al., 2010; Qiu et al., 2013).  
1.4.2.2.5 Senataxin (SETX) 
Heterozygous missense mutations in SETX are associated with a juvenile onset, slow 
progression form of ALS (ALS4), which mostly affects LMN but is not fatal (Chen et al., 
2004; Zhao et al., 2009; Avemaria et al., 2011). Homozygous or compound 
heterozygous mutations in this gene have also been observed in an autosomal recessive 
form of ataxia with oculomotor apraxia (Moreira et al., 2004; Duquette et al., 2005; 
Anheim et al., 2009). SETX encodes for DNA/RNA helicase, senataxin, which is involved 
in DNA repair and RNA synthesis (Chen et al., 2004), suggesting once again that RNA 
metabolism could play an important role in ALS pathogenesis.  
1.4.2.2.6 hnRNPs 
The heterogeneous nuclear ribonucleoprotein (hnRNP) family is a category of proteins 
that binds to newly synthesised RNA and participate in its transport and maturation 
(Piñol-Roma et al., 1988; Dreyfuss et al., 1993; Jean-Philippe, Paz and Caputi, 2013). 
hnRNPs, together with other important ALS-linked proteins such as FUS and TDP-43, 
bear a prion-like domain (PrLD), which, when mutated, makes these proteins particularly 
prone to aggregation. Only three variants for hnRNPA1 and one for hnRNPA2/B1 have 
been found in patients with ALS or multisystem proteinopathy (MSP), a group of 
neurodegenerative diseases that includes ALS (Kim et al., 2013; Q. Liu et al., 2016). 
Interestingly, both hnRNPA1 and hnRNPA2/B1 have been found to be expressed at 
lower levels in the CNS of Alzheimer’s patients (Berson et al., 2012), however the 
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mechanism of pathogenicity of these protein variants is, to date, unclear. Their 
aggregation prone properties seem to suggest that misfolding and fibrilisation might be 
involved in causing the disease, leading to a toxic gain of function hypothesis. However, 
a few studies have also suggested that their pathogenicity might be linked to a ‘loss of 
function’ (Kapeli, Martinez and Yeo, 2017).   
1.4.2.3 Genes discovered through a candidate gene approach 
The candidate gene approach uses what is known about a specific gene (i.e. biological 
function, association with diseases etc.) to associate it to the disease of interest. This 
technique has been fairly successful although severely criticised. Studies that found 
candidate genes through this approach, in fact, have been particularly difficult to 
replicate (Zhu and Zhao, 2007). Furthermore, it is worth noticing that a prior association 
of the gene with a similar disorder or with a relevant molecular mechanism is necessary 
in order to perform this gene-discovery technique. This method, therefore, heavily relies 
on prior knowledge of the gene’s biological, physiological or functional role, which might 
be insufficient to make a correct prediction. It is believed that this ‘hypothesis driven’ 
technique might be less effective than an ‘anonymous’ technique such as WES or 
GWAS, which do not depend on the ability to make a biologically plausible hypothesis 
(Tabor, Risch and Myers, 2002). Nonetheless, a few ALS-linked genes have been found 
using this method and they are listed below.  
1.4.2.3.1 SQSTM1/p62 
SQSTM1 encodes for a 440 amino acid protein Sequestosome 1, also named p62. This 
protein has been shown to colocalise with TDP-43, FUS and ubiquilin2 inclusions in ALS 
as well as other neurodegenerative diseases (Kwiatkowski et al., 2009; Vance et al., 
2009; Al-Sarraj et al., 2011; Marangi and Traynor, 2014; Bury et al., 2016). A candidate 
gene approach was, therefore, applied and rare mutations in SQSTM1 were found in 1-
2% of fALS and up to 4% of sALS (Fecto et al., 2011; Rubino et al., 2012; Teyssou et al., 
2013; Chen et al., 2014; Kwok, Morris and de Belleroche, 2014). SQSTM1 variants were 
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also previously found in patients affected by Paget’s disease of the bone (Laurin et al., 
2002). The presence of mutations on SQSTM1 was observed to be accompanied by 
TDP-43 pathology in ALS (Teyssou et al., 2013) and p62 inclusions in other 
neurodegenerative diseases (Brettschneider et al., 2012). p62 acts as an autophagy 
adapter, targeting polyubiquitinated proteins that are then processed by the proteasome 
or through other autophagy pathways (Moscat and Diaz-Meco, 2012). Although the 
pathogenic mechanism of these variants is still not clear, the strong association of p62 
with autophagy seems to be the more plausible explanation to mutant SQSTM1 
pathogenesis (Ling, Polymenidou and Cleveland, 2013).  
1.4.2.3.2 Ataxin 2 (ATXN2) 
Ataxin 2 (ATXN2) was reported to bear a CAG expansion corresponding to a 34 amino 
acid long poly-glutamine repeat in patients affected by Spinocerebellar ataxia type 2 
(SCA2) (Elden et al., 2010). Some of these patients reported some motor neuron 
degeneration and this led to the formulation of the hypothesis that ATX2 could have 
been involved in ALS. Many reports have now shown a correlation between mutations in 
this gene and ALS. In particular, 27-33 repeats have been associated with an ALS 
phenotype, 34 repeats with SCA2 manifestations and <27 with no clinical phenotype 
(Elden et al., 2010; Chen et al., 2011; Daoud et al., 2011; Ross et al., 2011; Van Damme 
et al., 2011; Yu et al., 2011; Gispert et al., 2012; Van Langenhove et al., 2012). This 
expansion accounts for 5% of all ALS cases (Morgan and Orrell, 2016). ATXN2 was 
found to aggregate and colocalise with TDP-43 in inclusions localised in the spinal cord 
of ALS patients (Elden et al., 2010). Interestingly, a recent study showed that ATXN2 
knockout or knock-down using ASOs to ATXN2 mRNA can significantly increase TDP-43 
transgenic mice survival (Becker et al., 2017).  
1.4.2.3.3 Heavy Neurofilament Subunit (NEFH) 
Insertion and deletion variants of NEFH have been reported in ALS patients by three 
independent studies (Figlewicz et al., 1994; Tomkins et al., 1998; Al-Chalabi et al., 
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1999). These variants were mainly found in sALS and did not show any segregation, 
which might be due to a low penetrance of NEFH variants (Al-Chalabi et al., 2012). No 
further NEFH variants have been associated with ALS patients since the late 1990’s. 
However, mutations in NEFH have recently been identified as a cause of Charcot-Marie-
Toooth Disease (CMT) in four families (Rebelo et al., 2016; Jacquier et al., 2017). The 
mechanism of pathogenicity of NEFH is not clear, however, degenerating lower motor 
neurons of ALS patients often present neurofilamentous inclusions. Furthermore, NEFH 
loss of function might cause impaired axonal transport (Al-Chalabi et al., 2012; Renton, 
Chiò and Traynor, 2013).  
1.4.2.3.4 Charged multivesicular body protein 2B (CHMP2B) 
Rarely identified in ALS cases (1% fALS), variants in this gene were initially reported in 
a large Danish pedigree with FTD (Skibinski et al., 2005; Parkinson et al., 2006). In ALS, 
variants of this gene, although rare, seem to be correlated with a form of the disease that 
prevalently affects lower motor neurons with variable age of onset (Cox et al., 2010). 
CHMP2B is an important element of the enodosomal sorting complexes and a few 
studies have shown that CHMP2B mutants might impair the endosome-lysosome 
mediated autophagy (van der Zee et al., 2008; Urwin, Authier, et al., 2010; Han et al., 
2012). However, the pathogenic mechanism of CHMP2B variants are still unclear. 
1.4.2.3.5 FIG4 
Mutations in FIG4 have been initially found to cause Charcot Marie Tooth (CMT) disease 
(Chow et al., 2007). One of the members of the families involved in the CMT study 
presented motor symptoms compatible with ALS manifestation. For this reason, Chow 
and colleagues decided to screen ~500 ALS patients variants in this gene and found 9 
variants (Chow et al., 2009). Since then no more FIG4 variants have been found in ALS 
cohorts. FIG4 encodes for a lipid phosphatase involved in regulating the amount of 
phosphatidyl-inositol-3,5-biphosphate (PI(3,5)P2). FIG4 null mice have weakly 
expressed PI(3,5)P2, resulting in disrupted autophagy in neurons and astrocytes, caused 
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by impaired formation and recycling of autolysosomes (Ling, Polymenidou and 
Cleveland, 2013). FIG4 positive inclusions were observed in the CNS of patients affected 
by Parkinson’s, Pick’s disease and Lewis body dementia (Kon et al., 2014). 
1.4.2.3.6 TAF15 and EWSR1 
After the discovery of TDP-43 and FUS involvement in ALS, the theory that RNA binding 
proteins might be linked to the disease pathogenesis became a popular belief. For this 
reason a few studies screened TATA-binding protein associated factor 15 (TAF15) and 
Ewing Sarcoma RNA-Binding Protein 1 (EWSR1) for variants in ALS patients (Couthouis 
et al. 2011a, 2012; Ticozzi et al. 2011). These two genes encode for two proteins that 
belong, together with FUS, to the FET family and are, therefore, structurally and 
functionally very similar to FUS and TDP-43 (Zufiría et al., 2016). To date, TAF15 
variants have been found in six families, while three EWSR1 variants have been 
reported in sporadic cases (Couthouis et al. 2011b, 2012; Ticozzi et al. 2011). Due to 
their low complexity domain these proteins are both prone to aggregation and they have 
been found to mislocalise and aggregate in the cytosol of motor neurons of ALS patients 
(Couthouis et al., 2011, 2012). 
1.4.2.3.7  Angiogenin (ANG) 
Chosen as a candidate gene because in linkage disequilibrium with APEX1, previously 
associated with ALS (Hayward et al., 1999), ANG gene encodes for another protein 
involved in RNA homeostasis (Ling, Polymenidou and Cleveland, 2013). To date, 17 
missense mutations have been identified in ALS cases (Chiò et al. 2012; Greenway et al. 
2004, 2006; Millecamps et al. 2010). However, only one of these mutations, occurring at 
higher frequency compared to the others, has been shown to segregate with ALS in a 
Dutch kindred (Pan et al., 2015). The involvement of ANG in ALS remains controversial 
as some of the supposedly pathogenic variants have been identified in healthy controls. 
Furthermore, some of the patients bearing mutations in ANG have also been found to 
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carry mutation in other ALS genes so it may be acting in conjunction as an oligogenic 
risk gene (Luigetti et al., 2011; Lattante et al., 2012).  
1.4.2.4 Genes discovered through whole exome sequencing  
Whole Exome Sequencing (WES) allows the recording of all the protein coding region of 
all known human genes (exome, roughly 2% of the whole genome). This powerful 
technique has been successfully applied in ALS gene hunting for the past few years and 
has identified a large number of genes involved in ALS pathogenesis, which are listed 
below. Whole exome sequencing is particularly useful in diseases, like ALS, that are late 
in onset, rapidly fatal and have low penetrance, which make traditional linkage studies 
challenging. One limitation of WES is that it fails to identify variants that map to non-
coding regions of the genome such as the intronic G4C2 repeat in C9ORF72. However, 
the majority of ALS gene mutations are in exons, making WES an ideal approach. Whole 
genome sequencing is now the preferred methodology but challenges remain in terms of 
manipulating such dataset, therefore prioritising exome analysis is, at the moment, the 
most efficient strategy for gene hunting in ALS.  
1.4.2.4.1 Vasolin Containing Protein (VCP) 
Vasolin Containing protein (VCP) was the first ALS-linked gene to be identified through a 
WES study (Johnson et al., 2010). This gene had already been associated with a form of 
FTD accompanied by Paget’s disease of bone and inclusion body myopathy (IBMPFD) 
(Watts et al., 2007). In some cases, overlapping between the two conditions exists as the 
VCP variants discovered in IBMPFD are also present in ALS cases. VCP mutations 
account for 1-2% of fALS, these patients show classic ALS phenotype with some 
evidence of cognitive impairment (Johnson et al., 2010). This gene encodes for the VCP 
protein (also called p97) that is involved in major autophagy pathways. Knock down of 
VCP in mammalian cells causes accumulation of immature autophagosomes, suggesting 
that this protein plays an important role in autophagy and that its dysfunction may lead to 
TDP-43 aggregation (Ju et al., 2009; Tresse et al., 2010). More generally, VCP is 
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involved in the degradation and recycling of ubiquitinated proteins, and has a similar role 
as other genes linked to ALS (i.e. SQSTM1, UBQLN2). Mutant VCP has been 
associated with mitochondria uncoupling causing a decrease of ATP production, which 
might explain the effect in different tissues (Bartolome et al., 2013). 
1.4.2.4.2 Spatacsin (SPG11) 
Mutations in SPG11 are the most frequent cause of hereditary spastic paraplegia 
associated with a thin corpus callosum (Stevanin et al., 2007). Using exome sequencing, 
SPG11 variants were later linked to ALS in cases presenting a recessive juvenile form of 
the disease. These patients presented mean age of onset of ~16 years old and slowly 
progressive phenotype with a mean survival of 34 years (Orlacchio et al., 2010; Daoud, 
Zhou, et al., 2012). SPG11 encodes for a 2443 amino acid protein, spatacsin. Although 
its physiological function is unknown, this protein has been shown to be required for the 
correct development of spinal motor neurons in zebrafish (Martin et al., 2012).  
1.4.2.4.3 Profilin 1 (PFN1) 
In 2012 another WES study reported PFN1 mutations in families with a form of 
autosomal dominant familial ALS (Wu et al., 2012). This study suggested a frequency of 
1-2% PFN1 variants in fALS, however, many studies have failed to identify mutations in 
this gene at a similar frequency (Chen et al., 2013; Daoud et al., 2013; Dillen et al., 2013; 
Ingre et al., 2013; Lattante et al., 2013; Tiloca et al., 2013; van Blitterswijk et al., 2013; 
Yang et al., 2013; Zou et al., 2013). PFN1 encodes for profilin 1, a protein that plays an 
important role in the regulation of actin polymerisation (Witke, 2004). When 
overexpressed in immortalised cell lines or in mouse primary motor neurons, mutant 
profilin 1, but not its wild type form, clusters in ubiquitinated aggregates (Wu et al., 2012), 
suggesting that mutant profilin 1 drives disease pathogenesis through a toxic gain of 
function mechanism. Overexpression of human mutant profilin 1 in mice causes 
progressive paralysis, motor neuron loss and premature death (Yang et al., 2016). 
Mutant PFN shows reduced ability to bind to actin in vitro which implies that a loss of 
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function disease mechanism may also exist (Wu et al., 2012). Furthermore, the growth 
defect phenotype induced by the deletion of PFN1 orthologue in C. Elegans is rescued 
by the expression of human wild type but not mutant PFN1 (Figley et al., 2014). 
1.4.2.4.4 Matrin 3 (MATR3) 
Mutations in MATR3 were found to be implicated in ALS through exome sequencing of 
four large families of European ancestry and an additional 108 fALS patients (Johnson et 
al. 2014). To date, 15 MATR3 variants have been identified accounting for ~0.8% of ALS 
cases (Fifita et al. 2014; Johnson et al. 2014; Leblond et al. 2016; Lin et al. 2015; 
Marangi et al. 2017; Millecamps et al. 2014; Origone et al. 2015; Xu et al. 2016). ALS 
patients bearing mutations in MATR3 commonly present with bulbar dysfunction and a 
slowly progressive phenotype (≥15 years) (Johnson et al. 2014; Marangi et al. 2017; 
Origone et al. 2015). Mutations in MATR3 have previously been associated with 
autosomal dominant, distal, asymmetrical myopathy with vocal cord paralysis (Feit et al., 
1998; Senderek et al., 2009). MATR3 encodes for a 125 kDa nuclear matrix protein, 
Matrin 3 (MATR3), which binds DNA and RNA and has been shown to interact with TDP-
43 in an RNA dependent way (Johnson et al. 2014). p.S85C mutant showed increased 
interaction with TDP-43 compared to MATR3 wild type and other mutants. Furthermore, 
patients carrying p.S85C show MATR3 and TDP-43 positive inclusions in skeletal 
muscle tissue (Johnson et al. 2014).  
1.4.2.4.5 Tubulin Alpha 4a (TUBA4A) 
An association between TUBA4A and ALS was found through a burden analysis study of 
rare variants in an exome sequencing in familial ALS cases (Smith et al., 2014). To date 
more than 10 variants have been linked to ALS with a low prevalence of FTD (Smith et 
al., 2014; Pensato et al., 2015). However, no TUBA4A variants have been found in a 
large Spanish cohort of FTD patients (Dols-Icardo, Iborra, et al., 2015). Clinically patients 
carrying TUBA4A variants present mainly spinal onset with UMN and LMN features 
(White and Sreedharan, 2016). TUBA4A encodes for Tubulin Alpha 4a, a protein 
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involved in microtubule cytoskeleton formation. It has been shown that some ALS-
associated TUBA4A variants aggregate and fail to be incorporated in microtubules in 
transfected cell line and primary motor neurons and compromise their acetylation (Smith 
et al., 2014; Perrone et al., 2017). This suggests that heterozygous mutant TUBA4A 
might have a dominant negative effect and cause the disease by disrupting transport 
leading to TDP-43 aggregation.   
1.4.2.4.6 Coiled-coil-helix-coiled-coil-helix domain containing 10 (CHCHD10) 
Mutations in CHCHD10 were first reported in a large French family affected by ALS, 
FTD, mitochondrial myopathy and cerebellar ataxia (Bannwarth et al., 2014). The same 
study showed that missense mutations in CHCHD10 cause mitochondria fragmentation 
and respiratory chain deficiency. Many CHCHD10 variants have been identified in ALS 
patients since then (Chaussenot et al. 2014; Chiò et al. 2015; Dols-Icardo et al. 2015; 
Johnson et al. 2014; Pasanen et al. 2016; Penttilä et al. 2016; Zhang et al. 2015) 
accounting for ~1% of ALS cases (Perry, Shin and Tainer, 2016). However, some of the 
disease associated variants have also been often found to be present in controls 
(Abdelkarim et al. 2016; Dols-Icardo et al. 2015; Marroquin et al. 2016; Wong et al. 
2015). CHCD10 encodes for a protein of unknown function. This has been found to be 
located in mitochondria intermembrane space where it is believed to play a role in 
oxidative phosphorylation, resulting in mitochondrial abnormalities when mutated 
(Bannwarth et al., 2014; Chiò et al., 2015). 
1.4.2.4.7 Tank Binding Kinase 1 (TBK1) 
Over 100 heterozygous TBK1 variants have been identified in ALS or FTD patients in 
only two years from the discovery of the implication of this gene in these pathologies. 
Mutations in TBK1 account for 1.9% of all ALS and FTD cases, making TBK1 the fourth 
most common genetic cause of ALS and FTD (Freischmidt et al., 2016). Mutations in this 
gene were initially identified by two independent studies using exome sequencing (Cirulli 
et al., 2015; Freischmidt et al., 2015). Around 30 of the variants found to date are 
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nonsense mutations, resulting in a truncated and likely non-functional protein. These 
mutations have shown high penetrance (up to 75% penetrance in patients over 60 years 
old). However, these numbers are based on a very limited amount of clinical data. 
Further studies with higher number of patients are required in order to draw any 
conclusion on TBK1 penetrance. The proposed hypothesis for TBK1 pathogenicity is 
haploinsufficiency (Cirulli et al., 2015) as most of the functional work on TBK1 variants 
has shown a reduced amount or a loss of function of the protein (Freischmidt et al., 
2015; Gijselinck et al., 2015; Kim et al., 2016; Tsai et al., 2016; Pozzi et al., 2017; van 
der Zee et al., 2017). TBK1 encodes for a multifunctional kinase, Tank Binding Kinase 1 
(TBK1), which is involved in many pathways such as autophagy, response against 
pathogens, inflammation and cell proliferation (Helgason, Phung and Dueber, 2013). An 
increased TBK1 copy number has been previously associated with another 
neurodegenerative disease: primary open angle glaucoma (POAG) (Ritch et al., 2014; 
Awadalla et al., 2015; Cai et al., 2017). Furthermore, heterozygous TBK1 loss of function 
has been associated with herpes simplex encephalitis in childhood, probably linked to a 
diminished toll like receptor 3 (TLR3) mediated immunity activity (Herman et al., 2012).  
TBK1 mechanism of pathogenicity in ALS is, to date, unclear however its pathology is 
similar to sporadic ALS with TDP-43 cytoplasmic inclusions. TBK1 is a multifunctional 
protein involved in many different pathways but the leading hypothesis is that mutations 
in TBK1 might cause defective autophagy. This pathway has already been extensively 
linked to ALS and many disease-associated genes are implicated in this mechanism (i.e. 
UBQLN2, SQSTM1, OPTN). TBK1 has been shown to phosphorylate autophagy 
receptors such as p62 and OPTN (Kiriyama and Nochi, 2015), promoting their ability to 
bind to LC3-II and ubiquitinated proteins (Heo et al., 2015). More specifically, this 
mechanism has been observed in mitophagy, degradation of dysfunctional mitochondria 
through autophagy. In this pathway Parkin, OPTN and Nuclear Dot Protein 52 (NDP52) 
are involved in the activation of TBK1 (Heo et al., 2015) that, in turn, phosphorylates p62, 
NDP52 and OPTN, enhancing their ability to bind defective mitochondria (Lazarou et al., 
2015). This suggests the existence of a positive feedback between OPTN, NDP52 and 
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TBK1 (Heo et al., 2015; Lazarou et al., 2015). A few functional studies have shown that 
some of the TBK1 variants found in ALS patients show defective binding of OPTN and/or 
lack of TBK1 kinase activity (Freischmidt et al., 2015; Gijselinck et al., 2015; Pozzi et al., 
2017). Furthermore, a recent study shows that a TBK1 variant, mapping in the domain 
responsible for OPTN binding, does not co-localise with mitochondria as the wild type 
form of TBK1 does, implicating a defective mitophagy process (Richter et al., 2016). 
Neuropathology observed in a reduced number of ALS, FTD and ALS/FTD patients 
harbouring mutations in TBK1, has reported TDP-43 and p62 positive inclusions in 
various brain regions (Freischmidt et al., 2015; Pottier et al., 2015; Van Mossevelde et 
al., 2016). These studies seem to support the autophagy/mitophagy theory, although no 
definite conclusion can be made, as more extensive studies are needed in order to 
clarify whether TBK1-mediated autophagy is actually involved in the pathogenesis of 
ALS and FTD. 
TBK1 is also involved in the defence against pathogens (Kawai and Akira 2007). 
Functional work on some TBK1 variants found in patients affected by ALS or ALS/FTD, 
has shown reduced or null ability to activate Interferon β (IFNβ) (Freischmidt et al., 2015; 
Gijselinck et al., 2015). In vitro and in vivo studies of the role of type I Interferons (IFNs) 
in ALS has shown a pleiotropic effect of this class of gene in neurone survival (van 
Boxel-Dezaire, Rani and Stark, 2006; Hofer et al., 2010; Wang, Yang and Zhang, 2011). 
Therefore, a reduced ability of TBK1 to activate IFNβ might also play a role in ALS and 
FTD pathogenesis.  
1.4.2.4.8 Annexin A11 (ANXA11) 
In a recent exome sequencing study Annexin A11 (ANXA11) mutations were associated 
with ALS as six mutations were identified in familial (1%) and sporadic (1.7%) ALS 
cases. Four of these variants were functionally investigated and showed defective 
binding of Calcyclin, which caused cytosolic aggregation of ANXA11 encoded protein, 
Annexin A11 (ANXA11). This was observed in transfected cells and striking Annexin A11 
63 
inclusions were identified in the spinal motor neurons and neocortex of a patient carrying 
the most frequent p.D40G mutation (Smith et al., 2017).  
1.4.2.4.9 NIMA Related Kinase 1 (NEK1) 
NIMA Related Kinase 1 (NEK1) mutations were described as strongly associated with 
ALS in an exome sequencing study of ~2900 patients and ~6400 controls (Cirulli et al., 
2015). This result was later confirmed by two other independent studies and it is now 
identified as a risk variant in 3% of European and European-American ALS cases 
(Brenner et al., 2016; Kenna et al., 2016). NEK1 encodes for a kinase, NEK1, that has 
been predicted to interact with ALS2 and VAPB (Cirulli et al., 2015), two proteins 
previously associated with ALS. Although promising, this gene cannot be considered 
causative of ALS until functional studies and/or neuropathology shows biological 
evidence of its involvement in the disease pathogenesis. 
1.4.2.5 Genes identified through genome wide association studies (GWAS) 
GWAS allows the identification of single nucleotide polymorphism (SNP) variants that 
are enriched in a disease cohort compared to matched controls through association 
analysis of genome-wide SNP data. This technique has successfully identified many 
genes associated with ALS (He et al., 2015). However, the biggest limitation for the use 
of GWAS in gene hunting is the sample size needed in order to successfully identify 
disease associated variants. GWAS studies, in fact, require sample size that are vast 
and difficult to achieve especially for low frequency diseases like ALS (Purcell, Cherny 
and Sham, 2003). SNP variants identified through GWAS cannot be considered to be 
directly involved in causing ALS until biological evidence of a functional effect implicates 
their role in the disease pathogenesis. Here I present the genes, identified by GWAS 
studies, which have shown some evidence of their involvement in ALS.  
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1.4.2.5.1 Elongation Protein 3 (ELP3) 
SNPs in ELP3 were associated with ALS in a GWAS study of three different populations, 
which also showed that mutations in this gene in Drosophila cause neurodegeneration 
(Simpson et al., 2009). This gene encodes for a protein, Elongation Protein 3 (ELP3), 
involved in RNA processing (Al-Chalabi et al., 2012), suggesting once again that RNA 
metabolism may play an important role in ALS pathogenesis. However, no ELP3 variant 
has been found, to date, in any familial or apparently sporadic case of ALS (Zufiría et al. 
2016).  
1.4.2.5.2 UNC13A 
SNPs in this gene were associated with ALS susceptibility through a GWAS study (van 
Es et al., 2009) and subsequently shown to influence survival (Jones et al., 2017), a 
result that was confirmed by later studies (Koppers, 2011; Lill et al., 2011). UNC13A was 
also identified as a modifying factor for survival and disease progression rate (van Es et 
al., 2009; Koppers, 2011). This gene encodes for a protein, UNC13A, involved in the 
regulation of neurotransmitter release (van Es et al., 2009). UNC13A deficient mice show 
impaired glutamate signalling and morphological anomalies in spinal cord neurons and 
neuromuscular junctions (NMJ) (Varoqueaux et al., 2005). 
1.5 Pathology 
In the 1860s Charcot observed a loss of anterior horn cells causing muscle wasting 
(amyotrophy) and scarring (sclerosis) in the lateral corticospinal tracts of the spinal cord 
of patients affected by motor neuron disease, and named the disorder after this key 
neuropathological feature (Charcot and Joffroy, 1869). Since then, great progress has 
been made in our understanding of ALS pathology and its main characteristics will be 
explained below. 
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1.5.1 Macroscopic Features 
Post mortem analysis of ALS patient nervous tissue has revealed loss of motor neurons 
in the motor cortex, in the brain stem and in the anterior horns of the spinal cord. In these 
patients muscles targeted by degenerating neurons undergo wasting and atrophy (Taylor 
et al. 2016). When dementia occurs, loss of neurons in the frontal and/or temporal cortex 
is often observed (Abrahams et al., 2005; Chang et al., 2005; Murphy et al., 2007). 
Autopsies of ALS patients have also revealed a loss of white matter, which appears most 
marked in the cortico-spinal tracts (Kiernan and Hudson, 1994; Kassubek et al., 2005; 
Roccatagliata et al., 2009). 
1.5.2 Microscopic Features 
The main pathological hallmark of ALS discovered to date is the presence of protein 
aggregates that are often ubquitinated and referred to as inclusions (Leigh et al., 1988). 
These aggregates have occasionally been found, in more advanced stages of the 
disease, co-localising with eosinophilic inclusions called “Bunina Bodies” (Okamoto, 
Mizuno and Fujita, 2008), however, the biological significance of these remains 
unexplained. TDP-43 aggregates take the form of fine and coarse skeins, granular or 
globular inclusions in the cytoplasm of upper and lower motor neurons and may also be 
present in the frontal and temporal lobe neurons (Figure 1.3) (Arai et al., 2006; Neumann 
et al., 2006; Mori et al., 2008). There are a few pathological hallmarks, briefly described 
in section 1.4.2, which are gene specific. For instance, patients that harbour the 
hexanucleotide expansion on C9ORF72 display intranuclear and cytosolic RNA foci in 
the cerebellum and hippocampus, as well as p62 and ubiquitin positive but TDP-43 
negative inclusions in the cerebellum and frontal and temporal lobes. These inclusions 
have a large stellate structure in the cytoplasm and a small round structure in the 
nucleus (Al-Sarraj et al., 2011), which were subsequently shown to contain di peptide 
repeat proteins (Figure 1.3)(Taylor, Brown and Cleveland, 2016).  
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Figure 1.3 – Characteristic of ALS pathology. Images of tissue analysis showing (from left to right, top to 
bottom) SOD1 aggregates in spinal motor neurons, cytosolic TDP-43 in spinal motor neurons, RNA foci in 
the nucleus and cytosol of a C9 ALS-FTD cortical neuron, GA inclusions in the dentate nucleus of a 
C9ORF72 patient and GR inclusions in the dentate nucleus of a C9ORF72 patient (adapted from Taylor et 
al. 2016).  
Another example of gene specific neuropathology is presented by SOD1 patients, who 
are negative for TDP-43 inclusions, but display SOD1 positive aggregates in motor 
neurons (Figure 1.3) as well as in surrounding cells such as glial cells (Bosco et al. 2010; 
Forsberg et al. 2010, 2011). Neuroglia has been shown to play an ambiguous role in 
ALS presenting both neuroprotective and toxic activity (described in section 1.6.8). 
These might be deleterious for neuron survival through a decline in the production of 
neurotrophic factors, or the release of neurotoxic agents and defective regulation of 
glutamate receptor homeostasis (Staats and Van Den Bosch, 2009).  
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1.6 Pathophysiology of ALS  
The study of ALS genetics has enabled the creation of in vivo and in vitro models that 
have been used to shed light on the biological mechanisms behind ALS, illustrated in 
Figure 1.4. Although substantial progress has been made, the reason behind motor 
neuron degeneration is still not clear. ALS is a complex disease and it is believed that 
several mechanisms are able to contribute to its pathophysiology. Here I will present 
evidence for the major cellular mechanisms identified to date.  
 
Figure 1.4 – Overview of ALS disease mechanism. (adapted from Taylor et al. 2016).  
1.6.1 Protein aggregation 
Protein aggregates are a hallmark of ALS and neurodegenerative disease in general 
(Lagier-Tourenne, Polymenidou and Cleveland, 2010). These inclusions are often found 
in the cytoplasm of spinal motor neurons and they are thought to overload protein 
homeostasis mechanisms, causing further stress to the cell (Saxena and Caroni, 2011; 
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Bendotti et al., 2012). The major component of these aggregates is TDP-43, which 
accumulates in the cytosol, possibly seeded from stress granules and prevents its entry 
to the nucleus leading to nuclear depletion. Interestingly, the majority of ALS cases 
(95%) have TDP-43 positive inclusions and only 1% have TARDBP mutations, 
suggesting that genetic mutations are not essential to its aggregation (Coan and Mitchell, 
2015). TDP-43 is often hyperphosphorylated, ubiquitinated and cleaved, which suggests 
that motor neurons harbouring these inclusions are somehow trying to remove them. 
Similarly, FUS has also been observed co-localising with stress granules and will form 
cytoplasmic inclusions in the motor neurons of ALS patients, although these patients 
always harbour genetic mutations in FUS.  
As mentioned above (section 1.4.2.1.1), patients carrying mutations in the SOD1 gene 
also show SOD1 protein inclusions that often present post-translational modifications. 
Mutant SOD1 result in an unstable protein that misfolds and accumulates in the 
cytoplasm to form SOD1-postive inclusions (Lindberg et al., 2005). Interestingly, these 
inclusions have been found to also contain mutant as well as wild type and post-
translationally modified wild type SOD1 (Bosco et al. 2010; Forsberg et al. 2010; Grad et 
al. 2014). These aggregates are thought to cause neuron death by toxic gain of function, 
altering the physiologic proteosomic function, obstructing axonal transport as well as 
other essential cellular activities (Bruijn et al., 1997, 1998; Williamson and Cleveland, 
1999).  
Patients harbouring the pathological hexanucleotide G4C2 expansion in C9ORF72 also 
display at least three different types of aggregates. As previously mentioned in section 
1.4.2.1.4, the C9ORF72 hexanucleoride expansion can be translated in five different 
dipeptide repeat protein through RAN translation: Poly-GP, Poly-GR and poly-GA, from 
the sense strand (Ash et al. 2013; Mori et al. 2013) and poly-PA, poly-GP and poly-PR, 
from the antisense strand (Gendron et al. 2013; Mori et al. 2013; Zu et al. 2013). These 
proteins aggregate in the hippocampus, frontal cortex, cerebellum, basal ganglia, motor 
cortex (Al-Sarraj et al., 2011; Cooper-Knock et al., 2012; Hsiung et al., 2012; Mahoney et 
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al., 2012; Troakes et al., 2012) and, in reduced amount, in the spinal cord (Gomez-Deza 
et al., 2015; Schipper et al., 2016) of ALS and FTD patients harbouring the C9ORF72 
G4C2 expansion long before symptoms onset (Proudfoot et al., 2014; Baborie et al., 
2015). These inclusions show co-localisation with p62 and ubiquitin but not with TDP-43, 
however, C9ORF72 FTD and ALS patients show TDP-43 pathology in the brain and 
spinal cord (Freibaum and Taylor, 2017).  
Poly-GA is the most abundant DPR found in frontal and spinal cord p62/ubiquitin-positive 
aggregates in C9ORF72 ALS and FTD patients (May et al., 2014; Zhang et al., 2014; 
Gomez-Deza et al., 2015; Mackenzie et al., 2015). These DPRs are the most aggregate 
prone and form amyloidogenic fibrils, which organise in parallel β-sheet structures that 
resemble the amyloid-beta peptide in Alzheimer’s diseases (Chang et al., 2016; Edbauer 
and Haass, 2016). Many in vitro studies have shown that this peptide has toxic features 
in neuronal cultures, which impair important cellular mechanisms such as endoplasmic 
reticulum homeostasis and proteasomal function (May et al., 2014; Zhang et al., 2014). 
These are thought to be caused by direct binding of poly-GA inclusions to important 
proteins involved in these processes (Freibaum and Taylor, 2017). However, the toxicity 
of these specific DPRs is controversial, a few studies, in fact, have shown that poly-GA 
DPR expression does not cause toxicity. Furthermore, even when toxic, poly-GA DPRs 
have been reported to have a far milder phenotype when compared to poly-GR and poly-
PR DPRs expression (Mizielinska et al., 2014; Wen et al., 2014; Freibaum et al., 2015).  
Poly-PR and poly-GR are linear and highly charged arginine rich peptides, which form 
star shaped cytosolic inclusions that are highly toxic in cellular models (Kwon et al., 
2014; Wen et al., 2014; Tao et al., 2015; Lee et al., 2016) as well as Drosophila models 
(Mizielinska et al., 2014; Wen et al., 2014; Freibaum et al., 2015; Lee et al., 2016). 
Expression of poly-PR and poly-GR have been shown to affect the formation and the 
physiologic role of membrane-less cellular structures such as nucleolus or stress 
granules (Lee et al., 2016; Boeynaems et al., 2017). Furthermore they also bind to 
proteins harbouring low complexity domains such as TDP-43 (Lin et al., 2016). 
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Little or no toxicity has been shown for poly-GP and poly-PA. Poly GP inclusions have 
been observed with rare frequency in the brain or spinal cord of C9ORF72 positive ALS 
and FTD patients (Gomez-Deza et al., 2015; Mackenzie et al., 2015) and neither of them 
has shown any toxicity when expressed in Drosophila neurons (Mizielinska et al., 2014; 
Wen et al., 2014; Freibaum et al., 2015; Lee et al., 2016). 
The mechanism through which these different types of aggregates may cause cell death 
is still unknown. These inclusions might themselves be cytotoxic or might be caused by 
other pathway impairments. It has been proposed that defective protein degradation (i.e. 
autophagy and ubiquitin proteasome system) might be involved in the formation of these 
aggregates, this hypothesis will be discussed in the following section.  
1.6.2 Protein degradation 
Damaged organelles and defective proteins in cells are physiologically degraded by two 
interconnected physiological clearance mechanisms: the ubiquitin proteasome system 
(UPS) and autophagy. These processes have both been implicated in ALS by many 
genetic and pathological studies (Taylor et al. 2016). The UPS is usually devoted to the 
clearance of short-lived proteins and small protein complexes while the autophagy 
pathways degrade dysfunctional organelles and larger protein aggregates (Nixon, 2013). 
Autophagy is a multistep process that is tightly regulated, whereby a bi-layered vacuole 
called autophagosome is formed, which is devoted to the engulfment of intracellular 
components. This will later fuse with lysosomes, forming round structures called 
autophagolysosomes. The autophagosome carries on both sides of its membrane 
surface a protein called 1A/1B-light chain 3 (LC3), which plays an important role in 
autophagy as it is recognised by autophagy receptors such as OPTN and p62, which are 
mutated in some ALS patients. These receptors bind to the ubiquinated 
proteins/dysfunctional organelles and conduct them to the autophagosome in order to be 
degraded and recycled (Tanida, Ueno and Kominami, 2008; Kiriyama and Nochi, 2015; 
Oakes, Davies and Collins, 2017). Mutations in many proteins involved in the UPS and 
autophagy have been implicated in ALS including: OPTN, UBQLN2, TBK1, VCP, 
71 
SQSTM1, CHMP2B, FIG4 and VABP have been described in ALS patients (see section 
1.4.2), implicating defective proteostasis in the pathogenesis of ALS. When autophagy-
related  genes 5 or 7 (Atg5 or Atg7), encoding proteins central to the autophagy process, 
are selectively downregulated in the CNS, mice develop sings of neurodegeneration 
(Hara et al., 2006; Komatsu et al., 2006). Furthermore, murine models of mutant SOD1 
and apparently sporadic patients harbouring SOD1 mutations have also shown an 
increase in the number of autophagosomes enclosed within their motor neurons 
(Morimoto et al., 2007; Li, Zhang and Le, 2008; Hetz et al., 2009; Tian et al., 2011).  
1.6.3 RNA metabolism and toxicity 
Mutations in many RNA processing genes have been linked to ALS including: TDP-43, 
FUS, MATR3, hnRNPs, C9ORF72, ATXN2, ELP3, SETX, TAF15 (described in section 
1.4.2). These genes have all been associated with at least one aspect of RNA 
metabolism. Among these, mutations in TDP-43 and FUS are the most frequent in ALS 
cases. These encode for two proteins that play a pivotal role in multiple steps regulating 
gene transcription, splicing, transport, translation as well as microRNA biogenesis (Ling, 
Polymenidou and Cleveland, 2013). A common feature of mutant TDP-43 and FUS 
proteins is their mislocalisation from the nucleus to the cytoplasm (Neumann et al., 2006; 
Sreedharan et al., 2008; Kwiatkowski et al., 2009; Vance et al., 2009). It is not yet clear 
whether their pathogenicity is due to a toxic gain of function, due to their aggregation in 
the cytoplasm, or by a loss of nuclear function or a combination of both (Peters, Ghasemi 
and Brown, 2015). Whatever the mechanism, years of investigation have clarified that 
there is a definite link between their alteration and ALS pathology. Many of these 
proteins are involved in RNA splicing where a loss of function of splicing activity could 
result in major disruption of protein synthesis. In line with these considerations, depletion 
of TDP-43 in murine models has been reported to cause the alteration of splicing events 
in the brain, damaging the production of synaptic proteins (Polymenidou et al., 2011). 
TDP-43 and FUS are also involved in the synthesis of small non-coding RNAs (micro 
RNAs, miRNAs), which are important in the regulation of gene expression. Knock out of 
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either TDP-43 or FUS from in vivo and in vitro models has shown a downregulation of 
miRNAs expression, resulting in an altered RNA silencing activity (Z. Zhang et al., 2013), 
which is consistent with what has been observed in the motor neurons of ALS patients 
(Valdez et al., 2014). Interestingly, the hexanucleotide repeat identified in C9ORF72 
shows a different scenario. The C9ORF72 gene is fully transcribed to RNA edited but it 
retains the G4C2 repeat containing intron that accumulates and aggregates to form 
intranuclear and occasionally cytoplasmic RNA foci, in neurons and glia in the brain and 
spinal cord (DeJesus-Hernandez et al., 2011). Microsatellite expansions have been 
hypothesised to cause neuronal death by toxic gain of function in at least 22 neurological 
diseases. RNA foci, can sequester RNA binding proteins diseases, leading to the 
splicing defects illustrated above (La Spada and Taylor, 2010). Recent work has shown 
that these G4C2 repeats, when transcribed, can form a secondary structure called G 
quadruplexes, which makes the transcript particularly stable and potentially toxic, 
however there is no evidence that they directly bind TDP-43 (Taylor, 2014; Burguete et 
al., 2015; Ishiguro et al., 2016). Furthermore, G4C2 repeats have also shown to generate 
short RNA fragment that have similar functions to miRNAs, again possibly affecting the 
regulation of gene expression (Peters et al. 2015). 
All these studies provide evidence that aberrant RNA metabolism plays an important role 
in the pathogenesis of ALS. Although considerable progress has been made in 
understanding some aspect of these mechanisms, further studies are needed to 
elucidate how RNA metabolism is involved in neuron death and whether it could 
represent a valuable therapeutic target.  
1.6.4 Nucleocytoplasmic transport 
The observation that cytosolic TDP-43 inclusions are present in the vast majority of ALS 
and ~45% of FTD cases (Ling, Polymenidou and Cleveland, 2013), led researchers to 
think that impairment of nuclear transport of TDP-43 might contribute to ALS aetiology 
(Winton et al., 2008). Furthermore, FUS cases also present with FUS cytoplasmic 
inclusions and about half of the FUS ALS and FTD-linked mutations map in the nuclear 
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localisation signal (NLS) of FUS, affecting its translocation to the nucleus (Ling, 
Polymenidou and Cleveland, 2013). Interestingly, a strong correlation between NLS FUS 
mutations and the severity of the patient phenotype has been found (Bosco et al. 2010; 
Chiò et al. 2009; DeJesus-Hernandez et al. 2010; Dormann et al. 2010), suggesting that 
the disruption of nuclear transport exacerbates ALS and FTD pathology. In accordance 
with this, analysis of post mortem brain and spinal cord from ALS and FTD patients 
showed a lower expression and/or mislocalisation of proteins involved in nuclear import 
including karyopherin β1 and β2 (Nishimura et al., 2010; Neumann et al., 2012; Takeuchi 
et al., 2013). 
Moreover, four independent studies have recently shown, using different models 
expressing G4C2 repeats or DPR dipeptides, that a number of proteins involved in 
nucleocytoplasmic transport, including karyopherins, Ran-GTP cycle regulators (such as 
the nucleocytoplasmic transport regulators RanGAP1, which activates RAs-related 
Nuclear protein (RAN) and keeps it in the GTP-bound state, and RanGEF, nuclear 
promoter of the RAN bound GTP by GDP) and members of the Nuclear Pore Complex 
(NPC, including Nup50, Nup205 and Nup107, which are components of the nuclear 
basket), are affected in C9ORF72 in vivo and in vitro models (Freibaum et al., 2015; 
Jovičić et al., 2015; K. Zhang et al., 2015; Boeynaems et al., 2016). Interestingly, one of 
the genetic modifiers of toxicity identified by these studies is GLE1, a gene that codes for 
a nucleoporin protein, involved in nuclecytoplasmic trafficking, which has been recently 
identified in one familial ALS and two sporadic cases (Kaneb et al., 2014). Impairment of 
nucleocytoplasmic transport is, therefore, considered one of the main ALS-FTD 
underlying mechanisms, especially in C9ORF72 ALS cases (Kim and Taylor, 2017).  
1.6.5 Cytoskeletal function  
The cytoskeleton is a cellular structure made of filamentous proteins that gives cells 
mechanical support and its architecture defines the cells morphology and function. It is 
composed by three main classes of proteins (microtubules, actin filaments and 
intermediate filaments) and it is particularly important in neurons, where it supports the 
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axon and plays an important role in intracellular transport. Neurons and motor neurons in 
particular, whose axons can reach a length of one meter, heavily rely on their ability to 
transport molecules from the soma to the synaptic terminus (anterograde transport) and 
vice versa (retrograde transport) (Pasinelli and Brown, 2006). Microtubules form 
structures along the axon that can be used by proteins such as cargoes and motor 
proteins, which, hydrolysing ATP, can transport important cell components such as 
messenger RNA, organelles and ribosomes (De Vos et al., 2008; Poppe et al., 2014).  
Very early on in ALS research, electron microscopy studies on patient material revealed 
axonal swellings enclosing aggregates of neurofilaments (Okamoto et al., 1990; Sasaki 
and Maruyama, 1992). Since then, axonal transport dysfunction has been closely 
investigated in ALS pathology. Murine models of mutant SOD1 present impairment of 
axonal transport, which occurs in pre-symptomatic stages of the disease (Collard, Cote 
and Julien, 1995; Zhang et al., 1997; Williamson and Cleveland, 1999; Kieran et al., 
2005; De vos et al., 2007). Post mortem tissue and mouse models of ALS have also 
shown that motor neurons may retract their axons from their synaptic terminal very early 
on in the course of the disease, before any manifestation of neuronal death (Frey et al., 
2000; Fischer et al., 2004). Furthermore, mutations in genes encoding cytoskeleton 
structure and axonal transport have been found in ALS patients, including: neurofilament 
heavy chain (NFH) (Figlewicz et al., 1994; Tomkins et al., 1998; Al-Chalabi et al., 1999) 
and Dynactin 1 (DCTN1) (Munch et al., 2004; Stockmann et al., 2013). This gene 
encodes for a protein, Dynactin 1, which plays a pivotal role in the retrograde axonal 
transport. In murine models, point mutations on DCTN1 cause impaired vesicular 
transportation, motor neuron degeneration and early death (Puls et al., 2003; Laird et al., 
2008).  
A more recent example of the involvement of the cytoskeleton in ALS is the discovery of 
TUBA4A variants as a possible cause of motor neuron disease (Smith et al., 2014). This 
gene encodes for a protein, Tubulin alpha-4A chain, which is one of the major 
components of microtubules. TUBA4A mutants have been shown to unsettle 
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microtubules assembly and stability, which will probably impair axonal transport in 
neurons (Smith et al., 2014; Vos et al., 2017). Other ALS linked genes involved in 
microtubules or axonal transport such as PFN1 and have been described in section 
1.4.2.  
1.6.6 Mitochondrial dysfunction 
Mitochondria are often described as the cell’s lung. This complex organelle is involved in 
many crucial cellular processes such as: cell respiration and ATP synthesis, calcium 
homeostasis and apoptosis (Delettre et al., 2000; Benard et al., 2007). Mitochondria 
activity is particularly important in neurons as they lack an efficient glycolytic system. 
Furthermore, because of their polarised nature, neurons require mitochondria to be 
transported and placed in sites of intense metabolic demand (Sheng, 2014). 
Mitochondria dysfunction has been implicated in many neurodegenerative diseases such 
as Alzheimer’s, Parkinson’s, Huntington’s disease and ALS (Jiang et al., 2015).  
Evidence of mitochondrial dysfunction includes: reduced ATP production (Mattiazzi et al., 
2002; Le Masson, Przedborski and Abbott, 2014); loss of antioxidant activity and over 
production of reactive oxygen species (ROS, mainly associated with SOD1 variants) 
(Pitkanen and Robinson, 1996; Genova et al., 2004; Adam-Vizi, 2005; Rizzardini et al., 
2005), as well as elevated Calcium (Ca2+) levels in ALS patients (Siklós et al., 1996) and 
animal models (Damiano et al., 2006; Kim et al., 2012; Parone et al., 2013).  
A closer look at mitochondria morphology has revealed that mitochondria are fragmented 
in mutant SOD1 models (Vande Velde et al., 2011; Song et al., 2013; Vinsant et al., 
2013; Magrané et al., 2014) as well as in mutant TDP-43 in vitro and in vivo models (Y. 
Xu et al., 2011; Y.-F. Xu et al., 2011; Wang et al., 2013; Magrané et al., 2014). The 
fragmentation of mitochondria is the result of a tilted balance of mitochondria fission and 
fusion towards fission (Jiang et al., 2015). This balance is important for the preservation 
of mitochondria function (Picard et al., 2013) as fusion helps in the recycling of damaged 
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mitochondria and fission is involved in the generation of new mitochondria (Twig et al., 
2008). 
Another important process involved in the recycling of damaged mitochondria is the 
mitophagy pathway. This is a mitochondria-specific type of autophagy and it is widely 
used by cells in order to maintain a healthy mitochondria population. Interestingly, 
several ALS-linked genes encode for proteins involved in this mitophagy including: 
OPTN, TBK1, VCP, SQSTM1. An example of this impairment, has been highlighted 
recently in the interaction between OPTN and TBK1. TBK1 can be activated by NDP52, 
Parkin or OPTN to function as a kinase and, in turn, phosphorylate NDP52, OPTN and 
p62. This activates these proteins, whose task is to bind LC3II and ubiquitin, functioning 
as autophagy receptors, which will flag damaged mitochondria and lead to their 
degradation by the autophagosome (Heo et al., 2015; Lazarou et al., 2015). Mutations in 
OPTN, TBK1 or SQSTM1 (p62) have been found in ALS patients and may disrupt 
mitophagy, resulting in an accumulation of damaged mitochondria, which are highly likely 
to contribute towards ALS by disrupting axonal transport (Oakes, Davies and Collins, 
2017).  
As mentioned above, mitochondria trafficking is particularly important for motor neurons, 
where, in physiological conditions, these organelles are concentrated at the synaptic 
terminals, which are sites of high metabolic demand (Jiang et al., 2015). ALS patients, 
however, have been found to display a concentration of mitochondria in the soma of 
motor neurons within the spinal cord, which suggests a mitochondria trafficking 
impairment (Sasaki and Iwata, 2007) already highlighted as a possible disease 
mechanism in many neurodegenerative diseases (Guo et al., 2005; Kieran et al., 2005). 
This was confirmed by in vitro and in vivo studies of models expressing disease 
associated mutant TDP-43 (Igaz et al., 2011; Janssens et al., 2013; Wang et al., 2013; 
Magrané et al., 2014) and SOD1 (De vos et al., 2007; Sotelo-Silveira et al., 2009).  
Another important mitochondria feature is their ability to associate with the endoplasmic 
reticulum (ER). Indeed, 5-20% of the total mitochondrial surface is in contact with the ER 
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through specific ER areas called Mitochondria Associated Membranes (MAMs) (Csordás 
et al., 2006; Rowland and Voeltz, 2012; Helle et al., 2013; van Vliet, Verfaillie and 
Agostinis, 2014). ER/mitochondria interaction is an important event which is thought to 
regulate a number of cellular processes including: Ca2+ exchange, intracellular trafficking 
and ER stress (Simmen et al., 2005; MacAskill et al., 2009; Rowland and Voeltz, 2012; 
Helle et al., 2013; van Vliet, Verfaillie and Agostinis, 2014). MAMs have been found to be 
damaged in various neurodegenerative disorders including ALS and FTD (Area-Gomez 
et al., 2012; De vos et al., 2012; Ottolini et al., 2013; Stoica et al., 2014). An example of 
this is VAPB, which is an important MAM protein and has been found to be mutated in 
patients suffering from a severe form of ALS (Nishimura et al., 2004)(section 1.4.2.2.4). 
Mutant VAPB is recruited to the MAMs in higher concentration than the wild type and 
causes major mitochondria calcium peaks by interacting with Protein Tyrosine 
Phosphatase-Interacting Protein 51 (PTPIP51), which tightens the interaction between 
the two organelles (De vos et al., 2012). Furthermore, overexpression of TDP-43 causes 
a peak in Glycogen synthase kinase 3 beta (GSK3β) activation, which reduces the 
strength of ER-mitochondria interaction. Indeed, transgenic TDP43 mice show a lower 
amount of ER-mitochondria associations, a result that is confirmed by NSC34 cells 
overexpressing wild type and mutant TDP-43, which also show reduced calcium 
exchange (Stoica et al., 2014). This highlights the importance of a balanced interaction 
between mitochondria and ER for neuronal health (Krols et al., 2016). 
How these impaired mitochondria dynamics contribute towards causing ALS remains to 
be determined, however, mitochondria abnormalities seem to occur early on in the 
disease, suggesting that these may play a key role in the pathogenesis of ALS (Jiang et 
al., 2015).   
1.6.7 Oxidative stress  
Closely related to mitochondria dysfunction is oxidative stress, this occurs when the 
generation of reactive oxygen species (ROS), mainly through the mitochondria oxidative 
chain, exceeds their removal. Oxidative stress can cause structural damage to DNA and 
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other cell elements as well as alteration of epigenetic mechanism and RNA editing, 
resulting in possible variation of gene expression (Meaney and Szyf, 2005; Hunter and 
McEwen, 2013; Griffiths and Hunter, 2014; Reul, 2014). The involvement of oxidative 
stress in ALS was initially suggested by the analysis of human tissue from ALS patients, 
which showed evidence of oxidative insult to cell components such as proteins, lipids 
and DNA (Agar and Durham, 2003; Henkel et al., 2004; Calingasan et al., 2005; Kato et 
al., 2005). This has been confirmed in cellular and murine models of mutant SOD1 
(D’Amico et al., 2013) and TDP-43 (Duan et al., 2010; Deng, Gao and Jankovic, 2014; 
Jaronen, Goldsteins and Koistinaho, 2014), where oxidative stress may contribute to the 
formation of protein aggregates.  
Oxidative stress was initially thought to be a stand-alone mechanism involved in the 
pathogenesis of ALS. It is now clear that this mechanism is deeply connected with 
mitochondria dysfunction and, probably, protein aggregation, which are, in turn, related 
to autophagy. This shows that ALS is a complex disorder and it is likely to be caused by 
more than one defective mechanism.  
1.6.8 Neuroinflammation 
Neuroinflammation, a specific type of inflammatory response that occurs in the CNS, is 
characterised by the infiltration of T lymphocytes, abundant synthesis of inflammatory 
cytokines and microglial and astrocyte activation in the nervous system. These events 
have been correlated with motor neuron loss in ALS, even in pre symptomatic stages, in 
animal and human tissue (Komine and Yamanaka, 2015). However, the implication of 
neuroinflammation in ALS pathogenesis is a double-edged sword, as immune cells have 
been shown to have both a damaging effect and a protective role for motor neurons (Liu 
and Wang, 2017).  
Many studies have highlighted the importance of microglia in ALS, as the first line of 
immune defence within the CNS. However, sick motor neurons are able to release 
aggregated proteins, such as SOD1 or TDP43, which induces microglia to switch from 
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an M2 phenotype, which has a neuroprotective role, to an M1 phenotype, which 
stimulates the production of pro-inflammatory cytokines, causing neuronal damage 
(Appel et al., 2011; Liao et al., 2012; Roberts et al., 2013; Zhao, Beers and Appel, 2013). 
Furthermore, murine models of mutant SOD1 (mSOD1) have shown that when the 
mSOD1 microglia was replaced with healthy glia, or when the expression of mSOD1 was 
selectively reduced in the mouse microglia, motor neuron degeneration was delayed and 
survival improved (Beers et al., 2006; Boillee et al., 2006).  
Astrocytes are the most abundant glial cells in the CNS and they provide structural as 
well as functional support for neurons. Motor neuron toxicity has been shown to occur 
when astrocytes express mSOD1 in vivo and in vitro, with a toxic effect observed 
uniquely in motor neurons (Di Giorgio et al., 2007, 2008; Nagai et al., 2007). 
T lymphocytes have shown to operate a protective action on motor neurons. The 
infiltration of CD4+ T cells, immune cells devoted to the recruitment of white blood cells 
when in proximity of possibly damaging molecules, is observed early on in the disease 
(Bowerman et al., 2013; Hooten et al., 2015). These play a protective role interacting 
with M2 microglia and astrocytes, and have been found to be lowly expressed in the 
blood of ALS patients (Henkel et al., 2013; Hooten et al., 2015). Interestingly, genetic 
suppression of CD4+ T cells increased disease progression (Beers et al., 2008; Chiu et 
al., 2008).  
From this review, it is clear that disturbance of many different pathways can contribute to 
the pathogenesis of ALS, but their relative importance is debated and interaction is 
complex. Neuroinflammation has been acknowledged as one of the contributors to motor 
neuron degeneration, however, due to the disease heterogeneity and the ambiguous role 
of immune cells, further research is necessary in order to fully understand disease 
related neuroinflammatory mechanisms.   
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1.7 Therapy 
ALS is an incurable disease and the only three drugs approved for the treatment of ALS 
by the Food and Drug Administration (FDA) in the US are: Riluzole, approved over 
twenty years ago, Nuedexta approved in 2010 and edaravone (Radicava), a free radical 
scavenger with neuroprotective properties (Sawada, 2017), approved in May 2017. 
Riluzole is the most commonly prescribed drug and it is believed to act by inhibiting 
glutamate release and reducing excitotoxicity, resulting in an extension of patient mean 
survival by three to six months (Bensimon, Lacomblez, and Meininger 1994; Lacomblez 
et al. 1996; Mitsumoto, Brooks, and Silani 2014).  
The heterogeneity of ALS pathophysiology and genetics represents a great challenge in 
the development of a therapy that is effective for all patients. It is becoming increasingly 
clear that precision medicine will be the way forward in the treatment of this syndrome. In 
line with this, a few targeted treatments have been developed and are undergoing pre-
clinical and clinical trials (Smith et al., 2006; Kieran et al., 2008; Rizvanov et al., 2009; 
Williams et al., 2009; Becker et al., 2017). In 2013 a Phase I study reported that SOD1 
antisense oligonucleotides (ASOs) successfully completed a randomised phase one 
clinical trial on mutant SOD1 fALS patients, which determined that it was safe (Miller et 
al., 2013). A Multi-centered Phase II SOD1 ASOs study is now underway and a Phase I 
trial of ASOs to C9ORF72 G4C2 expansion mutations is due to start imminently. The 
complexity of ALS genetics and the modest numbers of mutant gene carriers, represents 
a significant obstacle in the development of a successful gene targeted therapy for 
sporadic ALS patients.  
Another approach to treatment of ALS, and other neurodegenerative disorders, is stem 
cell transplantation, using either autologous or heterologous neuronal precursor or glial 
cells. Pre-clinical work has shown promising results in animal models (Silani et al., 2004; 
Corti et al., 2007, 2010; Giordano, Galderisi and Marino, 2007; Boucherie et al., 2008; 
Suzuki et al., 2008; Hwang et al., 2009; Kim and de Vellis, 2009; Gu et al., 2010; Wyatt 
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et al., 2011; Thomsen et al., 2014) however the mechanism of benefit is not cell 
replacement, indeed very few if any of the transplanted cells differentiate into motor 
neurons. In 2010 the first clinical trial using neural stem cells (NSCs) and another clinical 
trial for the transplant of bone marrow derived mesenchymal stem cells (MSCs) on a 
mixed cohort of patients with ALS and multiple sclerosis (Karussis et al., 2010) were 
approved in the US and Israel respectively. Both of these studies involved small patient 
numbers and have shown modest benefit. However, it is still too early to determine 
whether stem cell transplant will represent a useful therapy.   
Despite over fifty years of clinical trials, ALS is still considered a terminal disease and 
management is largely palliative. Considerable advances in gene discovery have 
enabled the identification of novel molecular mechanisms involved in the 
pathophysiology of ALS. The study of genetic models has supplied novel therapeutic 
targets, providing hope that this will lead to the development of more effective therapies.   
1.8 Study Aims 
The review of the literature presented above highlights how our understanding of ALS 
has advanced dramatically with progress in genetic and pathophysiological studies but 
that translation into effective therapies is still awaited. Although substantial progress has 
been made, the genetic basis for ~40% of fALS and ~85% of sALS is yet to be 
determined. Furthermore, the disease mechanism for most of the genes that have been 
discovered is unclear. It is crucial to fill these gaps in our knowledge of ALS in order to 
design any effective treatment.  
With this in mind, our team has carried out an extensive whole exome sequencing 
(WES) study of ~700 fALS index cases shared in a collaboration with other international 
researchers. WES has been proven to be a successful approach for gene discovery in 
ALS (section 1.4.2.4). Our team has identified several genes implicated in ALS (Smith et 
al., 2014, 2017), however, we have also discovered novel variants in known ALS genes 
that have provided new insight into disease mechanisms. It is important to replicate and 
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further investigate recently discovered genes in order to corroborate early findings and 
extend our knowledge. Therefore, we decided to investigate two of these variant-
enriched genes, MATR3 and TBK1, in our cohort and in an additional ~200 apparently 
sporadic ALS cases. This characterisation, which will be discussed in the following 
chapters, intended to answer two main biological questions:  
 What is the frequency and distribution of variants in MATR3/TBK1 in our cohorts? 
 How do these mutations affect physiology in cellular models and in patient 
material? 
In addition to this, through an international collaboration, we had access to a Middle 
Eastern consanguineous kindred affected by ALS. WES and subsequent homozygosity 
mapping identified a novel nonsense OPTN mutation. The aim of this project was to 
functionally characterise this OPTN variant in patient material, in order to further 
investigate OPTN role in ALS.  
The final aim of this PhD project was to shed light on the functional mechanisms that 
might be implicated in MATR3, TBK1 and OPTN related pathology, in the hope of 
improving our understanding of ALS pathophysiology and through these insights 




 – Material and methods 
2.1 DNA samples and Exome Sequences 
2.1.1 Familial ALS (fALS) DNA samples   
Analysis of fALS exomes was conducted via exome capture and next generation 
sequencing of DNA from the local Kings College London Motor Nerve clinic, the MNDA 
DNA Bank collection and DNA provided by collaboration from Frank Baas in Amsterdam, 
The Netherlands (n=12), Jacqueline de Belleroche in London, UK (n=18) and Kevin 
Talbot (n=4). All patients had a diagnosis of ALS according to the revised El Escorial 
criteria (Brooks et al., 2000) and at least one affected relative, which classifies them as 
familial ALS cases (fALS). Furthermore, full patient consent was obtained for research. 
Raw exome sequence data from an additional 655 fALS patients was also provided by 
collaboration. The full cohort was, therefore, composed of 932 samples, primarily of 
European ancestry of which 684 were isolated index samples (first to be diagnosed and 
only representative sample of a family) and 248 were multiple affected relatives from 73 
additional kindreds. These were originally from eleven countries, in descending order of 
group size: United States (283), United Kingdom (219), Italy (146), Spain (33), Germany 
(25), Israel (17), Ireland (17), Canada (9), Netherlands (4), Belgium (3) and New Zealand 
(1) (Table 2.1).   
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Patient Nationalities Probands (Affected Relatives) *Pathogenic Variants Identified 
USA 283 (54) 15 
UK 219 (65) 20 
Italy 146 (25) 8 
Spain 33 (11) 6 
Germany 25 (2) 2 
Israel 17 (4) 0 
Ireland 17 (7) 3 
Canada 9 (0) 1 
Netherlands 4 (7) 2 
Belgium 3 (0) 0 
New Zealand 1 (0) 0 
TOTAL 757 (932) 58 
Table 2.1 – Exome sequencing cohort. Breakdown of patient nationalities, probands, affected relative and 
mutation identified per ethnic group. * Number of index cases harbouring likely pathogenic mutations in 
known (published before 2017) or novel ALS genes. 
A small number of patients from the MNDA DNA Bank that had overlapping phenotypes 
such as Progressive Muscular Atrophy (PMA), Primary Lateral Sclerosis (PLS) and 
Progressive Bulbar Palsy (PBP) were also included in this study.  
All fALS exome captured by King’s were screened for mutations in known ALS genes 
(including SOD1, C9orf72, TARDBP, FUS, PFN1, UBQLN2, OPTN, VCP, and ANG). 
Mutant positive cases were excluded from novel variant analysis resulting in a final 
cohort of 699 probands. There has been increasing evidence in recent years of multiple 
oligogenic variants contributing to pathogenesis in some ALS patients (Marangi and 
Traynor, 2014), and so this approach may have prevented us from identifying novel 
variants in carriers of known mutations. However, it is not yet proven that oligogenicity is 
the primary mechanism in most patients with a familial history of disease and the aim of 
this study was to identify novel highly penetrant dominant Mendelian ALS genes, and so 
we believe that this is an appropriate strategy to adopt.  
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About 200 UK samples were previously exome captured in house by two fellow PhD 
students (Athina Soraya Gkazi and Jack W Miller) and sent for next generation 
sequencing at the Biomedical Research Centre (BRC) in Guy's and St Thomas’ NHS 
Foundation Genomics Facility before I joined the laboratory. Exome capture and next 
generation sequencing for the remaining samples were outsourced by us or our 
collaborators. The design of capture probes remained consistent throughout the study.  
2.1.2 Sporadic ALS (sALS) DNA samples 
Some of the samples used in this study had no detectable family history and were, 
therefore, considered sporadic ALS cases (sALS). We had access to a cohort of 174 
sporadic samples, which all had a definite ALS diagnosis that met the revised El Escorial 
criteria with full patient consent. These samples were Sanger sequenced in house in 
order to determine the frequency of mutations for each candidate ALS gene as a 
secondary cohort of cases, described in this thesis, which was discovered through 
exome sequencing of fALS cases. DNA was extracted from post mortem brain tissue 
supplied by the MRC London Degenerative Diseases Brain Bank. 
2.2 Whole Exome Sequencing and data analysis 
Whole Exome Sequencing (WES) allows the sequencing of all coding exons within the 
genome (exome). This process happens in two stages: stage one where specific probes 
isolate and purify known coding sequences from sonicated genomic DNA and stage two 
whereby whole exome is sequenced using Illumina sequencing by synthesis technology. 
This technique is a cost-effective way of identifying novel pathogenic variants. The 
exome, in fact, equals less than 2% of the whole human genome and this portion 
contains 85% of the disease causing variants discovered to date in Mendelian diseases 
(Choi et al., 2009).  
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2.2.1 Exome capture 
The exome capture step was partly (200 fALS UK samples) performed by my fellow 
PhD students Jack W Miller and Athina Soraya Gkazi, and partly outsourced by us and 
our collaborators. This was carried out making sure that the methodology and the design 
of capture probes was consistent throughout the study.  
The exome capture procedure was carried out following the Illumina HiSeq protocol 
(Illumina TruSeq DNA Sample preparation guide) adapted to Nimblegen SeqCap EZ 
Exome library (Roche) version 3.0 (2012). This version comprises over 300,000 exons 
covering over 20,000 genes in the human genome (from RefSeq RefGene CDS 
(GRCh37), CCDS, miRBase v14 databases, 97% Vega, 97% Gencode, and 99% 
Ensembl databases) with a total size of the region covered by the probes of 64 Mb. An 
initial concentration of 5g of DNA was processed. After each step the DNA was purified 
using SPRI Ampure XP beads (Beckman Coultier) and measured using Agilent 
Bioanalyser (Agilent 1000 DNA chip, Roche diagnostics) to check the quality and the 
amount of DNA purified.  
Once the samples were captured, these were subjected to PCR in order to amplify the 
captured DNA. The samples were then washed using Qiagen Elute protocol (Qiagen, 
28106), eluted in 50 l of double distilled water (ddH2O) and ran on an Agilent chip in 
order to verify if the hybridisation with the probes was successful. If this was the case, 
samples were quantified using Qubit Fluorometer (Life Technologies), diluted to a 
concentration of 10pM and sent out for next generation sequencing. 
2.2.2 Next Generation Sequencing 
Samples were sent to the Biomedical Research Centre (Genomics Facility) in Guy's and 
St Thomas’ NHS Foundation Trust where they performed next generation sequencing 
using Illumina platforms (HiSeq2000 and HiSeq2500 machines and in a minority of 
cases the GAII platform). Once the sequencing was completed we obtained the HiSeq 
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raw sequencing data, and these were converted into FASTQ formatted files, which were 
further analysed using the Illumina supplied program bcl2fastq.  
2.2.3 Bioinformatic analysis of WES 
The bioinformatics analysis was performed by my colleagues and bioinformatician Simon 
Topp and Michael Simpson. Novocraft NovoAlign was used to align the FASTQ files to 
the hg19 human reference and variants called with SAMtools v1.1 mpileup producing 
Variant Call Format (VCF) files, which were then normalised with bcftools v1.1 norm. 
Common ancestry between samples was taken from existing familial annotation where 
available and also deduced from IBD analysis in PLINKv1.07 (Purcell et al., 2007). VCF 
files were filtered by the following criteria: DP≥10, QUAL>20, GQ≥50, and MQ≥50. 
Functional annotation, pathogenicity predictions, AdaBoost (ADA) & Random Forest 
(RF) splicing predictions (Jian, Boerwinkle and Liu, 2014) and matches to 1000 genomes 
were added with table_annovar.pl (Wang, Li and Hakonarson, 2010), whereas all other 
annotations including variant frequencies in ESP (http://evs.gs.washington.edu/EVS), 
ExAC (http://exac.broadinstitute.org) and UK10K (www.uk10k.org), were added via 
custom perl scripts. Variants were removed if they had a carrier frequency of greater 
than 1 in 20,000 in the Non-Finnish European subset of ExAC (MAF>0.0025%) or were 
predicted benign by at least 15 of the 20 pathogenicity prediction algorithms. 
Synonymous and intronic variants were assessed by NetGene2 and GeneSplicer and 
excluded if no changes in scores were observed compared to the reference allele at 
locations matching to known Refseq acceptor or donor splice sites. 5’ and 3’ UTR 
variants were excluded from consideration in this analysis.   
2.3 Genetics  
2.3.1 Primer design 
Primers were designed using Primer3 version 4.0.0 (http://primer3.ut.ee/) using a DNA 
sequence template imported from Ensembl Genome Browser 91 
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(http://www.ensembl.org/index.html). They were designed so that they were as specific 
as possible to the template, with a GC content between 40% and 60% and, when 
possible, between 18-24 base pairs. All primers used in this study are listed in Appendix 
A and section 2.3.10. Primers were synthesized by Eurofins MWG (Germany) or 
Integrated DNA Technologies (IDT, Belgium). On arrival, primers were diluted and used 
at a working concentration of 10 M. The optimal annealing temperature was determined 
by gradient PCR using high quality control PCR sample as template. Gradient PCR 
follows a PCR protocol similar to the one illustrated in section 2.3.2 with the difference 
that it uses a different annealing temperature on each one of the 12 columns of a 96 well 
plate with a range that goes from 50 to 68 °C.  
2.3.2 Polymerase Chain Reaction (PCR)  
The Polymerase Chain Reaction is a technique developed by Kary Mullis and colleagues 
in 1980s (Mullis et al., 1986). This technique uses the enzyme DNA polymerase to copy 
a desired fragment of DNA exponentially. The most commonly used enzyme is Thermus 
aquaticus (Taq) Polymerase, an enzyme extracted from a thermo-resistant bacterium. 
This enzyme generates fragments with A-overhangs and, in this study, it was widely 
used for cloning and Sanger sequencing. Other enzymes are also used as the 
Pyrococcus-like Phusion, which has a lower error rate due to its proof reading function 
and generates blunt end fragments. This was used for the amplification of larger, GC rich 
or more problematic fragments. 
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Different protocols were used for either Taq or Phusion polymerase as illustrated below 
(Table 2.2 and Table 2.3). 
Component Volume (l) for one sample 
dH20 13.4 
10x buffer 2.5 
MgCl2 (50 mM) 1.0 
dNTP (5mM) 1.0 
Primer F (10 pmol/l) 1.0 
Primer R (10 pmol/l) 1.0 
Taq polymerase 0.1 
Total Volume 20 
Table 2.2 – Reagents for Taq polymerase PCR reaction. All products were purchased from Thermo 
Fisher 
Component Volume (l) for one sample 
dH20 13.4 
HF 5x buffer 2.5 
dNTP (5mM) 1.0 
Primer F (10 pmol/l) 1.0 
Primer R (10 pmol/l) 1.0 
Phuison polymerase 0.1 
10% enhancer 2.5 
Total Volume 20 
Table 2.3 - Reagents for Phusion polymerase reaction. All products were purchased from New England 
Biolabs 
In the Phusion polymerase reaction a PCR enhancer (Thermo Fisher) was used at 10% 
final concentration in order to facilitate the expansion (see Table 2.3).  
The reagents were mixed together and aliquoted in equal volume (20 l) in a 96 well 
plate PCR together with DNA (concentration range 10-50 ng depending on availability 
and aim of the PCR).  
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The thermal cycling conditions for Taq and Phusion polymerase and are illustrated in 
Table 2.4 and Table 2.5. 
Step Temperature Time Cycles 











Final extension 72 °C 7 min 1 
Hold 4 °C Until needed  
Table 2.4 - Thermal cycling conditions for the Taq PCR protocol. 
Step Temperature Time Cycles 











Final extension 72 °C 10 min 1 
Hold 4 °C Until needed  
Table 2.5 - Thermal cycling conditions for the Phusion PCR protocol 
Thermal cycling was carried out on Tetrad-2 Peltier Thermal cycler (Bio-Rad) or MJ 
Research PTC-225 Gradient Thermal Cycler (Marshall Scientific).  
2.3.3 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to check the quality, abundance and specificity of 
DNA available after PCR amplification.  
Agarose (Helena Bioscience) was melted in 1x tris-acetate-EDTA (TAE) buffer in a 
concentration dependent on the size of the amplicon. 2% agarose gels were used for 
amplicon of 200-800 bp 1% agarose gels were used for amplicons > 800 bp. The molten 
agarose was left to cool and an aliquot of Ethidium Bromide (EtBr) was added to a final 
concentration of 100 g/ml, EtBr intercalates between the DNA strands allowing the DNA 
to be visible under UV light, fluorescing at a wavelength of 302 nm. The gel was left to 
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cool in a mould with an appropriate number of combs inserted. DNA samples were 
mixed with 6X loading dye (Life technologies) and ran for a ranging time (20min-2hr) and 
voltage (120-180 V) depending on the size of the amplicon. For amplicons < 1000 bp a 
100 bp DNA ladder was used (TriDye 100 bp DNA Ladde, NEB), for amplicons > 1000 
bp a 1kb DNA ladder was used (NEB) in order to verify the fragment’s size. 
Agarose gels were imaged with 2UV Benchtop trans illuminator (UVP). 
2.3.4 Gel purification  
When needed, DNA was extracted from the agarose gel. The desired band was cut on a 
UV panel and stored in an Eppendorf tube. The DNA was extracted using QIAquick Gel 
Extraction Kit (Qiagen) following manufacturer’s protocol. Concentration and quality of 
DNA was verified using Nanodrop 2000 spectrophotometer (Thermo scientific) as 
explained in section 2.3.7. 
2.3.5 Sanger sequencing 
Sanger sequencing is a DNA sequencing method that relies on the incorporation of 
fluorescently labelled modified oligonucleotides (with a dideoxynucleotide substitution) 
that cause a premature termination of a polymerase chain reaction.  
2.3.5.1 Purification of PCR product  
Successful Sanger sequencing requires a pre-cleanup stage in order to remove excess 
buffers, dNTPs, salts, primers and enzyme, and purify the PCR product that contains the 
fluorescent dideoxynucleotides (ddNTPs). The PCR product was, therefore, cleaned 
using Microclean (Microzone Ltd, UK). An equal volume of diluted DNA (1:2 or 1:3 in 
water depending on the abundance of PCR product) was added to Microclean (usually 6 
l) in a 96 well plate and spun for 40 minutes at 2,442g. The supernatant was then 
decanted spinning the plate upside down for 15 seconds at 449g, leaving a purified 
product ready for the Sanger sequencing reaction. 
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2.3.5.2 Sequencing reaction  
BDT premix, composed by Big Dye Terminator V1.1 (Life Technologies) mixed with 5X 
sequencing buffer (Life Technologies), was added to the PCR products in order to 
prepare the samples for the sequencing reaction. Big Dye V1.1 contains a mix of the 
fluorescent ddNTPs and DNA polymerase as well as other reagents in a recipe 
optimised for the sequencing reaction. Either a forward primer or a reverse primer was 
added to this mix (volumes illustrated in Table 2.6). The primer was chosen considering 
the distance from the desired sequence (30 bp <distance< 200 bp) and the amount of T 
bases or A bases separating the primer from the desired sequence (not more than 7 of 




Table 2.6 - Volumes added to the sequencing mix. 
The sequencing reaction is similar to a PCR reaction (protocol shown in Table 2.7) with 
the difference that, when a ddNTP (ddA, ddC, ddG, ddT) gets incorporated in the 
sequence, the extension is terminated. This results in the formation of amplicons of 
different lengths with ddNTPs at the 3’ end.  
Temperature (°C) Time Cycles 
96 1 min 1 
96 30 sec 
28 50 15 sec 
60 4 min 
20 2 min 1 
4 Until needed - 
Table 2.7 - Thermo cycling for sequencing reaction. 
Reagent Volume (l) 1X 
ddH2O 6.8 
BDT premix 3 
Primer (10 pmol/l) 0.2 
Total 10 
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2.3.5.3 Purification of sequencing PCR products 
Following the sequencing reaction, the PCR products were cleaned from all the excess 
reagents to avoid unspecific signal and damage to the machine. The samples were 
cleaned through two steps. In the first step samples were cleaned with ethanol (100%) 
complemented with 8% EDTA 125 mM, 32.5 l of the mix were added to each well. The 
plate was centrifuged at 2,442g for 40 minutes. Successively, the supernatant was 
removed spinning the plate upside down at 449g for 15 seconds.  In the second step a 
solution of 70% ethanol in double distilled water was added to each sample in a volume 
of 50 l/well and spun at 543g for 20 minutes to precipitate the extension products. 
Supernatant was removed as described above and 10 l/well of highly deionised 
Formamide (Hi-Di Formamide, Life Technologies) were added. The plate was then 
heated at 95 °C for 2 minutes to resuspend and denature the extension products.  
2.3.5.4 Capillary electrophoresis 
The plate was loaded on an ABI3130 (3130 Genetic Analyzer, Applied Biosystems (ABI) 
Ltd). The extension products, resuspended in formamide, were injected electrokinetically 
in capillaries filled with polymer (POP7, Life Technologies). A high voltage is applied so 
that the DNA fragments migrate towards the cathode depending on their size. This 
technique can distinguish between molecules that differ by one dNTP. These fragments 
move through a laser beam that will excite the fluorescent portion of the ddNTPs. Each 
ddNTP (ddA, ddC, ddG, ddT) will be conjugated to a different fluorophore. The machine 
reads this fluorescence translating it as chromatograms sequences represented by 4 
colour peaks each characteristic of each base (A=green, C=blue, G=black, T=red). 
2.3.5.5 Analysis of the sequencing data 
Raw data was extracted from ABI3130 in the form of chromatogram .ab1 files and 
analysed using Sequencher 5.1 (GeneCodes Corporation, MI, USA). The .ab1 files were 
aligned against the reference sequence downloaded as FASTA format from Ensembl or 
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UCSC. Chromatograms were assembled into contigs and scrutinised by eye to identify 
any variant. Any variant found was investigated further in genome browsers (i.e. 
Ensembl and UCSC). No novel variant was identified in this study by Sanger 
sequencing.  
2.3.5.6 Preparation of plasmid DNA for sequencing 
As plasmid DNA is already pure and in high concentrations, it was diluted to a 
concentration of 10 ng/l. 6l were aliquoted in each well and 4 l of sequencing mix 
was added to each sample. The sequencing mix was prepared as follows: 
 
 
Table 2.8 - Volume added for plasmid sequencing PCR. 
Samples were then spun down, processed through sequencing PCR (as described in 
section 2.3.5.2) and, from this point, treated identically to PCR products.  
2.3.6 Total RNA extraction from primary cell lines 
Patient and control derived fibroblasts (5x106 cells), limphoblasts (1X107 cells) or 
HEK293T (1X107 cells) cells were harvested and washed once in PBS. The total RNA 
was extracted using RNeasy Mini Kit (Qiagen, cat no 74104) according to manufacturer’s 
protocol with some variations. Cells were resuspended on ice using the appropriate 
amount of buffer RLT, they were then lysed using a 1 ml syringe attached to a 27 Gauge 
needle. The lysate was resuspended in 70% ethanol and transferred in a RNeasy Mini 
spin column placed in a 2 ml collection tube and spun at 8000 g for 15 seconds. The flow 
through was discarded and the column was washed with 350 l of RW1 buffer prior 
treatment with RNAse free DNAse set (Qiagen) according to manufacturer instructions. 
This treatment uses DNAse I mixed with RDD buffer to eliminate any trace of DNA 
Reagent Volume (l) 1X 
BDT Premix 3 




contamination. The RNA was then washed in RPE buffer twice and eluted in 30-50 l of 
RNAse-free water in an RNAse free tubes (Ambion). 
2.3.7 Quantitation and purity assessment of nucleic acids  
The concentration and quality of nucleic acid was assessed using Nanodrop 2000 
spectrophotometer (Thermo Scientific). The purity of the nucleic acid was checked using 
the absorbance ratio 260/280 and 260/230. Nucleic acids absorb light at 260 nm, 
therefore, the ratio absorbance 260/280 was used to measure the level of protein 
(absorb light at 280 nm) contamination and it was considered pure if  1.8 for DNA and  
2.0 for RNA. Absorption at 230 nm was used to detect contamination by organic 
compounds (i.e. ethanol contamination) and both DNA and RNA were considered pure 
when a ratio  2.0 was displayed. No samples were considered for any study if the 
quality values veered below the rations given above.  
2.3.8 First strand cDNA synthesis 
The extracted RNA was used as a template for the synthesis of complementary DNA 
(cDNA) through reverse transcription, using SuperScript® III Reverse Transcriptase (Life 
Technologies, cat no 18080044). Up to 1 g of RNA was mixed with 1 l of 50 M oligo 
dT (deoxy-thymine nucleotides), 1 l of annealing buffer and necessary amount of 
RNAse-free water to bring the solution up to 8 l. Oligo dT is a mix of specific primers for 
the polyA tail of mRNA which allows transcription of the mRNA only, starting from the 3’ 
of the transcript. The master mix was incubated at 65°C for 5 minutes and immediately 
placed on ice for at least 1 minute. Then 10 l of 2x reaction mix and 2 l Superscipt 
III/RNAseOUT enzyme mix was added to each sample. For each reaction at least one 
negative control with no enzyme added was included. The samples were then placed on 
the thermal cycler at 25 °C for 10 minutes followed by 50 minutes at 50°C terminating the 
reaction with 5 minutes at 85°C. Samples were stored at -20 °C. 
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2.3.9 Genomic DNA contamination and cDNA synthesis test 
After cDNA synthesis  25ng of newly synthesised cDNA were amplified by PCR using 
GAPDH primers (Table 2.9) in order to verify if the cDNA synthesis had been 
successfully completed. The samples were run alongside at least a negative control 
(RNA reverse transcribed with no enzyme) and a positive control (control DNA) to check 
for the efficiency of the GAPDH PCR. Samples were then run on a 2% agarose gel (see 
section 2.3.3) to check if the newly synthesised samples had been amplified and if the 
negative control showed any DNA contamination.  
2.3.10 Quantitative real-time PCR 
2.3.10.1 Primer design 
Primers were designed as described in section 2.3.1 with the difference that the 
quantitative PCR (qPCR) primers design was optimised for a fragment of 100 bp. When 
possible, they were designed to map on exon extremities overlapping a large amount of 
intronic DNA, so that they would not amplify genomic DNA if present. GAPDH primers 
did not span exon boundaries as they were used for genomic DNA contamination test. 
All the primers used for qPCR in this study are illustrated in Table 2.9.  
Gene Forward primer Reverse primer 
GAPDH ATCATCAGCAATGCCTCCTGC ATGGCATGGACTGTGGTCATG 
RPL13A CCTGGAGGAGAAGAGGAAAGAGA TTGAGGACCTCTGTGTATTTGTC 
SDHA AGGAATCAATGCTGCTCTGG CTGCTCCGTCATGTAGTGGA 
OPTN GTCCTTGATGGAGATGCAGAG GGGCAGGAATGAATCGGAATA 
Table 2.9 - Sequence of the qPCR primers used in this study. 
2.3.10.2 qPCR protocol  
All the samples tested for the same gene were included on the sample plate following 
the sample maximisation approach (Hellemans et al., 2007). cDNA samples were diluted 
to a concentration of 5 ng/l and 4 l of each sample (total of 20 ng) were aliquoted in a 
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white welled 96 well plate (Thermo Scientific) in technical triplicates. The samples were 
mixed with primers at a concentration of 0.2 M, 1X FastStart Universal SYBR Green 
Master (Rox) (ROCHE) diluted to a volume of 20 l with RNAse free water. The protocol 
used for qPCR is illustrated below (Table 2.10). 
Step  Temperature (°C) Time Cycles 
Initial denaturation 95  15 minutes 1 
Denaturation 95 
30 seconds 45 Annealing  60 
Extension 72 
Table 2.10 - Thermo cycling for qPCR reaction. 
For each cycle fluorescence was recorded. A melting curve was developed recording a 
plate read every 1 ºC increase from a temperature range between 60-95 ºC. All the 
samples were run on a Chromo4™ Real-Time PCR detector (Bio-Rad). Furthermore, all 
experiments were carried out in technical and biological triplicates to correct for technical 
and biological variability. The same batch of FastStart Universal SYBR Green Master 
(Rox) was used within the same experiment to reduce variability. For every plate ran, two 
negative controls we added where RNAse free water replaced DNA. For every sample a 
total of three housekeeping genes (GAPDH, RPL13A, SDHA) (Table 2.9) were run and 
used as reference genes in the data analysis process. 
2.3.10.3 qPCR data analysis 
Opticon Monitor™ (Bio-Rad) was used for a first analysis of the data. Using this 
software, a threshold was selected (placing it in a region where all the curves were 
parallel) and melting curve assessed. Data files were then exported to Excel 2017 
(Microsoft), more specifically cycle threshold (CT) and efficiency values were exported. 
Technical replicates were averaged to values representing the biological replicates, used 
for statistical analysis. The analysis was carried out applying the Pfaffl mathematical 




Equation 1 - Pfaffl equation. ∆CTtarget = target gene cycle threshold, ∆CTref = mean of reference gene CTs, 
and E = PCR efficiency.  
The aim of this analysis is to enable a relative quantification of the target gene compared 
to an endogenous standard, represented by the reference genes.  
2.4 Plasmids and Cloning  
2.4.1 Gateway Cloning  
2.4.1.1 pDONR reaction 
A MATR3 construct was ordered from Creative Biogene Biotechnology untagged and 
inserted in the donor vector pDONR221 (Figure 2.1). Primers were designed following 
the procedure illustrated in section 2.3.1 in order to insert an HA tag at the N-terminus of 
MATR3. These primers included the following sequences in-frame, firstly a 
comprehensive of HA tag sequence (on the Forward (5’) primer), followed by the Kozak 
translation initiation sequence and restriction enzyme sites (attB1 on the Forward (5’) 
and attB2 on the Reverse (3’) primers).  
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Figure 2.1 - pDONR221 and pDONR/Zeo vector map (Life Technologies) 
These primers were used to amplify the construct through PCR as described in section 
2.3.2. After PCR the amplicon would contain the N-terminal HA tag, Kozak sequence 
and attB1 and attB2 restriction sites that can be ligated into pDONR221 vector. This was 
done using the Gateway Cloning Protocol (Life Technologies). This includes a BP 
reaction, mixing the enzyme BP clonase with the pDONR221 (75ng) and the amplicon 
(75 ng) at 25 °C for 1 hour, which would cut the pDONR221 on the attP restriction sites. 
These are complementary to the attB restriction sites and recombine with those so that 
the amplicon can be inserted in the pDONR221. Once the reaction had taken place, the 
samples were treated with Proteinase K for 10 minutes at 37 °C to terminate the reaction 
and transformed into bacteria as described in section 2.4.1.2.  
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2.4.1.2  Bacteria transformation and plasmid extraction 
Once the reaction was terminated, 1 μl of the product was added to 20 μl of Max 
Efficiency® DH5α™ competent cells (Invitrogen) and they were incubated for 10-30 
minutes on ice. The samples were then placed at 42°C for 30 seconds and back on ice 
for 2 minutes, in order to heat shock the cells and aid the transformation. Super Optimal 
broth with Catabolite repression (S.O.C.) Medium (Invitrogen) was added to the cells and 
the samples were shaken at 37°C for one hour. The transformed bacteria were plated on 
LB Agar (Sigma-Aldrich) plates with 0.05 mg/ml Kanamycin (Bioline) or 0.1 mg/ml 
Ampicillin (Bioline). Bacteria were left growing overnight at 37°C. Colonies were picked 
and added to LB broth (Sigma-Aldirch) complemented with 0.05 mg/ml Kanamycin 
(Bioline) or 0.1 mg/ml Ampicillin (Bioline). The samples were left shaking at 37°C 
overnight and the morning after the bacteria were mini-prepped with plasmid purification 
kit (Macherey-Nagel) following manufacturer’s instructions. DNA concentration was 
determined using Nanodrop 2000 (Thermo Scientific). 
2.4.1.3 pDEST reaction 
The second step of the gateway cloning is inserting the product in an expression vector 
(pDEST, Invitrogen). After extraction, 75 ng of the entry clone (pDONR comprising of the 
PCR product), was combined with pT-Rex-DEST30 (Life Technologies, 75 ng/μl) 
illustrated in Figure 2.2, TE buffer and LR Clonase™ II (Life Technolgies) and incubated 
at 25°C overnight. The enzyme LR Clonase catalyses the combination reaction that flips 
the construct to the destination vector using the attL restriction sites. The following day 
proteinase K was added, transformation and plasmid extraction was performed as 
explained in section 2.4.1.2. The construct was then ready to be expressed.  
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Figure 2.2 - pT-Rex_DEST30 vector map (Life Technologies) 
In the interest of time, HA-tagged TBK1 wild type (NM_013254.2, Figure 2.4) and FLAG-
tagged OPTN (BC013876, Figure 2.3) were custom made and purchased from Sino 
Biological (Cat no HG11023-NY and HG14478-NF, respectively). 
 




Figure 2.4 - pCMV-HA-ORF backbone map 
2.4.2 Mutagenesis 
All the variants analysed in the current study were modelled using Q5® Site-Directed 
Mutagenesis (New England Biolabs). This kit is designed for rapid incorporation of 
insertion, deletions and single nucleotide changes on double stranded plasmid DNA.  
2.4.2.1 Mutagenesis primer design 
In order for modifications to be incorporated in the plasmids, primers were designed 
using the QuikChange Primer Design platform provided by Agilent 
(http://www.genomics.agilent.com/primerDesignProgram.jsp). Primers were then ordered 
as described in section 2.3.1 and they are listed in Table 6.2. 
2.4.2.2 Mutagenesis protocol 
As specified above all the mutagenesis reactions were carried out using Q5® Site-
Directed Mutagenesis (New England Biolabs) according to manufacturer’s instructions. 
Briefly, this kit includes a Q5 Hot Start High fidelity DNA polymerase, which exponentially 
amplifies the template using custom designed primers (see section 2.4.2.1). The 
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amplicons are then incubated with a mix of kinase, ligase and DpnI that facilitates the 
circularisation of the PCR products. The resulting plasmids are then transformed into 
bacteria, plated on agar plates and extracted (if the reaction is successful) as illustrated 
in section 2.4.1.2. This process is illustrated in Figure 2.5. 
 
Figure 2.5 - Q5 site directed mutagenesis kit overview (NEB). 
Once extracted, the plasmids were quantified (section 2.3.7) and sequenced verified in 
house by Sanger Sequencing as illustrated in section 2.3.5. If the mutagenesis reaction 
was successfully confirmed by sequencing, the plasmids were ready to be transfected in 
mammalian cells.  
2.5 Cell culture  
2.5.1 Human Embryonic Kidney cells 293T (HEK293T) 
HEK293 cell line was generated for the first time in 1977 by Graham and Smiley 
(Graham, 1977). It is derived from human embryonic kidney cells and it is widely used for 
biochemical assays. In this study, we use the HEK293T cell line (DuBridge et al., 1987), 
which expresses the SV40T antigen that allows transfected plasmid that carry SV40T 
origin of replication to be amplified, making this cell line particularly valuable for 
overexpression studies.  
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2.5.1.1 Maintenance of HEK293T 
HEK293T cells were grown in adhesion in Nunc 175cm Flask (Fisher) in Dulbecco’s 
Modified Eagle Medium (DMEM) complemented with 4.5g/L D-Glucose (Life 
Technologie), 10% FBS (Fetal Bovine Serum, Life Technolgies), 5% PenStrep (penicillin 
100 U/ml and streptomicin 100 U/ml, Life Technologies) and 5% L-Glutamine (Life 
Technologies). The flasks were kept in a water-jacketed 5% CO2 incubator.  
Once the cells reached confluence they were passaged by removing the old media, 
washing the adherent cells with Dulbecco's phosphate-buffered saline (DPBS, Life 
Technologies) and incubating the cells for 3 minutes at room temperature with 1 ml of 
Trypsin/EDTA solution (TE, Life Technologies). TE is a mixture of proteases derived from 
bovine pancreas widely used to dissociate cells. Once the cells were detached and 
floating in the TE, 9 ml of complemented DMEM were added to the flask. The FBS in the 
media inhibits the action of the proteases, this avoids any damage to the cells, which 
would happen if the cells were kept in TE for a long time. The mixture of media and cells 
was then pipetted up and down a few times to make sure that the cells were correctly 
dissociated and only 1/10 of the mixture was plated in the flask and ~10 ml of media 
were added to it. The rest of the cells were either thrown away or used for plating.  
All the reagents used in this process were heated at 37ºC for at least 30 min before 
being used in order to avoid any heat shock to the cells.  
2.5.1.2 Plating of HEK293T 
Cells were plated using a method based on the plate surface area. According to this 
method the surface area of the desired well in cm2 (i.e. 6 well/plate, 24 well/plate, 96 
well/plate) was multiplied by the desired confluency (i.e. 25% for transfection 
experiments). The obtained number was then multiplied by the amount of wells to be 
plated (plus one extra to make sure to have enough cells) resulting in the total surface 
area to be plated. The obtained number was then divided by the surface area of the flask 
(usually a T75), this number would give the amount (in ml) of cells needed in a fully 
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confluent flask. The number obtained was multiplied by 10 which was the amount of 
liquid present in the flask. This number was then detracted from the final amount of 
media needed in total. All the numbers used in these calculations were taken from the 
Life Technologies website (Table 2.11) 
Cluster Plates Surface Area (mm2) Growth Medium (ml) 
6 well 962 2-5 
12 well 401 1-2 
24 well 200 0.5-1 
Flasks 
T25 2500 3-5 
T75 7500 8-15 
T160 16000 15-30 
Table 2.11 - Surface area of plates and flasks used in this study (Life Technologies) 
Below is an example of how to calculate the amount of cells needed (in ml) for a full 6 
well plate at 25% confluency starting from a confluent t75 flask: 
Surface area of one well of a 6 well plate = 9.62 cm2 
0.25 * 9.62 cm2 = 2.4 cm2 
7 (wells) * 2.4 cm2 = 16.8 cm2 
16.8 cm2 / 75 cm2 = 0.224 cells needed for a confluent T75 flask 
0.224 * 10 ml = 2.24 ml of cells  
2ml (volume of media needed per well) * 7 (number of wells wanted) = 14 ml 
14 ml – 2.24 ml = 11.76 ml of media needed  
Usually for immunocytochemistry (ICC) a 24 well plate would be used whereas for 
western blotting and other biochemical assays a 6 well plate would be used.  
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2.5.2 SH-SY5Y cell line 
Derived from the bone marrow of a 4 year old neuroblastoma patient SH-SY5Y cell line 
was described for the first time in 1978 (Biedler et al., 1978). This cell line has neuronal 
characteristics such as neuron outgrowth and dopamine activity. These characteristics 
make the cell line a better model than HEK293T for the study of disorders of neurological 
nature. However, these cells are more difficult to grow and transfect and, therefore, less 
useful for biochemical assays.  
2.5.2.1 Mantainance of SH-SY5Y 
SH-SY5Y cells were grown in adhesion on T75 flasks (Nunc, Life Technologies) in 
DMEM-F12 medium (Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12, Life 
Technologies) complemented with 4.5g/L D-Glucose (Life Technologie), 10% FBS (Fetal 
Bovine Serum, Life Technolgies), 5% PenStrep (penicillin 100 U/ml and streptomicin 100 
U/ml, Life Technologies) and 5% L-Glutamine (Life Technologies).  The flasks were kept 
in a water-jacketed 5% CO2 incubator.  
Cells were passaged as described in section 2.5.1.1 with the exception that instead of 
DMEM, complemented DMEM/F-12 was used.  
2.5.2.2 Plating of SH-SY5Y 
SH-SY5Y were plated using the plate surface area method explained in section 2.5.1.2 
with the exception that SH-SHSY grow much slower and were initially plated at a higher 
confluency (~30%).  
2.5.3 Cell transfection 
HEK293T and SH-SY5Ycells were mainly used for overexpression studies. 24 hours 
after plating these cells were transfected with the appropriate plasmid using 
Lipofectamine 2000 (Life Technologies) and OPTIMEM (Life technologies) using the 
following protocol:  
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For a 6 well plate: 
50 µl of OPTIMEM per sample were mixed with 2 µl of Lipofectamine per sample (i.e. for 
6 samples 300 µl of OPTMIMEM were mixed with 12 µl of Lipofectamine), spun down 
and left to rest for 5 minutes. 
In the meantime, for each sample, 1 µg of DNA was mixed with 50 µl of OPTIMEM. 
50 µl of the OPTMIMEM and Lipofecatmine mix was pipetted in each sample, vortexed, 
spun down and left to incubate at room temperature for 20-50 minutes. 
100 µl for each sample were added to each well. Cells were harvested after 48 hours 
from transfection.  
For a 24 well plate the process was very similar with the only difference being in the 
amount of reagents used: the total volume of OPTIMEM used was 25 µl, Lipofectamine 
was used at 0.5 µl/sample and the total amount of DNA used per sample was 250 ng. 
Cells were usually transfected alongside an empty GFP clone used as a positive control 
for the transfection reaction.  
2.5.4 Fibroblast primary lines 
Through a collaboration with Doctor Marc Gotkine (Hadassah University Hospital, Israel) 
we obtained some Fibroblast primary lines from four members of a consanguineous 
Palestinian family affected by fALS and carrying a truncation mutation in OPTN 
(p.S174X). Skin biopsies were obtained in Shaare Zedek Medical Centre and fibroblasts 
were derived following a well-established protocol. Briefly, skin biopsies were minced 
and placed in a 35X10mm cell culture dish in 1 ml medium of BioAmph 2 (Biological 
Industries) in a 5% CO2 incubator at 37ºC. The tissue would then attach to the dish and 
culture fresh media would be added every other day. After a period of 1-3 weeks 
fibroblast would start to attach to the bottom of the well. When 70% of confluency was 
reached, the cell would be trypsinised, harvested and frozen or re plated. Four lines were 
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generated from the family (three carrying a heterozygous truncated mutation on OPTN 
and one carrying a homozygous mutation). Additionally, four fibroblast control lines were 
kindly donated to us from Professor Fiona Watt’s laboratory. These cells were 
commercially available Normal Human Dermal Fibroblasts (NHDF) derived from adult 
female provided by PromoCell (lot number 4032503.1, 4081903.2, 3102301.3, 
4012203.1).  
2.5.4.1 Maintenance of primary fibroblast lines 
SH-SY5Y cells were grown in adhesion on T75 flasks (Nunc, Life Technologies) in 
DMEM complemented with 4.5g/L D-Glucose (Life Technologie), 20% FBS (Fetal Bovine 
Serum, Life Technolgies), 5% PenStrep (penicillin 100 U/ml and streptomicin 100 U/ml, 
Life Technologies) and 5% L-Glutamine (Life Technologies). The flasks were kept in a 
water-jacketed 5% CO2 incubator.  
Once the cells reached confluence they were passaged removing the media, washing 
the adherent cells with DPBS and adding 3 ml of TE (Life Technologies). The cells were 
put back in the incubator for ~5 minutes, the flasks were then gently tapped and, with the 
use of a bright field microscope, cells were examined to make sure that they detached 
from the bottom of the flasks. 4 ml of media was then added to each flask and the cells 
were resuspended in a mix of media and TE. The liquid was then removed from the flask 
and put in 15 ml falcons (Alpha). The falcons were then spun for 4 minutes at 1000 g, 
supernatant was removed, cells were resuspended in media and the appropriate amount 
of cells was replated in the flask. The rest of the cells were either plated (as described in 
section 2.5.4.2), processed for freezing (as described in section 2.5.6) or processed for 
functional studies (as described in section 2.6). Number and date of passage was noted 
on the flask.   
2.5.4.2 Plating of primary fibroblast lines 
Once the cells were pelleted and the supernatant removed, they were resuspended in 1-
2 ml of medium. 19 µl of resuspended cells were mixed with 1 µl of Solution 13 
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(Chemotech, 30 µg/ml Acridine orange mixed with 100 µg/ml DAPI in water).10 µl per 
sample were pipetted in each chamber of a NC-Slide A8 (Chemotech) and loaded on 
NucleoCounter® NC-3000™, which is an image cytometer that uses fluorescence 
imaging to characterise cell properties. Cells were counted using the Viability and Cell 
Count Assay. This program uses the acridine orange staining to identify each cell and it 
uses the DAPI staining to detect the non-viable cells, as DAPI can not penetrate the cell 
membrane if the cell is healthy. This program reveals the amount of cells present in 1 ml. 
Fibroblasts were then plated in the correct amount. Usually ~10,000 cells/well were 
plated for 96 well plates, ~3,000 cells/well were plated for 24 well/plate (usually for 
immunocytochemistry) and ~100,000 cells/well were plated for 6 well/plate. The 
appropriate amount of media was then added to a volume of ~100 µl for a 96 well plate, 
500 µl for a 24 well plate and 2 ml for a 6 well plate.  
2.5.5 B-lymphoblastoid cell lines 
B-lymphoblastoid cell lines were derived from fALS patients and healthy controls by the 
European Collection of Authenticated Cell Cultures (ECACC). Human B cells, extracted 
from patients’ and healthy volunteers’ blood, were infected with Epstein-Barr virus (EBV). 
EBV establishes a latent infection resulting in an immortalised cell line. The cell lines 
derived from patients have the advantage of having an endogenous expression of the 
variant of which the patient is carrier.  
2.5.5.1 Maintenance of B-lymphoblastoid cell lines 
B-lymphoblastoid cell lines were grown in RPMI media (Gibco, Life Technologies) 
complemented with 10% FBS (Fetal Bovine Serum, Life Technolgies), 5% PenStrep 
(penicillin 100 U/ml and streptomicin 100 U/ml, Life Technologies) and 5% L-Glutamine 
(Life Technologies). These cells grow in suspension and were, therefore, kept in upright 
T25 flasks (Nunc, Life Technologies) in a water-jacketed 5% CO2 incubator.  
These cells were passaged weekly by aspirating half of the flask content and replacing it 
with fresh media. The removed flask content was either thrown away or pelleted and 
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processed for RNA extraction (as described in section 2.3.6) or western blotting (as 
described in section 2.6.2). 
2.5.6 Freezing and thawing cells 
For freezing procedures all cells were harvested (trypsinised if they were growing in 
adherence), spun down at 1000g for 4 minutes and the supernatant removed. Cells 
were, then, resuspended in the appropriate amount of FBS complemented with 10% 
DMSO and 500 µl was transferred in each appropriately labelled cryotube (VWR). DMSO 
is a cryoprotective reagent that reduces ice crystal formation when the media around the 
cells freezes. Cryotube were then transferre to a Mr. Frosty™ Freezing Container 
(Thermo Fisher Scientific) and placed at -80 °C.  
When thawed, cells were resuspended in the appropriate and preheated medium and 
transferred in falcon tubes, which were spun at 1000g for 4 minutes to eliminate any 
trace of DMSO, toxic for the cells. Supernatant was aspirated and the cells were 
resuspended in ~2 ml of appropriate media and, if grown in adherence, plated in a T25 
flask until confluence.  
2.6 Functional and biochemical assays 
In this section I will describe all the functional assays used in this study to characterise 
the role of the genes and the variants studied.  
2.6.1 Immunocytochemistry (ICC) 
Immunocytochemistry (ICC) is a widely used technique that allows the visualisation, 
when observed through a fluorescence or confocal microscope, of cellular localisation 
and distribution of specific proteins when labelled with fluorescent antibodies.  
For immunofluorescence, cells were plated in 24 well-plates on thirteen-mm-diameter, 
1.5-mm-thick coverslips (VWR), these were treated with poly-D-lysine (Sigma-Aldrich), a 
positively charged polymer that strengthens the interaction between the cell membrane 
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and the culture surface, for an hour and then washed once with DPBS before plating. 
Depending on whether the cells had to be transfected (in the cases of HEK293T or SH-
SY5Y) or not (in the case of primary fibroblasts) cells were fixed 48 hours or 24 hours 
after plating with 4% paraformaldehyde (PFA) at room temperature for fifteen minutes. 
They were then washed 3 times with DPBS, permeabilised with 0.2% Triton-X-100 
(Sigma) for 30 minutes and blocked with 5% Goat or Donkey Serum (Sigma), depending 
on the choice of secondary antibody, for one hour at room temperature. Samples were 
incubated with primary antibody (Table 2.12) in 1% Goat Serum overnight at 4 °C. They 
were washed twice with DPBS for 10 minutes each time and incubated with fluorescent 
tagged secondary antibodies (Alexa Fluor 488 Goat IgG Antibody, Alexa Fluor 568 Goat 
IgG Antibody, Donkey Anti-Sheep IgG H&L (Alexa Fluor® 568),1/500 Life Technologies. 
Alexa Fluor® 647 AffiniPure Donkey Anti-Chicken IgY (IgG) (H+L), Jackson Immuno 
Reseach 1/500) for fluorescence detection in 1% donkey or goat serum (the choice of 
serum has to stay consistent throughout the protocol) for 2 hours at room temperature in 
the dark. As a negative control samples were incubated with primary antibody only or 
secondary antibody only. Following two 10 minute washes with DPBS cells were 
incubated with DAPI (4’, 6-diamidino-2-phenylindole) to detect the nuclei. Coverslips 
were washed twice in DPBS and mounted on microscope slides (Thermo Scientific) 
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Table 2.12 - Table showing all the antibodies used in this study, their characteristics and their work 
concentration. 
2.6.1.1 MitoTracker  
MitoTracker (Thermo Fished Scientific, M7512) is a cell permanent probe which contains 
a mildly thiol-reactive chloromethyl moiety for mitochondria labelling. This technique was 
used on live fibroblasts.  
Live cells were plated in 24 well plates as described in section 2.5.4.2 and 2.6.1 before 
fixation fresh media was added to the cells containing MitoTracker at a concentraton of 
100nM. The cells were then put back in the incubator for 20 minutes. After the incubation 
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time cells were fixed, washed, incubated with DAPI and mounted on microscope slides 
as described in section 2.6.1. 
2.6.1.1.1 MitoTracker analysis 
Cells were imaged at Leica DM5000B microscope using a 63x HCX PL Fluotar phase 
objective (Milton Keynes, UK). Images were taken randomly across the coverslips being 
careful not to image the same section twice, 15 images were taken per sample.  
The analysis was carried out using Fiji (ImageJ) (Schindelin et al., 2012) more 
specifically, an ImageJ Mitochondrial Morphology macro developed by Ruben K. Dagda 
at the University of Pittsburgh (Dagda et al., 2009). This analysis allows the identification 
of different morphologic characteristics of mitochondria such as area, solidity, 
circumference and average size (see Figure 2.6). In order to obtain an accurate 
identification of singular mitochondria a threshold has to be manually set, for this reason 
the analysis was carried out blinded. The data obtained from this analysis was further 
analysed using GraphPad as described in section 2.7. 
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Figure 2.6 – Mitochondria morphology analysis. Representation of the mitochondria morphology 
analyses conducted on fibroblasts using the ImageJ macro developed by Ruben K. Dagda. 
2.6.2 Western Blotting  
Western blotting (or immunoblotting) is a widely used technique that allows identification 
and quantification of overexpressed or endogenous proteins through the use of an 
electrophoresis system and immuno-labelling.  
2.6.2.1 Cell harvesting and protein quantification assay 
Once the cells had been plated, and transfected when necessary, they were harvested 
using the appropriate buffer, depending on the required assay. For regular western 
blotting, cells were washed with PBS complemented with phosphatase inhibitors 
(PhoSTOP, Roche) and proteinase inhibitors (COMPLETE, Roche) and lysed in 1x lysis 
buffer (62.5 mM TRIS-HCL pH 6.8, 2% SDS, 1% glycerol). All the samples were 
sonicated for 10 seconds each. The amount of protein was quantified using the DC 
Protein Assay Kit II (BioRad) according to manufacturer’s protocol. In order to have an 
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accurate measure of the protein concentration a standard curve was made using a 
ranging concentration of BSA (Bovine Serum Albumin, Fisher Scientific) from 0 to 2 µg/µl 
(total of 9 concentrations, in duplicate, 5 µl per well of a clear 96 well plate (Fisher)). 2.5 
µl of lysate per sample was mixed with 2.5 µl of 1x lysis buffer in a 96 well plate and 
every sample was analysed in technical duplicate. Then 25 µl of a mix of Reagent A and 
Reagent S (50:1) and 200 µl of Reagent B were sequentially added to each sample, the 
plate was then left in the dark for 15 minutes. The absorbance was measured at a wave 
length of 450 nm using FLUOstar Omega plate reader (BMG Labtech). Protein 
concentrations were calculated on the base of the mean absorbance of sample 
duplicates in relation to the BSA standard curve.  
2.6.2.2 Gel electrophoresis 
Once the samples were quantified, 5-20 µg of protein was mixed with an appropriate 
amount of loading buffer (lysis buffer complemented with bromophenol blue for sample 
visualisation) to a volume of 15 µl. These samples were then boiled at 100 ºC for 10 
minutes and loaded, alongside 1.5μl of Precision Plus Protein Dual Color Standard 
(BioRad) used to determine protein size, on a NuPAGE Novex 10% Bis-Tris Midi gels 
(26 wells). These were run in 1x Morpholinepropanesulfonic acid (MOPS, Life 
Technologies) buffer at a ranging voltage of 100-180 V until needed, depending on the 
level of size separation wanted. Furthermore, ice was added in a separate compartment 
to cool down the gel as the temperature increases during the electrophoresis process. 
2.6.2.3 Protein transfer 
Once the proteins in the lysate were separated via gel electrophoresis, they were then 
transferred on a nitrocellulose membrane in order to be detected by immunoblot. This 
was done using iBlot (successively upgraded to iBlot 2, ThermoFisher Scientific) dry 
blotting system according to manufacturer’s instructions. Briefly, NuPAGE™ Transfer 
Buffer (20X) (ThermoFisher Scientific) was diluted in 50 ml of ultra-pure water and 
complemented with 10% methanol. The NuPAGE Novex 10% Bis-Tris Midi gel was 
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removed from the plastic container and washed in transfer buffer for 5 minutes, this was 
then positioned on the transfer stack and the iBlot was operated for 7 minutes. In this 
system, the proteins were transferred to the nitrocellulose membrane using a shortened 
gap between electrodes and high currents for 7 minutes, the proteins bind to the 
membrane thanks to hydrophobic and electrostatic interactions.  
Following the transfer, the membrane was incubated with 1x Pounceau S (Sigma), which 
unspecifically weakly binds to any protein, for 1 minute to verify that the transfer had 
worked correctly. The membrane was then washed in TBS-T (50 mM Trizma base 
(Sigma), 150mM NaCl (Sigma) at a pH of 7.6 complemented with 0.05% Tween20 
(Sigma)) until clear from Pounceau staining.  
2.6.2.4 Immunoblotting 
In order to avoid any unspecific binding of primary or secondary antibody to the 
membrane, this was blocked with either 5% fat free milk (Sigma) or, rarely, 5% BSA 
(Fisher Scientific) in TBS-T for 1 hour.   
The membrane was then incubated overnight at 4ºC with primary antibody in a 1% fat 
free milk or BSA solution. The following day the membrane was washed in TBS-T three 
times and incubated with the relevant IRDye secondary antibodies (1:5000, Li-Cor) 
diluted in TBS-T complemented with 1% fat free milk or BSA for 1 hour at room 
temperature in the dark. The membrane was then washed three times and either 
scanned with the Odyssey Infrared Imaging System (Li-Cor Biosciences) or developed 
using ECL system (as described in section 2.6.2.4.1) to detect the fluorescent signal.  
2.6.2.4.1 Enhanced chemiluminescence (ECL) 
When the signal was predicted to be weak (mainly when detecting endogenous, lowly 
expressed proteins) enhanced chemiluminescence (ECL) method was used to detect 
fluorescent signal. In this technique horseradish peroxidase (HRP) secondary antibodies 
for mouse (Millipore, 12-349) or rabbit (Millipore, 12-348) were used at a concentration of 
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1:2000. Following washes, the membrane was treated with Immobilon Western 
Chemiluminescent HRP Substrate (Millipore, WBKLS0500) following manufacturer’s 
instructions. The mix of reagents was distributed on the membrane and excess reagent 
removed. Following incubation in the dark for 2 minutes, the membrane was inserted in 
an autoradiography cassette and carried to a dark room. Here, a radiography film (VWR 
International, 28-9068-36) was left exposing for the appropriate amount of time 
(depending on signal intensity) and developed using Medical Film Processor SRX-101A 
(Konica Minolta).  
2.6.2.5 Western blot quantitative analysis 
Western blots were quantified using Fiji (Schindelin et al., 2012). Bands representing the 
different proteins were quantified and normalised against loading control. All the 
biological replicates for each experiment were normalised against the average of wild 
type or controls.  
2.6.3 Solubility assay  
This biochemical assay aims to examine the solubility of a given protein. In this study, 
this analysis was used to check whether ALS linked variants can cause altered solubility 
of the protein of interest. This assay can be carried out with a range of detergents that 
have different protein solubilisation abilities. In this study I use the RIPA/Urea based 
assay, which has a moderate level of solubility. 
Transfected HEK293T cells were harvested using PBS complemented with proteinase 
inhibitors (Pi) and phosphatase inhibitors (Pho-STOP), they were spun for 30 seconds at 
10,000 g at 4ºC, the supernatant was removed and the cells were resuspended in 200 µl 
of RIPA buffer (150mM NaCl, 1% triton, 0.1% SDS, 0.5% DOC (2,5-Dimethoxy-4-
chloroamphetamine), 20mM Tris (pH 7.4), proteinase inhibitors (1 tablet per 50mL) and 
phosphatase inhibitors (PhoSTOP; 1 tablet per 50mL)). The cells were left on ice for 10 
minutes and sonicated briefly, 20 µl of lysate was mixed with 20 µl of 2X lysis buffer 
(described in section 2.6.2.1), boiled for 10 minutes and stored at -20 ºC. The rest of the 
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lysate was spun down at 21,293g in 4ºC for 30 minutes, this step separated the insoluble 
fraction (pellet) from the soluble fraction (supernatant). 60 µl of the supernatant were 
mixed with 60 µl of 2X lysis buffer, boiled for 10 minutes and stored at -20 ºC. The rest of 
the supernatant was discarded and the pellet was washed with 1 ml of RIPA buffer twice. 
Samples were then spun at 21,293g in 4ºC for 30 minutes and the supernatant discarded 
again. Pellets were then resuspended in 10 µl of urea buffer (7M Urea, 2M Thiourea, 4% 
CHAPS (3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate), 30mM Tri-HCL 
pH 8.5, stored at -20ºC) and shaken for 30 minutes at room temperature to dissolve the 
insoluble fraction. 10 µl of 2X lysis buffer were added to the insoluble fraction and the 
samples were stored at -20ºC. 
The samples were analysed by western blotting as described in section 2.6.2. Lysate 
fractions were quantified as described in section 2.6.2.1 and an equal amount of the 
three fraction per sample was loaded on the gel. Prior loading the lysate and the soluble 
fractions were boiled for 10 minutes and the insoluble fraction was centrifuged for 30 
minutes at 4 ºC at 21,293g to avoid loading debris on the gel. 
All the fractions were quantified in relation to the lysate and, when possible, normalised 
against a loading control. 
2.6.4 Nuclear/cytoplasmic fractionation  
This assay analyses the ratio of protein contained in the nucleus against the amount of 
protein localised the cytoplasm. This analysis was used to verify whether ALS linked 
variants, found in fALS patients, altered this ratio.   
Transfected HEK293T cells were harvested using PBS complemented with Pi and Pho-
STOP, they were spun for 30 seconds at 10,000 g at 4ºC, supernatant was removed and 
the pellets were resuspended in 70 µl of HBL buffer (10mM Tris pH 7.4, 10mM NaCl, 
3mM MgCl2, 21mM EGTA ((ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic 
acid), 1mM EDTA, proteinase inhibitors) and left on ice for 10 minutes. During this time 
cells were lysed using a 1 ml syringe (Fisher) with a 25G needle (Fisher) 10 times, which 
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would lyse the outer membrane of the cells leaving the nucleus intact. 20 µl of the lysate 
were then mixed with 20 µl of lysis buffer (described in section 2.6.2.1) and stored at -
20ºC. The rest of the lysate was spun down for 5 minutes at 4ºC at 978g. 40 µl of the 
supernatant were mixed with 40 µl of lysis buffer and stored at -20ºC. All the supernatant 
was removed and the pellets were washed in HBL buffer complemented with 1% NP-40 
(Calbiochem) twice, resuspended in 50 µl of RIPA buffer (described in section 2.6.3), 
briefly sonicated and stored at -20ºC. 
Samples were then quantified as illustrated in section 2.6.2.1, diluted in loading buffer 
(described in section 2.6.2.2) and analysed by western blot as described in section 2.6.2. 
All the fractions were quantified in relation to the lysate and normalised against a loading 
control. 
2.6.5 Immunoprecipitation (IP) assay  
This technique allows the precipitation of a particular protein with its binding partners 
through the specific binding of the protein to an antibody. This reveals which proteins 
interact with the protein of interest. In this study this technique was used to verify 
whether the binding of the protein of interest with a specific binding partner was altered 
by the integration of ALS linked variants. In this study IP were carried on with HA tagged 
proteins.  
Transfected (or co-transfected) HEK293T cells were harvested using PBS 
complemented with Pi and Pho-STOP, they were spun for 30 seconds at 10,000 g at 
4ºC, supernatant was removed and the pellets were then resuspended in 150 µl of IP 
buffer (50mM tris pH 7.4, 150 mM NaCl, 1% triton X-100, proteinase inhibitors). Samples 
were left on ice for 10 minutes and then centrifuged at 21,293g in 4ºC for 30 seconds. 
Pellets were discarded and the supernatant transferred in a different tube. 20 µl were 
taken from each sample and mixed with 2x loading buffer (described in section 2.6.2.2) 
complemented with 1M Dithiothreitol (DTT, Sigma) in a 1:4 ratio (i.e. 200 µl of 1M DTT in 
800 µl of loading buffer), boiled for 10 minutes and stored at -20 ºC. The rest of the 
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lysate was then “pre-cleaned” by incubation with 20 µl of Dynabeads Protein G for 
Immunoprecipitation (Life Technologies, 10003D) for 2 hours at 4ºC to avoid any specific 
binding of the protein of interest with the magnetic beads. Following the pre-cleaning 
phase, beads were separated from the lysate using a magnet, 20 µl from each sample 
were mixed with 2x loading buffer complemented with DTT, boiled for 10 minutes and 
stored at -20 ºC. The remaining lysate was then transferred to a new tube where the 
antibody for the protein of interest was added at the appropriate concentration (in this 
study rabbit antibody against HA tag was used at a concentration of 1:100). 20 µl of 
Dynabeads Protein G were added to the mix and the samples were left to roll at room 
temperature for 2 hours. In this time beads would bind to the antibody, which would bind 
to the protein of interest, obtaining its precipitation. After this time beads were separated 
from the flow through using a magnet and 20 µl from each sample (Flow through, FT) 
were mixed with 2x loading buffer complemented with DTT, boiled for 10 minutes and 
stored at -20 ºC. The rest of the supernatant was discarded. The beads were then 
washed six times with 500 µl of IP buffer each time, resuspended in 20 µl of 2x loading 
buffer complemented with DTT and boiled at 100 ºC for 10 minutes.  
IP processed samples were not quantified. 4 µl of lysate (and flow through when 
possible) and 9 µl of IP fraction were loaded on the gel and analysed by wester blotting 
as described in section 2.6.2.  
2.6.6 Phosphorylation assay  
Cells were harvested with PBS complemented with proteinase inhibitors spun down as 
described in section 2.6.2.1 and resuspended in RIPA buffer (see section 2.6.3) 
complemented with proteinase inhibitors. The amount of protein was quantified as 
explained in section 2.6.2.1 and 6 µg of protein per sample was put in a new tube. 
Samples were then sonicated briefly and processed as described in protein 
dephosphorylation protocol provided by abcam 
(http://www.abcam.com/protocols/protein-dephosphorylation-protocol). Briefly, they were 
incubated at 37 °C for 30 minutes with 3µl of 1X CIP buffer (100 mM NaCl, 50 mM Tris-
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HCl, 10 mM MgCl2, 1 mM dithiothreitol, pH to 7.9 at 25ºC) complemented with proteinase 
inhibitors and 3µl of alkaline phosphatase (Roche). As a control all the samples had an 
untreated duplicate that was processed identically only without adding the alkaline 
phosphatase. Samples analysed by western blotting as described in section 2.6.2 with 
the difference that the samples were ran on a NuPAGE Novex 3-8% Bis-Tris Midi gels.  
2.6.7 Non denaturing (or native) gel  
This technique allows the analysis, discerning on the size and the antibody labelling, of 
the interaction of the protein with itself, molecular mass estimations, and assessment of 
the purity of native proteins. In this study, this technique was used to verify the ability of 
TBK1 to homo dimerise when mutated compared to the wild type form. 
In this technique transfected HEK293T cells were harvested with PBS complemented 
with Pis and PHOstop centrifuged at 30 seconds at 10,000 g at 4ºC. Samples were then 
processed using The NativePAGE™ Novex® Bis-Tris Gel system (Thermo Fisher 
Scientific) following manufacturer’s instructions. This system uses Coomassie G-250 
instead of SDS, which confers the protein a negative charge so that they can migrate 
towards the anode during electrophoresis, but it does not disrupt their binding or folding. 
Briefly, samples (24 l) were lysed using 4X NativePAGE™ Sample Buffer (8l, Thermo 
Fisher Scientific) and pipetting samples up and down. Cells were then centrifuged at 
20,000 g for 30 minutes at 4°C and the supernatant was loaded in a NuPAGE Novex 4-
12% Bis-Tris Protein Gels (1.5mm; 10 well, Thermo Fisher Scientific) alongside 
NativeMark™ Unstained Protein Standard (Thermo Fisher Scientific). As a running buffer 
1X NativePAGE™ Anode Buffer was used for the externa chambers of the running tank, 
prepared according manufacutrer’s instructions. 1X NativePAGE™ Cathode Buffer (light 
blue) was used for the internal chamber prepared according to manufacturer’s 
instructions. The gel was run at 150 V for 2 hours and transferred using wet transferred 
method. The gel was removed from its plastic case and placed over a Polyvinylidene 
difluoride (PVDF) membrane, which was pre-activated with methanol for 30 seconds. On 
either side of the PVDF membrane and the gel, filter paper or 4 layers of sponge 
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previously wetted in transfer buffer (50 ml of NuPAGE® Transfer Buffer (20X, Life 
Technologies), 20% methanol, ultra-pure water to 1 litre). This was placed in a transfer 
tank which was filled with transfer buffer. The transfer reaction was operated at 300 mA 
for 1h in ice. Subsequently, the PVDF membrane was incubated with 20 ml of 8% acetic 
acid (Sigma) for 15 minutes to fix the proteins on the membrane. This was then washed 
with ultra-pure water, air dried and rinsed with methanol to remove the stains gained in 
the transfer stage. The membrane was then washed in ultra-pure water, incubated with 
5% BSA as described in section 2.6.2.3 and analysed with immunoblotting as described 
in section 2.6.2.4.  
2.6.8 Membrane potential assay  
This analysis was carried out using the NucleoCounter NC-3000 (Chemotec) and was 
employed to detect disruption of mitochondrial membrane potential in individual cells. 
This is known to precede apoptosis and chemical-hypoxia-induced necrosis as well as 
being an index of the level of mitochondrial damage. This technique uses a lipophilic 
cationic dye (JC-1) that shows a potential dependent accumulation in mitochondria. In 
healthy cells, mitochondrial membranes will be negatively charged and this will cause the 
accumulation of JC-1 in the mitochondrial matrix. When JC-1 accumulates in the 
mitochondria, this forms precipitate which will become red fluorescent. In apoptotic cells, 
the mitochondria potential collapses and JC-1 will remain green fluorescent in the 
cytoplasm.  
In this study, this technique was only used to analyse primary fibroblasts. About 100,000 
cells were harvested per sample as described in section 2.5.4. Pellets were then 
resuspended in 100 l of PBS, 1.25 l of Solution 7 (Chemotech), containing the JC-1 
dye, were added to each sample and incubated for 30 minutes at 37 °C. The stained 
cells were then centrifuged at 400 g for 5 minutes and the supernatant discarded. The 
pellet was then washed with 1 ml of PBS twice and resuspended in 20 l of PBS 
complemented with 1µg/ml DAPI, this will penetrate only dead cells, which will be 
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excluded from the analysis. 10 l of the resuspended cells were then loaded on a NC-
slide A8 (Chemotec) and ran on the nucelocounter using the “Mitochondrial Potential 
Assay” protocol. As a positive control I used a control fibroblast line treated with 100 M 
FCCP for 30 minutes. The analysis was conducted using the positive control as a 
reference to establish an unbiased gating criteria.  
2.6.9 Cell mitochondria stress test  
This assay was carried out using the Seahorse XFe96 Analyser (Agilent), this machine 
allows the measurement of oxygen consumption rate (OCR) and the extracellular 
acidification rate (ECAR) in a 96 well plate format. These two parameters are used to 
compare the metabolic state of the cells, indicating the level of mitochondria respiration 
and glycolysis activity, respectively.  
 
Figure 2.7 - Diagram of the effect of the used compounds in the electron transport chain (Agilent). 
In this study I used the Agilent Seahorse XF Cell Mito Stress Test (Agilent), which 
indicates important parameters of mitochondrial function by measuring the OCR of the 
cells. The assay uses three sequential drug injections (oligomycin, FCCP, and a mix of 
rotenone and antimycin A) and it measures basal respiration, ATP production, maximal 
respiration, and non-mitochondrial respiration at different time points (as illustrated in 
Figure 2.7). Proton leak and spare respiratory capacity are then calculated using these 
parameters.  This test was carried out using the Agilent Seahorse XF Cell Mito Stress Kit 
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(Agilent) following manufacturer’s instructions. Briefly, primary fibroblasts were plated in 
the provided 96 well plate 48 hours before the day of the test at a density of 10,000 
cells/well. The day prior to the assay the machine was switched on and the sensor 
cartridge was left hydrating in Seahorse XF Calibrant (Agilent) in an incubator at 37 °C 
with no CO2. On the day of the test the medium was prepared by supplementing 
Seahorse XF Base Medium (Agilent) with 1 mM pyruvate, 2 mM glutamine and 10 mM 
glucose, warming it up to 37 °C and adjusting the pH to 7.4. The compounds were then 
prepared at the desired stock concentrations and loaded on the cartridge at the 
concentration needed (oligomycin 2 M, FCCP 1M, Rotenone/Antimycin A 0.5 M). 
The cartridge was then loaded on the machine, which was left calibrating while the 
plated cells were kept at 37 °C with no CO2 for 45 minutes. After the incubation time, the 
plate was loaded on the machine and the Agilent Seahorse XF Cell Mito Stress Test was 
started.  
The data obtained from this analysis was downloaded and analysed in GraphPad 




Figure 2.8 - Profile of key parameters of mitochondrial respiration (Agilent). OCR=oxygen consumption 
rate.  
2.7 Statistical analysis  
All statistical analysis was carried out using GraphPad (Prism 7.02). p values were 
considered significant when <0.05. In particular: * refers to p < 0.05, ** refers to a 
p<0.01, ***refers to p<0.001 and **** refers to p< 0.0001. Different statistical test were 
applied on different sets of data. All statistical tests used in this study are explained 
below:  
 A t-test was used to compare the mean of two groups of data. Unless otherwise 
stated, t tests were unpaired, two tailed with 95% confidence intervals. A multiple t-
test using Holm Sidak method (alpha=0.05) was used to compare two groups 
composed by two sets of data.  
 Fisher’s test and Chi square tests were used to analyse categorical variables. Chi 
square followed by Yate’s correction was used on variables of large value.  
 One way ANOVA was used to compare the mean of three or more sets of data. This 
test was adjusted by Dunnett’s correction when means were compared with one 
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control mean, whereas when every mean was compared with every other mean 
Tukey’s correction was used. 
 When three or more groups of data were analysed by two factors a two way ANOVA 




 – Genetic and functional characterisation of TBK1 
ALS-associated variants 
3.1 Background 
In March 2015, heterozygous loss of function variants in TANK-binding kinase 1 (TBK1) 
were found to be significantly enriched in ALS patients against control by two 
independent studies (Cirulli et al. 2015; Freischmidt et al. 2015). Following this 
discovery, over 100 TBK1 variants have been identified in ALS and FTD patients 
(Appendix B), making TBK1 mutations the third or fourth most frequent cause of ALS 
and FTD, respectively, in populations of European ancestry (Freischmidt et al., 2016).  
TBK1 encodes for a ubiquitously expressed 729 amino acid protein kinase, TBK1, which 
is involved in many pathways such interferon (IFN) and pro-inflamatory cytokine 
production in the defence against pathogens (Fitzgerald et al., 2003), autophagic 
digestion of protein aggregates, organelles and pathogens (Thurston et al., 2009; Wild et 
al., 2011; Pilli et al., 2012) and cell growth (Clément, Meloche and Servant, 2008) 
(Figure 3.1).  
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Figure 3.1 - TBK1 molecular pathways. From left to right: TBK1 involvement in autophagy, mitophagy, in 
the production of proinflammatory cytokines and IFN signalling (adapted from Markey et al. 2016) 
3.1.1 An insight into TBK1 structure 
TBK1 is composed by four domains: a kinase domain (KD), responsible for its kinetic 
activity, an ubiquitin-like domain (ULD), a scaffold dimerization domain (SDD) and a C-
terminal domain (CTD), involved in TBK1 association with binding partners such as 
optineurin (OPTN), an important autophagy receptor (Tu et al., 2013) (Figure 3.4a,b). 
TBK1 has been shown to homo-dimerise through a central axis formed by the two SDD 
domains interacting with each other (Figure 3.4c). This structure is stabilised by the ULD 
and the KD that interact with each other and with the SDD axis, forming a globular head 
that stabilises the whole structure (Tu et al., 2013). The linker region between the ULD 
and the SDD also contributes to the tertiary structure by interacting with the SDD axis. 
The interactions between the ULD, the SDD and their linker region are highly 
hydrophobic and prevent the homodimer from being dissociated when carrying out its 
functions. On the other hand, interactions of the KD within this structure are mainly polar 
(Tu et al., 2013).  
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TBK1 activation has been demonstrated to be a multistep process that begins with the 
Lys-63-linked polyubiquitination, which is required for Ser172 phosphorylation within the 
activation loop. This causes a critical change in protein conformation promoting the 
active position of the C-helix in the SDD domain and facilitating the final step of homo-
dimerisation, essential for mature kinase activity (Ma et al., 2012; Tu et al., 2013).  
3.1.2 TBK1 in inflammatory pathways 
In the inflammatory pathways, TBK1 is activated by toll like receptor 3 (TLR3), which is, 
in turn, activated by double strand RNA (dsRNA), mainly carried by retroviruses. Toll like 
receptors (TLRs) are a family of proteins that play an important role in pathogen 
recognition and activation of innate immunity (Markey et al., 2015). TLR3 activates TBK1 
through the recruitment of its adaptor TRIF (TIR-domain-containing adaptor-inducing 
interferon-β). Active TBK1 will, in turn, phosphorylate Interferon Regulatory Factor 3 
(IRF3) which will homodimerise and migrate to the nucleus, where it will carry out the 
transcription of antiviral type I and III interferons (IFNα/β/λ) (Fitzgerald et al., 2003; 
Sharma, 2003; Yamamoto, 2003). TBK1 can also be activated by cytoplasmic factors 
such as RIG-I-like receptors (RLRs), activated by viral RNA (Ishii et al., 2006; Paz et al., 
2006; Loo and Gale, 2011), or cytoplasmic DNA receptors activated by double strand 
DNA (dsDNA) (Sun et al., 2013). TBK1 activation by these factors also results in the 
phosphorylation of IRF3 and, occasionally, IRF7, leading to the production of IFNα/β/λ 
(Ishikawa and Barber, 2008; Saitoh et al., 2009).  
It is not clear whether TBK1’s role in the innate immune response is relevant for ALS 
pathogenesis. Interestingly, several recent studies have demonstrated that some ALS-
associated TBK1 variants abolish or reduce the ability of TBK1 to phosphorylate IRF3 
(Freischmidt et al., 2015; Kim et al., 2016; Tsai et al., 2016; Pozzi et al., 2017). IRF3 
levels were also found to be decreased in patient derived fibroblast harbouring p.I472Sfs 
TBK1 variant (Kim et al., 2016). Furthermore, two studies have shown that interferon 
beta (IFNβ) activation is diminished by some ALS-linked TBK1 variants, when compared 
to wild type (Freischmidt et al., 2015; Kim et al., 2016).  
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3.1.3 TBK1 in autophagy 
Autophagy is a homeostatic process conserved throughout evolution that induces the 
degradation of dysfunctional organelles, unnecessary or unwanted cellular proteins or 
pathogens in order to maintain healthy cell functions (Klionsky, 2007). This process 
takes place intracellularly, where bulk cargo (i.e. protein aggregates or dysfunctional 
organelles) are recruited in autophagic lysosomes for destruction or amino acid recycling 
(Figure 3.2). Autophagy is a tightly regulated and highly specific process which relies on 
the efficient organisation of a vast number of components, autophagy related proteins 
(ATGs) such as beclin-1 (ATG6), ATG16L, ATG12 and ATG5 (Klionsky, 2007; Fujita et 
al., 2008; Klionsky and Schulman, 2014). A special category of proteins, called 
autophagy receptors, including OPTN, nuclear dot protein 52 kDa (NDP52) and p62, 
recognises ubiquitinated cargoes and binds them to the autophagic membrane through 
light chain 3 (LC3-II). LC3-II is found on the surface of the autophagophore, which 
engulfs and recycles the ubiquitinated cargoes into an autophagosome (Stolz, Ernst and 
Dikic, 2014) (Figure 3.1). The role of TBK1 in autophagy has been extensively studied in 
the context of Salmonella infections, where TBK1 is involved in the phosphorylation of 
OPTN and NDP52, which recognise ubiquitinated Salmonella and deliver it to the 
autophagosome (Morton et al., 2008; Thurston et al., 2009). This will, eventually, fuse 
with lysosomes to form a structure called autophagolysosome that degrades and 
recycles its contents (Figure 3.2). TBK1 is also thought to play a key role in the formation 
of the autophagolysosome (Pilli et al., 2012).  
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Figure 3.2 - Overview of the autolysosome formation. Starting from the highly regulated formation of the 
phagophore. Elongation of the membrane around the targets of autophagy and its closure to form the 
autophagosome, which fuses with a lysosome to form the autolysosome, where the degradation takes place. 
MVB, multivesicular body; PAS, preautophagosomal structure. (Adapted from Nixon 2013).  
In the context of ALS, TBK1 has been found to co-localise with OPTN in SOD1 
aggregates in HeLa cells and in a SOD1 transgenic murine model harbouring SOD1 
p.G93A. Here, TBK1 is thought to phosphorylate OPTN on Ser177 which will deliver 
SOD1 protein aggregates to the autophagolysosome (Korac et al., 2013).  
Since TBK1 variants were reported in ALS, a few studies have looked at the interaction 
between TBK1 and OPTN and shown that some ALS-associated nonsense variants, or 
those mapping in the SDD domain (p.L59Ffs, p.R444X, p.Ile472Serfs*8, p.M559R, 
p.E696K, p.690-713del), affect TBK1 binding with OPTN (Freischmidt et al. 2015; Kim et 
al. 2016; Pozzi et al. 2017; Richter et al. 2016; Tsai et al. 2016). Further investigation of 
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how TBK1 is involved in the autophagy pathway and how disease associated TBK1 
variants impact this mechanism is necessary in order to elucidate molecular mechanisms 
involved in these diseases. 
3.1.3.1 TBK1 in mitophagy 
TBK1 has recently been associated with a selective type of autophagy which specifically 
targets damaged mitochondria, mitophagy. This process was discovered in yeast 
(Kiššová et al., 2004), whereby autophagy receptors recognise defective mitochondria 
and carry them to the autophagophore, where these receptors bind to LC3 through their 
LC3-interacting region (LIR) motif (Wild, McEwan and Dikic, 2014). One of the most 
studied pathways that regulates mitophagy is the PTEN-induced putative kinase 1 
(PINK1)/Parkin mediated autophagy (Martinez-vicente, 2017). Disruption of this pathway 
has been linked to Parkinson’s disease (PD), a neurodegenerative disease that 
selectively targets dopaminergic neurons (Kitada et al., 1998; Valente, 2004). When 
mitochondria are damaged PINK1 accumulates in the outer mitochondrial membrane 
(OMM) where it recruits and activates Parkin, inducing its ubiquitin ligase activity 
(Matsuda et al., 2010; Narendra et al., 2010; Shiba-Fukushima et al., 2014). Parkin 
successively ubiquitinates many proteins in the OMM (Geisler et al., 2010; Chan et al., 
2011), these ubiquitinated proteins can then be recognised by autophagy receptors such 
as OPTN (Wong and Holzbaur, 2014; Calcagno et al., 2016) and p62/SQSTM1 (Geisler 
et al., 2010), which will guide the defective mitochondria to the autophagophore as 
described above. The binding of these cargo proteins to the autophagophore depends 
upon activation by TBK1, which is co-recruited together with OPTN (Matsumoto et al., 
2015; Moore and Holzbaur, 2016). Li and colleagues have hypothesised a model where 
both OPTN and TBK1 homodimerise and then associate in a heterotetramer, which is 
stabilised by the interaction of TBK1 CTD (residues 677–729) with OPTN n-terminal 
domain (NTD, residues 26–119). The hetero-tetrameric complex recognises the ubiquitin 
chains assembled by Parkin. TBK1 can now phosphorylate OPTN on Ser177 (Wild et al., 
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2011) and Ser473 (Richter et al. 2016), which will proceed in the mitophagy pathway (Li 
et al., 2016).  
3.1.4 TBK1 in ALS and FTD 
TBK1 was associated with ALS for the first time in 2015 when a WES study found an 
enrichment of TBK1 loss of function variants in 2869 ALS patients when compared to 
6405 controls (Cirulli et al. 2015). This finding was confirmed by an independent study 
which identified a TBK1 mutation segregating with disease in a large family and an 
enrichment of TBK1 variants in 252 fALS. This study was the first to conduct functional 
characterisation of TBK1 mutations and showed that a subset of TBK1 mutations 
impaired IRF3 phosphorylation and/or OPTN binding. 
Since then over 100 variants have been identified in ALS, ALS-FTD and FTD patients 
(Appendix B), however only seven studies have undertaken functional characterisation of 
any variants and the mechanisms underlying mutant TBK1 pathogenicity are still unclear 
(Gijselinck et al., 2015; Pottier et al., 2015; Kim et al., 2016; Tsai et al., 2016; Pozzi et 
al., 2017; van der Zee et al., 2017). There is a general consensus that TBK1 truncation 
mutations cause a loss of function through haploinsufficiency, as hypothesised by 
Freischmidt and colleagues in 2015 (Freischmidt et al., 2015). As illustrated in Figure 
3.3, the most abundant types TBK1 ALS-associated variants are missense variants. The 
pathogenicity of these variants is often determined by co-segregation and in silico 
predictions (Freischmidt et al., 2016), however, these tools are not accurate, and 
functional characterisation is necessary in order to determine the pathogenicity of each 
singular variant. One study has found that some TBK1 missense mutations, including 
p.K401E and p.E969K, result in a lower expression of TBK1, leading once again to the 
haploinsufficiency hypothesis (Pottier et al., 2015). However this does not seem to be 
true for every missense mutation (Freischmidt et al., 2016; Kim et al., 2016). 
Overexpression of some missense variants has shown that these fail to 
phopshorylate/bind IRF3 (i.e. p.R47H, p.D118N, p.R308Q, p.R357Q and p.M559R) or 
bind OPTN (i.e. p.M559R, p.E696K) (Freischmidt et al., 2015; Pozzi et al., 2017). This 
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suggests that missense mutations might be causing ALS and FTD through a loss of 
function mechanism. 
 
Figure 3.3 – Number of TBK1 variants found in ALS and FTD patients divided by subtype. For more 
details and references all variants are listed in Appendix B 
Three post mortem studies have reported neuron loss, TDP-43 proteinopathy as well as 
p62 inclusions in post mortem brain tissue of patients harbouring TBK1 mutations 
(p.Gly272_Thr331del, p.Thr79del, Val97Phefs*2, p.Ala417Ter and p.Arg117Ter together 
with OPTN p.Gly538Glufs*27) (Gijselinck et al., 2015; Pottier et al., 2015; van der Zee et 
al., 2017). The current hypothesis is that loss of TBK1 function impairs autophagy 
leading to the accumulation of TDP-43 aggregates, a hallmark of ALS.  
Table 3.1 - Summary of the clinical data available in the literature. Adapted from Pozzi et al. 2017. 
3.1.5 TBK1 in other pathologies 
Heterozygous missense mutations in TBK1 have been found in patients with herpes 











FTD  M+F M F 
All 110 (80) 57 (17) 16 19 45/39 60.4±10.9 58.1±11.3 62.0±10 
Loss of 
function 
59 (32) 30 (13) 10 12 30/24 62.5±9.7 61.0±9.6 64.3±9.7 
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herpes simplex virus-1 (HSV1) infection (Whitley and Gnann, 2002). It is believed that 
these complication might arise in the case of an impaired TLR3-IFN pathway which can 
be caused by mutations in TBK1 (Zhang et al., 2013). It is not clear how TBK1 causes 
HSE and both dominant negative and haploinsufficiency mechanisms have been 
hypothesised (Herman et al., 2012).  
TBK1 has also been linked to glaucoma, a neurodegenerative disease that affects the 
retinal ganglion cells in the optic nerve that is also linked to OPTN mutations (Quigley, 
2011). More specifically, an increased number of copies of TBK1 has been reported in 
patients affected by normal tension glaucoma (NTG) (Ritch et al., 2014; Awadalla et al., 
2015). Interestingly, in this case the disease is thought to be caused by a gain of function 
(Fingert et al., 2011), presenting a different disease mechanism from ALS.  
3.1.6 TBK1 mouse models 
TBK1 in vivo characterisation has been particularly challenging. TBK1 is highly 
conserved in mammals (Tojima et al., 2000) and homozygous deletion of TBK1 in mice 
is lethal early on in the embryonic stage due to apoptosis and hepatic tissue loss 
(Bonnard et al., 2000). However, a mouse model expressing a truncated form of TBK1 
(devoid of exon 2, in the kinase domain) in homozygosity, survives the embryonic phase 
and shows a reduced levels of TBK1 protein, with no kinase activity. Macrophages from 
these mice have shown reduced IRF3 DNA binding property and IFNβ response, 
however, there was no mention of any neurological phenotype or autophagy deficits 
(Marchlik et al., 2010).   
3.2 Aim of this project 
The aim of this project was to identify and functionally characterise a subset of protein 
changing and potentially damaging TBK1 variants, identified in a cohort of 699 fALS 
cases. The ultimate aim of the project was to contribute to the clarification of TBK1 role 
in the pathogenesis of ALS.  
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3.3 Material and methods  
Cell culture and molecular and biochemical assays have been carried out as described 
in Chapter 2. Techniques specific to this chapter are explained below.  
3.3.1 Nucleotide variant and significance analysis   
This analysis was carried out by the Shaw lab bioinformatician Simon Topp. To assess 
the relative abundance of TBK1 variants in our patients, a burden test was performed 
using ExAC database as a control cohort. In brief, significance was assessed in the 
burden test using a Fisher’s Exact, two tailed statistic calculated on the number of fALS 
and ExAC Non-Finnish European (NFE) variants remaining after annotation and filtering 
by the criteria described in section 2.2.  
Common ancestry between samples was taken from existing familial annotation, where 
available, and also deduced from inheritance by descent (IBD) analysis in vcftools (Yang 
et al., 2011) and King (Manichaikul et al., 2010), using only variant positions covered to a 
depth >10 in >85% of fALS cases, and recoding all missing data to a heterozygous 
reference genotype (0/0).  
3.3.2 PCR amplification and sequencing of c.992+1G<A (p.G272_T331del) 
RNA was extracted and cDNA synthesised from the lymphoblastoid cell lines derived 
from the patient carrying the c.992+1G<A (p.G272_T331del) mutation and from a 
healthy control, as described in section 2.5.5. The whole TBK1 gene was then amplified 
using primers located in the first and last exons to amplify the entire open reading frame 
of the transcript. The product was sequenced using the forward and reverse primers 




 Forward Reverse 
Amplification ATGCAGAGCACTTCTAATCATCTGTGGC CTAAAGACAGTCAACGTTGCGAAG 
Sequencing TTGAAGGGCCTCGTAGGAAT TCAGCCATCGTATCCCCTTT 
Table 3.2 – Primers used for amplification and genotyping of c.992+1G<A (p.G272_T331del). Primers 
were designed using Primer 3 as described in section 2.3.1. Sequences are represented 5’ – 3’. 
3.4 Results 
3.4.1 No TBK1 variants are present in TBK1 variant hotspots in 174 sALS cases 
In order to determine whether the variants identified in the exome sequencing project 
were also found and possibly replicated in a cohort of 174 apparently sporadic cases, I 
Sanger sequenced exon 2, 3, 5, 6, 7, 8, 9, 12 and 18. This was also conducted to 
identify any novel TBK1 mutations. When this project was initiated in 2015, these were 
considered hotspots for TBK1 ALS-linked mutations. The replication of the same variant 
in familial and apparently sporadic ALS cases is considered further evidence of the 
variant pathogenicity, however, no variants were identified in this cohort. 
3.4.2 Whole Exome Sequencing in a fALS cohort detects 16 TBK1 variants  
Exome sequencing had been performed by previous lab members on 699 index cases 
from a cohort of fALS from eleven countries (UK, USA, Italy, Spain, Canada, Germany, 
Netherlands, Belgium, New Zealand, Israel and Ireland) (Table 2.1). These patients were 
negative for mutations in other known ALS genes including: SOD1, TDP43, C9ORF72, 
FUS, PFN1, UBQLN2, OPTN, VCP, and ANG, and the intronic C9ORF72 repeat 
expansion. The DNA extraction and exome capture were performed by previous lab 
members Athina Soraya Gkazi and Jack Miller and sequencing was outsourced mainly 
to the Genomic Core Facility at Guy’s Hospital.  
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Exome sequence data analysis described below was performed by Simon Topp  who 
identified sixteen potentially deleterious protein-changing variants in TBK1, which were 
novel, or had an ExAC NFE carrier frequency of <1:20,000 individuals (Table 3.3). In 
concordance with results from other published ALS studies, this showed an abundance 
of potentially protein-changing TBK1 variants in our familial cohort (p=1.02e-10, Fisher’s 
two-tailed test). Thirteen of these variants were absent from the following databases: 
1000 genomes, UK10K, Exome Variant Server (EVS), and ExAC databases (n > 
72,000). Two variants (p.R357Q, p.C471Y) were found once and one variant (p.R358H) 
was found. The p.G217R variant is present in two Dutch cases predicted to be first 
degree relatives (King kinship coefficient=0.314, vcftools Ajk=0.451), and is their only 
shared novel variant in a gene or pathway previously linked to ALS. Interestingly, the 
variant p.R357X is also present in a single fALS case in the ALS data browser (ALSdb, 
http://alsdb.org/index.jsp), however, this individual is unlikely to be closely related to the 
p.R357X carriers identified in our sequencing as they do not share any other rare 
variants. Amongst the previously excluded fALS samples, another novel missense 
variant (p.Y394D) was identified in a patient who harboured the known pathogenic 
p.M337V TARDP mutation, which segregated in their affected sibling. However, the 
available exome data did not have sufficient coverage to determine if the sibling also 
shared the TBK1 variant and DNA was not available to allow us to perform Sanger 
sequencing. Furthermore, the TBK1 variant p.R358H was present in both first-degree 
relatives of a kindred, but both were also carriers for the particularly aggressive p.R521C 
FUS mutation.  
By mapping TBK1 missense variants separately from nonsense variants we observed a 
striking difference in their distribution (Figure 3.4). Whilst nonsense variants were spread 
across the whole protein, missense variants tended to cluster within the functional kinase 
(KD) and ubiquitin-like domain (ULD). Interestingly, the ULD has been reported to 
interact with both the SDD and KD and these interactions play a vital role in the correct 
folding and dimerization of TBK1 (Li et al., 2012; Tu et al., 2013).  
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From a clinical point of view, the patients analysed in this study display an age of onset 
of 55.8 and a ration of male to female of 8/8 with an average duration of the disease 

























2 c.4C>T p.Gln2Ter 1 0/82,513 F ALS S 60 - (Cirulli et al. 2015; Gijselinck et al. 2015) 
9 c.1069C>T p.Arg357Ter 1{1} 0/82,519 F ALS UL 76 - (Cirulli et al. 2015) 
18 c.1869_1875del p.Met623IlefsdTer9 1 0/82,359 F ALS - 43 20.4 - 
18 c.1887_1890del p.Gln629HisfsTer4 1 0/82,445 F ALS - - - - 
In Frame 
Deletions 
4 c.236_238delCAA p.Thr79del 1 0/82,314 M ALS R 67.8 7.3 (van der Zee et al., 2016) 
- 992+1 G>A p.Gly272_Thr331del 1{1} 0/80,635 M ALS - 46 24 - 
18 c.1928_1930delAAG p.Glu643del 1{1} 0/82,323 M ALS UL 64 48 
(Cirulli et al. 2015; Freischmidt et al. 2015; Gijselinck 
et al. 2015; van der Zee et al. 2016) 
Missense 
Variants 
2 c.64A>C p.Asn22His 1{1} 0/82,490 F ALS - 49 12 (Cirulli et al. 2015) 
2 c.92A>G p.Thr31Ala 1 0/80,639 M ALS - - - - 
5 c.385A>G p.Asn129Asp 1 0/82599 M ALS L 68 - (Cirulli et al. 2015) 
6 c.649G>A p.Gly217Arg 1 (1*) 0/82,595 M,M ALS - - - (Cirulli et al. 2015) 
9 c.1070G>A p.Arg357Gln 1 {1} 1/82,519 M ALS LL 50 94 (Freischmidt et al., 2015; Pozzi et al., 2017) 
9 c.1073G>A p.Arg358His 1(1*) 7/82519 - - - - - - 
9 c.1180T>G p.Tyr394Asp 1{1#} 0/82,080 F ALS B 40 - (Cirulli et al. 2015) 
12 c.1412G>A p.Cys471Tyr 1 1/79,400 F ALS - - - (Cirulli et al. 2015) 
15 c.1694A>C p.Gln565Pro 1 {1} 0/75,603 F ALS UL 50 36 (Cirulli et al. 2015) 
Table 3.3 – TBK1 mutations identified in ALS patients by this study and their clinical phenotype. a Mutation nomenclature as recommended by the Human Genome Variation 
society www.hgvs.org, utilising +1 as the A of the initiator Met codon, translation start site. (*) affected relative from the present cohort. Cases number=699. The number in brackets ({}) 







3.4.3 Selection of subset of variants likely to be pathogenic  
To focus our functional characterisation of TBK1 variants identified in this cohort, a short-
list of three variants from the sixteen found was chosen on the basis of the following 
criteria. The first selection criterion was based on familial segregation and replication 
between published studies. To date, only one TBK1 missense mutation segregating with 
disease within a family has been identified (van der Zee et al., 2017). We have shown 
relatedness for two individuals in our exome cohort carrying the p.G217R variant that 
made it a priority to study. The p.R357X variant was also detected in a second individual 
in ALSdb database, which is a further evidence of pathogenicity. The second criterion 
considered was the proportion of algorithms which predicted the variant to be damaging, 
and the third criterion was the location of the variant in the functional domains of TBK1 
based on the homodimer crystal structure (PDB 4IM0, Figure 3.4). Three variants all 
scored highly: p.G217R (located in the KD, shared by an affected relative, and predicted 
to be damaging by 17/20 applied algorithms), p.R357X (located in the ULD and found to 
remove the entire SDD) and p.C471Y (located in the SDD and potentially involved in 







Figure 3.4 – TBK1 mutations identified to date and their location in TBK1 structure. (a,b) Schematic 
representation of TBK1 protein structure (Tu et al. 2013) showing a map of nonsense (a) and missense (b) 
variants found in literature and in our cohort. (KD = Kinase domain, ULD = Ubiquitin like domain, SDD = 
Scaffold dimerization domain, CTD = C-terminal domain). (c) TBK1 homodimer crystal structure (PDB 4IM0) 
mapping the mutations found in our study excluding premature stop codons and frameshift deletions. Figure 





      
3.4.4 ALS-linked TBK1 variants decrease the phosphorylation of the TBK1 target 
IRF3 
Some ALS and FTD associated TBK1 variants have previously been shown to diminish 
or abolish phosphorylation of the TBK1 target IRF3 (Freischmidt et al., 2015; Kim et al., 
2016; Tsai et al., 2016; Pozzi et al., 2017). The efficiency of p.G217R, p.R357X and 
p.C471Y to phosphorylate IRF3 was therefore tested. HEK293T cells were transiently 
transfected with wild-type (WT) or mutant TBK1 and IRF3 phosphorylation was 
quantified by western blot. The levels of total endogenous IRF3 were unchanged, but the 
level of phospho-IRF3 (pIRF3) as measured by western blot was significantly reduced in 
p.G217R and p.R357X variants compared to the WT (Figure 3.5a,b), however, the 
p.C471Y variant, which was predicted to be pathogenic by bioinformatics analyses, 
showed no difference from WT. Transfected HEK293T cells analysed for pIRF3 by 
immunocytochemistry confirmed that p.G217R and p.R357X abolished IRF3 
phosphorylation, and, therefore, confirmed that these two mutations impair TBK1 kinase 





Figure 3.5 - TBK1 p.G217R and p.R357X impair TBK1 IRF3 phosphorylation. (a) Western Blot analysis 
of IRF3 (left) and pIRF3 (right). (b left) Quantitative analysis of blot in (a) left showing a similar expression 
level of endogenous IRF3 in cells (n=3 analysed by One Way ANOVA followed by Dunnet’s correction 
p=0.5221). (b right) Quantitative analysis of blot in (a) right showing a significant decrease of expression of 
endogenous pIRF3 in cells transfected with TBK1-p.G217R and p.R357X (n=3, analysed by One Way 
ANOVA followed by Dunnet’s correction p<0.0001). Error bars represent the standard error of the mean 
(SEM) (c) Qualitative immunocytochemistry of HEK293T transfected with TBK1-WT, p.G217R, p.R357X and 





3.4.5 ALS-linked TBK1 variants decrease binding to and phosphorylation of 
OPTN  
As described above, TBK1 is known to phosphorylate and regulate the activity of OPTN, 
a key receptor for poly-ubiquitinated proteins and mitochondria in the autophagy 
pathways (Richter et al. 2016). Co-immunoprecipitation (Co-IP) of HEK293T transiently 
co-transfected with Flag tagged OPTN and HA tagged WT, p.G217R, p.R357X and 
p.C471Y TBK1 was performed in order to determine whether these variants bound 
OPTN. HA tagged WT and p.C471Y consistently pulled down Flag tagged OPTN (Figure 
3.6a). Interestingly, the same variants that impaired IRF3 phosphorylation (p.G217R and 
p.R357X) also dramatically reduced TBK1 binding to OPTN and its phosphorylation 
which occurred when WT and p.C471Y were co-transfected with OPTN. Phosphorylation 
was confirmed as the higher OPTN band, observed in WT and p.C471Y and absent for 






Figure 3.6 - TBK1 p.G217R and p.R357X impair TBK1 binding with OPTN and its phosphorylation. (a) 
Co-IP with HA tag pull down (TBK1) showing no binding of OPTN in any of the mutated samples with the 
exception of p.C471Y (n=3). (b) HEK293T were transiently co-transfected with Flag-OPTN WT and HA-
TBK1 WT, p.G217R, p.R357X or p.C471Y, treated with alkaline phosphatase and analysed by western blot 
showing lack of OPTN phosphorylation in all mutated samples a part from p.C471Y. 
3.4.6 ALS-linked TBK1 variants decrease its phosphorylation 
Since TBK1 phosphorylation is a fundamental aspect of the TBK1 activation, the variants 




HEK293T cells, transiently transfected with each variant, were probed with an antibody 
specific for phosphorylated Serine at position 172. Total TBK1 expression was similar 
among WT and all of the ALS-associated variants (Figure 3.7a,b). Robust levels of 
phospho-Ser172 TBK1 were evident in WT and p.C471Y transfected cells but were 
absent in cells expressing p.G217R and p.R357X variants (Figure 3.7a,b, p<0.0001). 
Transfected HEK293T cells were probed for phopsho-S172 TBK1 by 
immunocytochemistry, which confirmed that TBK1 phosphorylation was absent in cells 
expressing p.G217R and p.R357X mutants (Figure 3.7c). This indicates that the 
p.G217R and p.R357X but not the p.C471Y variant abolished the capacity of TBK1 for 






Figure 3.7 - TBK1 p.G217R and p.R357X impair TBK1 phosphorylation and auto phosphorylation.  (a) 
Western blot analysis of TBK1 expression levels (left) and pTBK1 (right) (b left) Quantitative analysis of blot 
in (a) left showing a similar expression level of TBK1 in cells (n=4, analysed by One Way ANOVA followed 
by Dunnett’s correction p<0.6754).  (b right) Quantitative analysis of blot in (a) right showing a significant 
decrease of expression of pTBK1 in p.G217R and p.R357X (n=4 analysed by One Way ANOVA followed by 
Dunnett’s correction p<0.0001). Error bars represent the standard error of the mean (SEM) (c) Qualitative 
immunocytochemistry of HEK293T transfected with TBK1-WT, p.G217R, p.R357X and probed for p-TBK1 
confirming the result obtained by Western Blot analysis (Scale bar = 10 µm) 
3.4.7 ALS-associated TBK1 variant p.G217R disrupts TBK1 homo-dimerisation 
TBK1 has to homo-dimerise in order to be functional and does so via a central axis 
formed by aligning the two SDD domains in a parallel orientation. The ULD and KD 
domains interact with each other at one end of the dimer creating a globular structure 
and stabilising the homodimer (Tu et al., 2013) (Figure 3.4d, described in section 3.1.1). 




formation, HEK293T cells were transfected with TBK1 WT, p.G217R, p.R357X and 
p.C471Y and run on non-denaturing gels, which lack SDS that would unfold the protein 
and disrupt the hydrostatic bonds between dimers (Figure 3.8a). Native blots revealed 
two strong high and low molecular weight bands for WT and p.C471Y TBK1, indicating 
that a similar proportion exists as a homodimer and monomer. Little dimerisation was 
evident for the p.G217R mutant and no band was visible for the p.R357X truncation 
mutant (Figure 3.8a,b). When quantified, p.G217R showed a significantly lower ratio of 
TBK1 dimer/monomer compared to TBK1 WT (p=0.0306) (Figure 3.8b).  
 
 
Figure 3.8 - TBK1 p.G217R reduces TBK1 homodimerisation. (a) Native gel showing dimer and 
monomer (indicated by black arrows) in TBK1-WT and TBK1-C471Y, weaker dimer and monomer in 
p.G217R sample and no dimer or monomer in R357X sample (b) quantitative analysis of gel in (a) showing 
significant reduction in dimer formation for p.G217R (positive control on the right TBK1 WT treated with DTT, 
n=3, analysed by One Way ANOVA followed by Dunnet’s correction p=0.0009) 
3.4.8 TBK1 variant c.992+1G<A produces an in-frame deletion of exon 8 
The c.992+1G<A variant, also observed in ALSdb (Table 3.3), mutates the same base 
as a previously reported splice mutation (c.992+1G<T) that resulted in an in frame 
deletion of exon 8, within the ULD (Gijselinck et al., 2015). More recently, another 
splicing mutation was reported (c.992+4_992+7delAGTA) in a FTD-ALS case that is 
predicted to produce the same in frame deletion (p.Gly272_Thr331del) (van der Zee et 




was made from a lymphoblastoid cell line (LCL) derived from the patient harbouring 
c.992+1G<A variant. cDNA from patient and control lines was amplified using primers 
enclosing the whole of the TBK1 gene. When PCR products were ran on an agarose gel 
we observed a deletion of  200 bp corresponding to the size of exon 8 (Figure 3.9). The 
PCR product was then Sanger sequenced in house, which revealed the presence of a 
double sequence starting from the very first base of exon 8, confirming the result 
obtained with the agarose gel (Figure 3.9).   
 
Figure 3.9 - TBK1 variant c.992+1G<A produces in frame deletion of exon 8.  Agarose gel of cDNA 
extracted from WT and c.992+1G<A (p.G272_T331del) LCL showing two different sized bands for the WT 
allele and the mutated allele carrying c.992+1 G<A compared to the sample carrying both WT alleles 




boxes above and below show the sequencing of the WT/WT sample and the sequencing of the 
WT/c.992+1G<A sample, respectively. 
3.4.9 Characterisation of patient derived LCLs harbouring TBK1 variants 
In order to assess whether TBK1 variants decrease endogenous phospho-TBK1 levels, 
the amount of total TBK1 and phospho-TBK1 was measured in five patient derived LCLs 
heterozygous for TBK1 variants: p.T31A, p.G272-T331del, p.R358H, p.Q565P, 
p.E643del compared to seven control derived LCLs. Western blot analysis revealed that 
total TBK1 levels in mutant and control LCLs were similar (p=0.6054, Figure 3.10a,b). 
Western blot analysis of phopsho-S172-TBK1 revealed a lower level of TBK1 





Figure 3.10 - Patient derived LCLs harbouring TBK1 variants show reduced level of TBK1 
phosphorylation. (a left) Western blot analysis of TBK1 expression levels in patient and control derived 
LCLs. (a right) Western blot analysis of phospho-TBK1 expression levels in patient and control derived LCLs. 
(b) quantification of TBK1 (right, n=5) and phopho-TBK1 (left, n=3) showing similar levels of TBK1 mutant 
and control lines (analysed by unpaired t test, two tailed p=0.6054) and reduced levels of phopsho-TBK1 in 
all mutant samples (analysed by unpaired t test, two tailed p=0.0614). Error bars represent SEM. 
When the level of phospho-TBK1 in the different lines was adjusted for the level of total 
TBK1 and controls were compare against mutant lines, an unpaired t test revealed a 
significant difference in the phopsho-TBK1/totalTBK1 between control and patient LCLs 





Figure 3.11 – pTBK1/totalTBK1 shows a significant difference between patient and control LCLs. 
Quantification of the ratio between phospho-TBK1 and total TBK1 (n=3) showing a significantly higher ratio 
in control compared to patient derived LCLs (analysed by unpaired t test, two tailed p=0.0229). Error bars 
represent SEM. 
3.4.10 TOM20 and COXIV maintain similar expression in HEK293T cell transiently 
transfected with ALS-linked TBK1 variants  
As previously described, TBK1 has been shown to be involved in autophagy and more 
specifically in mitophagy (section 3.1.3.1). For this reason, expression of mitochondria 
markers was checked by western blotting in HEK293T cells transiently transfected with 
p.G217R, p.R357X and p.C471Y. No difference was detected in the expression of 
translocase of outer mitochondrial membrane 20 (TOM20), protein which is located in a 
mitochondrial receptor complex (TOM), or in the expression of cytochrome C oxidase 






Figure 3.12 - TOM20 and COXIV maintain similar expression in HEK293T cell transiently transfected 
with ALS-linked TBK1 variants. (a) Western Blot analysis of TOM20 and COXIV expression levels in 
HEK293T cells transiently over-expressing HA-TBK1 WT, p.G217R, p.R357X or p.C471Y and untransfected 
cells (UNTR=untransfected) (b) Quantitative analysis of blot in (a) showing a similar expression level of 
TOM20 across samples (analysed by One Way ANOVA followed by Dunnett’s correction p=0.4523). (c) 
Quantitative analysis of blot in (a) showing a similar expression level of COXIV across samples (analysed by 
One Way ANOVA followed by Dunnett’s correction p=0.9580). Error bars represent SEM. 
3.5 Discussion 
This study shows the systematic analysis of samples from 699 index fALS patients that 
were devoid of mutations in known ALS genes. From this analysis an enrichment in 
variants was observed in TBK1, a gene recently associated with ALS (Cirulli et al. 2015; 
Freischmidt et al. 2015). The missense variants predominantly map within the functional 
domains of TBK1, and were most frequent in the kinase and ubiquitin-like domains 




in the ULD domain (Figure 3.4a,b), which has been reported to be important in TBK1 
homo-dimerisation (Li et al., 2012; Tu et al., 2013). 
We identified 16 TBK1 variants, of which four were nonsense, predicted to generate 
mRNA degraded by nonsense mediated decay or to be translated as truncated proteins, 
three were in frame deletions and nine missense. Four of these variants (p.M623fs, 
p.Q629fs, T31A, R358H) are novel. Twelve of these variants have previously been 
reported (p.Q2X, p.T79del, p.R357X, p.E643del, p.N22H, p. N129D, 
c.992+1A<G/p.G272_T331del, p.G217R, p.R357Q, p.Y394D, p.C471Y and p.Q565P). 
Of these only p.R357Q, p.E643del and T79del have been functionally investigated 
(Freischmidt et al., 2015; Gijselinck et al., 2015; van der Zee et al., 2017). Mutations at 
the same nucleotide c.992+1G<T (p.G272_T331del) and c.992+4_992+7delAGTA 
(p.G272_T331del) have previously been reported to splice out the whole of exon 8 
(Gijselinck et al., 2015; van der Zee et al., 2017), resulting in an in frame partial deletion 
of the ULD, a finding that was replicated for c.992+1G<A (Figure 3.9). Furthermore, the 
patient harbouring the variant p.R358H was found to carry the FUS mutation p.R521C. 
Interestingly, Freischmidt and colleagues also reported the presence of a TBK1 variant 
(p.Y185X) in a patient harbouring the p.R524G FUS mutation (Freischmidt et al., 2015). 
This, together with the observation that the patient harbouring TBK1 variant p.Y394D 
was found to carry the p.M337V TARDP mutation, supports the theory of an oligogenic 
basis of ALS, postulated by others (Van Blitterswijk, Van Es, et al., 2012). Interestingly, 
the patient harbouring TBK1 p.Y394D and TARDP p.M337V displays the earliest age of 
onset in the cohort here presented (Table 3.3), which is abundantly below the average 
age of onset described in literature (Table 3.1). This phenomenon was also described by 
Freischmidt and colleagues in the patients (all three affected relatives) harbouring TBK1 
p.Y185X and FUS p.R524G (Freischmidt et al., 2015).  
Functional investigation was carried out on three variants selected on the basis of their 
predicted disruption to TBK1 structure and homo-dimerisation (Figure 3.4d). The variants 




putative affected sibling; p.R357X as it lies within the ubiquitin like domain (ULD) and 
was found in an unrelated case in ALSdb; and p.C471Y, which lies within the scaffold 
dimerization domain (SDD). Only p.G217R and p.R357X TBK1 variants, but not 
p.C471Y, abolished the phosphorylation of IRF3 (Figure 3.5). This has previously been 
described for other ALS associated variants (Freischmidt et al., 2015; Kim et al., 2016; 
Tsai et al., 2016). The same two TBK1 variants, p.G217R and p.R357X, also abolished 
TBK1 binding to OPTN and prevented its phosphorylation (Figure 3.6). The inhibition of 
TBK1 binding to OPTN has been previously observed in ALS TBK1 variants, mainly 
located in the C-terminal region of the protein (p.L59Ffs, p.R444X, p.Ile472Serfs*8, 
p.M559R, p.E696K, p.690-713del) (Freischmidt et al., 2015; Kim et al., 2016; Tsai et al., 
2016; Pozzi et al., 2017). Phosphorylation is necessary for OPTN to be activated and 
function as an autophagy receptor (Richter, et al. 2016). The impairment of OPTN 
phosphorylation by TBK1 suggests a link between ALS associated TBK1 variants and 
the autophagy pathway. However, no difference in the expression of mitochondria 
markers, TOM20 and COXIV, was observed among HEK293T cells transfected with 
mutant TBK1 constructs, at least in normal conditions (Figure 3.12), which would 
suggest no direct involvement of these variants in the mitophagy pathway. However, this 
might change should the cells be put in a stressful environment following an exogenous 
challenge such as heat shock treatment, oxidative or endoplasmic reticulum stress. 
Furthermore, it has previously been shown that OPTN and TBK1 are recruited in 
proximity of damaged mitochondria to direct their autophagic digestion (Richter et al. 
2016). Looking at TBK1, OPTN and mitochondria co-localisation in HEK293T cells 
transiently transfected with the TBK1 variants analysed in this study, may well shed light 
on their involvement in the mitophagy pathway. 
To become activated TBK1 must form a homo-dimer and phosphorylate itself or be 
phosphorylated by other kinases (described in section 3.1.1). Here we show that the 
same two TBK1 variants found to impair OPTN binding as well as OPTN and IRF3 




Figure 3.7). This observation is in line with a recent study that showed the lack of TBK1 
phosphorylation in ALS-associated TBK1 in frame deletions (p.T79del, p.D167del, 
p.E643del)  (van der Zee et al., 2017). We also show that p.G217R affects TBK1 ability 
to homodimerise, although located the KD. However, a limitation of this study is having 
used a non-denaturing gel that shows high background noise and is difficult to quantify 
accurately. Furthermore, no band was detected for p.R357X in any of the three 
replicates. A confirmation of this result via co-IP with TBK1 WT bearing a different tag 
(i.e. GFP or FLAG), would give further support to this conclusion.  
TBK1 phosphorylation and dimerisation are two pivotal properties for its function. In 
contrast to the result from all our functional studies, the p.C471Y variant, which lies in the 
SDD, is able to phosphorylate and homo-dimerise at similar levels to wildtype TBK1 
protein and therefore if it does play a pathogenic role, it is likely to be due to a different 
mechanism.  
Lastly, the ALS patient derived lymphoblastoid lines analysed in this study harbouring 
TBK1 mutations, show reduced TBK1 phopshorylation, approaching significance (Figure 
3.10). When corrected for the amount of total TBK1, the difference in phosphorylation 
between patient and controls became significant (Figure 3.11), suggesting that there is 
indeed a lower level of TBK1 phosphorylation of LCLs derived from patients harbouring 
the five mutations p.T31A, p.G272-T331del, p.R358H, p.Q565P, p.E643del, when 
compared to controls. This supports the hypothesis that disease linked TBK1 variants 
might impair TBK1 phosphorylation, disrupting its ability to bind and phosphorylate 
multiple partners including OPTN, an important component in the autophagy pathway 
(OPTN’s role in autophagy will be further discussed in section 4.1.2). We also found that 
total TBK1 was expressed in similar amount in all the lines. This result supplies further 





In conclusion, this study identified four novel and twelve previously described ALS-
associated TBK1 variants. Functional studies on three of those (p.G217R, p.R357X and 
p.C471Y) suggest that nonsense mutations in the kinase domain (p.G217R) and 
truncation mutation in the ubiquitin-like domain (p.R357X) impair TBK1 kinase activity 
and its binding to OPTN. We also show that p.G217R significantly reduces TBK1 ability 
to homodimerise when compared to wild type. This, in turn, prevents auto-
phosphorylation or phosphorylation of TBK1 by other kinases into its active form as well 
as the phosphorylation of other TBK1 substrates such as IRF3 and OPTN. Thus, 
missense mutations in critical functional domains may also cause disease through a loss 
of TBK1 function similar to the truncation mutations. Our results in overexpression 
models and endogenously expressed TBK1 variants, further support the hypothesis that 
TBK1 mutations result in haploinsufficency as a possible mechanism of pathogenesis 
(Cirulli et al. 2015; Freischmidt et al. 2015, 2016). Further investigation of how ALS-
linked TBK1 variants alter TBK1 structure, phosphorylation and dimerisation will help 




 – A novel Optineurin truncation mutation identified in 
an adult onset consanguineous Palestinian family with ALS 
4.1 Background 
Optineurin (OPTN) mutations have been associated with a number of disorders including 
normal tension glaucoma (NTG) (Rezaie et al., 2002), Paget’s disease of the bone 
(Albagha et al., 2010; Obaid et al., 2015), Crohn’s disease (Smith et al., 2015) and ALS 
(Maruyama et al., 2010). OPTN encodes for a highly conserved 577 amino acid protein 
(OPTN) involved in many important cellular pathways such as cell division, autophagy, 
vesicle trafficking and defence against pathogens (Ying and Yue, 2016; Markovinovic et 
al., 2017). OPTN protein inclusions have been shown to colocalise with protein 
aggregates in many neurodegenerative diseases not associated with mutations in 
OPTN, including Alzheimer’s, Parkinson’s and Huntington’s disease, which provides 
further evidence that OPTN is involved in proteostasis (Maruyama et al., 2010; 
Hortobágyi et al., 2011).  
4.1.1 Structural insight of OPTN 
Located on chromosome 10, OPTN contains 16 exons of which 13 are coding. OPTN is 
a ubiquitously expressed protein, with highest presence in brain, retinal ganglion cells, 
heart, spleen and skeletal muscle (Li, Kang and Horwitz, 1998; Rezaie et al., 2002, 
2005; De Marco et al., 2006; Ying and Yue, 2012). OPTN has five functional domains: 
two coiled coil domains, CC1 (aa 38-170) and CC2 (aa 238-509), an LC3 interacting 
region (LIR, aa178-181), a ubiquitin binding region of A-20 binding inhibitors of NF-kB 
(ABIN) proteins and NF-kB modulators (NEMO) (UBAN, aa 461-493) and a zinc finger 
domain (ZF, aa 553-557) with unclear function (Zhu et al., 2007; Morton et al., 2008; 




4.1.1.1 Coiled coil domains  
CC1 and CC2 are hydrophobic sequences that cover 70% of OPTN surface 
(Markovinovic et al., 2017). They are known to trigger interaction with hydrophobic 
regions such as other CC domains (CCDs). Therefore, it has been proposed that OPTN 
forms oligomers with itself through its CCDs (Ying et al., 2010; Gao et al., 2014). These 
interactions can be cross-linked in case of oxidative stress (Gao et al., 2014). OPTN also 
uses its CCDs to interact with other proteins such as TBK1 (Li et al., 2016), which is 
discussed further in section 3.1.3. 
4.1.1.2 LC3 interacting region  
The LIR domain is a common feature of autophagy receptors as it allows OPTN and 
other autophagy receptors such as p62 and NDP52, to recognise LC3 and deliver its 
cargo to the autophagosome (Wild et al., 2011). OPTN’s ability to function as an 
autophagy receptor relies heavily on its activation by phopsho-kinases, particularly by 
TBK1 (Pilli et al., 2012). 
4.1.1.3 Ubiquitin-binding region of ABIN proteins and NEMO (UBAN) 
The UBAN domain in OPTN is mainly devoted to ubiquitin chain recognition, enabling it 
to bind polyubiquitinated proteins and recruit them to the autophagosome through its LIR 
domain binding to LC3 (Wild et al., 2011).  
4.1.2 OPTN in autophagy 
OPTN is involved in different forms of autophagy, which can be ubiquitin-dependent or 
ubiquitin-independent as described below. 
4.1.2.1 OPTN in Xenophagy  
Xenophagy is a specific subtype of autophagy that selectively recognises the 




2014). The role of OPTN, as well as TBK1, in this type of autophagy has been 
extensively studied in the clearance of Salmonella bacteria as OPTN’s affinity to LC3 is 
greatly enhanced by the phosphorylation of its Ser177 by TBK1 (Wild et al., 2011). 
4.1.2.2 Mitophagy 
The role of OPTN in miotophagy involves the delivery of polyubiquitin tagged 
malfunctioning mitochondria to the autophagophore (illustrated in section 1.6.2; Wong 
and Holzbaur 2014). The loss of OPTN inhibits LC3 mediated recruitment and 
degradation of defective mitochondria, which can be reversed by the expression of WT 
OPTN but not of ALS-linked mutant p.E478G OPTN, which impairs the function of the 
UBAN domain. The same outcome was observed when expressing OPTN constructs 
with mutations in the LIR domain (Wong and Holzbaur, 2014).  
4.1.2.3 Aggrephagy 
Aggrephagy is a form of autophagy that selectively targets large protein aggregates. 
OPTN has been shown to play a role in the degradation of mutant hungtintin (mHtt) in an 
ubiquitin-dependent manner (Shen et al., 2015). OPTN can also be involved in 
aggrephagy in an ubiquitin-independent manner as it was found to co-localise with SOD1 
p.G93C and Htt aggregates even when carrying the p.E478G mutation, which disrupts 
OPTN binding with ubiquitin. This suggests that OPTN can still be involved in the 
degradation of these aggregates even if devoid of its ability to bind ubiquitin (Korac et al., 
2013). 
4.1.3 OPTN in vesicle and membrane trafficking 
OPTN has been shown to interact with a number of proteins involved in intracellular 
vesicle trafficking such as myosin VI and Rab8. Myosin VI is a multifunctional motor 
protein that binds to OPTN through its C-terminal region. When OPTN is knocked down, 
myosin VI is no longer recruited to the Golgi apparatus and the process of exocytosis is 




induces its dimerization, which triggers the movement of myosin VI towards the minus 
end of the actin filaments (Phichith et al., 2009). Since OPTN also functions as an 
autophagy receptor, it binds the autophagosome through its LIR and carries the whole 
complex inducing their fusion with the lysosome (Tumbarello et al., 2012). Indeed, knock 
down of OPTN in HeLa cells inhibits autophagy (Wild et al., 2011) and exocytosis 
(Sahlender et al., 2005). Decreased interaction between OPTN and myosin VI has been 
reported in the spinal cord tissue of apparently sporadic ALS patients, suggesting that 
disruption of OPTN function could impair the autophagy pathway in ALS 
(Sundaramoorthy et al., 2015).  
4.1.4 OPTN in neuroinflammation 
Toll like receptors (TLRs) and cytosolic DNA and RNA receptors activate two 
mechanisms: pro-inflammatory cytokine synthesis, regulated by NF-kB (Sen and 
Baltimore, 1986; Medzhitov, Preston-Hurlburt and Janeway, 1997) and the TBK1 
pathway, which regulates the transcription of IFN type I production (Akira, Uematsu and 
Takeuchi, 2006).  
Neuroinflammation has been associated with ALS in mutant SOD1 mouse models, 
where microglial activation was found to precede motor neuron symptoms (Hall, 
Oostveen and Gurney, 1998). This result was confirmed in patients whose PET scans 
reported extensive microglial activation (Turner et al., 2004). Interestingly, OPTN has 
been found to suppress TNF-mediated NF-kB activation when overexpressed in HEK293 
cells (Zhu et al., 2007; Nagabhushana, Bansal and Swarup, 2011). In support of this 
data, ALS-associated OPTN variants lack the ability to suppress NF-kB in 
neuroblastoma spinal cord 34 (NSC-34) lines (Zhu et al., 2007; Maruyama et al., 2010; 
Akizuki et al., 2013; Nakazawa et al., 2016). However, recent studies have shown that 
immune cells derived from OPTN deficient mice may activate NF-kB equally well 
(Gleason et al., 2011; Munitic et al., 2013; Slowicka et al., 2016). Therefore, this topic 




that suggests that OPTN carries out a neuroprotective role by inhibiting inflammation and 
necroptosis, a caspase-independent subtype of cell death that resembles necrosis 
(Markovinovic et al., 2017).  
4.1.5 OPTN in ALS 
OPTN was linked to ALS in 2010 when a Japanese study found two nonsense and one 
missense mutations in OPTN by homozygosity mapping in four consanguineous families 
affected by ALS (Maruyama et al., 2010). Around 40 OPTN variants have been found in 
ALS patients since then (Figure 4.1) with a great variability in terms of frequency and 
penetrance, which may depend on the patient’s ethnicity. Mutations in OPTN appear to 
occur with higher frequency in Chinese and Japanese populations (3% in fALS and 1% 
in sALS against a total frequency of 1% in Caucasian populations) (Maruyama et al., 
2010; Del Bo et al., 2011; Iida et al., 2012; Tümer et al., 2012; Van Blitterswijk, Van 
Vught, et al., 2012; Weishaupt et al., 2013; Soong et al., 2014; Li et al., 2015; Özoğuz et 
al., 2015; Fifita et al., 2016). To date, only a few OPTN mutations have been published in 
non-Asian populations, suggesting a genetic founder effect (Markovinovic et al., 2017). 
In support of this, the homozygous variant c.691_692insAG (p.S121fs*) was recently 
found to recur at a frequency of 5.8% and 0.3% in a Moroccan and an Ashkenazi Jewish 





Figure 4.1 – OPTN structure, binding partners and ALS-associated variants found to date (adapted 
from Markovinovic et al. 2017). The figure shows the five OPTN domains (Zhu et al., 2007; Morton et al., 
2008; Laplantine et al., 2009; Gleason et al., 2011; Liu et al., 2014; Li et al., 2016), OPTN binding partners 
and their binding regions (* indicates the need of S177 to be phosphorylated in order for LC3 to bind and 
K193 to be polyubiquitinated for p62 to bind). The diagram also shows all the OPTN variants found in ALS 
patients to date divided by null nonsense, missense. Δe = exon deletion. Above are OPTN binding partners 
and their regions of interaction. In red are the proteins that are believed to be involved in neuroprotection 
(MYPT1= Myosin phosphatase target subunit 1; mGLuR1a= Metabotropic Glutamate Receptor 1A; TFIIIA= 
Transcription Factor for polymerase III A; CYLD=Ubiquitin carboxyl-terminal hydrolase; HACE= HECT 
domain and ankyrin repeat containing E3 ubiquitin protein ligase 1; RIPK1= Receptor Interacting 
Serine/Threonine Kinase 1). 
Clinical reports suggest that OPTN mutations cause a moderately progressive 
phenotype with long progression prior to respiratory failure (Maruyama et al., 2010)  and 




The more frequently hypothesised mechanism for OPTN pathogenicity is its loss of 
function, including haploinsufficiency, by null and nonsense mutations. It is noteworthy 
that most OPTN nonsense mutations have been found as homozygous variants 
appearing to cause disease in an autosomal recessive fashion. However, the same 
nonsense homozygous mutations (excluding p.Q398X), as well as many deletion and 
missense mutations, have also been found as heterozygous variants, suggesting that 
haploinsufficiency might be enough to induce ALS (Tümer et al., 2012; Goldstein et al., 
2016).  
Around 20 potentially damaging missense OPTN variants have been found in ALS 
patients (Maruyama et al., 2010; Del Bo et al., 2011; Millecamps et al., 2011; A. Chiò et 
al., 2012; Naruse et al., 2012; Van Blitterswijk, Van Vught, et al., 2012; Lattante et al., 
2012; Weishaupt et al., 2013; Kenna et al., 2013; Soong et al., 2014; Beeldman et al., 
2015; Morgan et al., 2015; Özoğuz et al., 2015; Li et al., 2015; Bury et al., 2016; Fifita et 
al., 2016), however, their mechanism of pathogenicity is largely unknown. A clustering of 
these variants is observed at the C-terminal region of OPTN, responsible for its 
oligomerisation and binding with ubiquitin (Figure 4.1). The p.E478G OPTN mutation, 
associated with ALS in 2010, has been the most extensively studied. This variant has 
been shown to: 
 inhibit binding with ubiquitin (Mao et al., 2017) and myosin VI (Sundaramoorthy 
et al., 2015), 
 fail to suppress the NF-kB pathway (Maruyama et al., 2010; Nakazawa et al., 
2016),  
 to cause demyelination of corticospinal tracts in post mortem tissues (Maruyama 
et al., 2010),  
 decrease OPTN solubility in human patient spinal cord lysate (Sundaramoorthy 




These results support a loss of function mechanism, however, toxic gain of function 
cannot be completely excluded for this specific variant (Markovinovic et al., 2017).  
Interestingly, a recent study reported a patient with pathological features of FTD 
harbouring an OPTN (p.G538Efs*27) and a TBK1 variant (p.R117X) that had no 
evidence of motor neuron degeneration. Analysis of post mortem tissue revealed atrophy 
of the frontotemporal lobe along with TDP-43 and p62 proteinopathy. Protein and mRNA 
levels of OPTN and TBK1 were decreased, supporting the hypothesis of 
haploinsufficiency as disease mechanism (Pottier et al., 2015). Several reports describe 
detection of OPTN variants coinciding with TARDP or C9ORF72 mutations, providing 
evidence that heterozygous OPTN mutations may be acting to increase disease risk in 
concert with mutations in other genes, supporting an oligogenic basis for disease 
pathogenesis in some cases of ALS and FTD (Weishaupt et al., 2013; Pottier et al., 
2015). 
4.1.6 OPTN in primary open angle glaucoma 
ALS and primary open angle glaucoma (POAG) are two neurodegenerative diseases 
that affect different subtypes of neurons. Three missense and one nonsense OPTN 
variants were first associated in 2002 with normal tension glaucoma (NTG), a form of 
POAG (Rezaie et al., 2002). The most widely studied OPTN variant found in NTG is 
p.E50K, which has been shown to cause disease by toxic gain of function (Markey et al., 
2015). Interestingly, this OPTN mutant shows an increased ability to bind TBK1 (Morton 
et al., 2008; Li et al., 2016). TBK1 is also thought to play distinct roles in ALS and NTG, 
whereby mutants can cause the disease through haploinsufficiency and toxic gain of 
function respectively.  
4.1.7 OPTN mouse models 
Mice knocked out for OPTN (optn-/-) display axonal loss and dysmyelination in the spinal 




olygodendrocites, myeloid cells or microglia but not when knocked out from motor 
neurons or astrocytes (Ito et al., 2016). Optn-/- mice also induced higher susceptibility of 
mice to Salmonella infections (Slowicka et al., 2016). An OPTND477N/D477N knock-in mouse 
model was also generated. The p.D477N OPTN mutant lacks the ability to bind to 
ubiquitin, however these mice did not show any motor neuron degeneration even after 
12 months (Gleason et al., 2011). In contrast, OPTNI407X/I407X show embryonic lethality 
with incomplete penetrance and the surviving animals express a truncated form of OPTN 
at low levels, however this model also shows no symptoms of motor neuron 
degeneration (Munitic et al., 2013).  
4.2 Aim of this project 
The aim of this project was to genetically and functionally characterise a novel recessive 
OPTN variant (p.S174X) identified in a consanguineous Palestinian family with an 
aggressive adult onset ALS using primary fibroblast lines derived family members.   
4.3 Material and methods 
The skin biopsy and initial fibroblast culture was performed by collaborators in Israel, as 
described in Chapter 2. Techniques specific to this chapter are explained below.  
4.3.1 Clinical data and sample collection 
The family were seen by our collaborator, Neurologist Dr Marc Gotkine in an outpatient 
clinic at Hadassah Hospital. Because the affected individuals were siblings and the 
parents were known to be first cousins we predicted that the disease allele was 





Figure 4.2 – Consanguineous family harbouring the p.S174X variant and sequencing confirming the 
phenotype of some of the components of the family. On the left, the consanguineous kindred carrying 
the OPTN variant p.S174X with genotype specified under every individual (when known). Female and male 
individuals are marked with round and square shapes respectively. The patients affected by ALS are marked 
with dark circle/square. The patient affected by Alzheimer is marked by blue square. Age of onset (AOO) and 
age of death (AOD) specified when known. The arrow indicates the proband and the stars indicate the 
individuals we obtained fibroblast lines from. On the left, the confirmation of the genotype by Sanger 
sequencing of five individuals belonging to the family: three homozygous for the p.S174X mutation (IV-1, IV-
3, IV-5), one heterozygous (III-1) and one wild type (IV-6). Blue peaks indicate cytosine, red peaks indicate 
thymine, green peaks indicate adenine and black peaks indicate guanine. Sequencing was carried out by my 
fellow PhD student Chun Hao Wong. 
DNA was obtained from the proband (IV-1), one affected brother (IV-3), one unaffected 
sister (IV-6) and the unaffected mother (III-1) (Figure 4.2). Skin punch biopsy explant 
culture from III-1, IV-5, IV-8 and IV-9 (Figure 4.2) individuals was carried out in Shaare 
Zedek Medical Centre as described in section 2.5.4. The pedigree in Figure 4.2 was 




4.3.2 Shared regions of homozygosity  
Following informed consent, blood samples were taken, DNA extracted and SNP 
genotyping was performed on individuals IV-1 and IV-3 using HumanOmniExpress-12v1-
1 chips, which assess ~2.5 million bi-allelic variants distributed throughout the genome. 
Regions of shared homozygosity (RoH) were identified in Plink. In parallel their DNA was 
exome sequenced as described in section 2.2 and correlated with the SNP genotyping 
data by Simon Topp. 19,355 high quality homozygous variants were found and were 
filtered by the following criteria: protein changing variants, not present as a homozygote 
in any of the control databases analysed (670 KCL exomes; EVS/ESP; ExAC; GME 
exomes) and ExAC coverage by >10 reads in >50% of samples (Table 4.1). This 
analysis was carried out by my bioinformatician colleague Simon Topp. 
4.4 Results 
4.4.1 Clinical assessment of proband confirmed the diagnosis of ALS 
The clinical assessment of these patients was carried out by a Neurologist, Dr Marc 
Gotkine. The proband’s parents were first cousins. The father died at age 81 after being 
diagnosed with Alzheimer’s disease three years prior to his death. The mother was 79 
and healthy and the family denied the presence of neurological disease in previous 
generations. Three of their offspring developed neurological symptoms and were 
diagnosed with ALS: the proband (IV-1) and 2 of her brothers (IV-2 and IV-3) (Figure 
4.2). 
The proband presented at the age of 54 with a two year history of progressive gait 
difficulty, which she attributed to bilateral lower limb weakness. Roughly one year later 
she noted bilateral upper limb weakness followed within a few months by 
breathlessness, slurred speech and a dropped head. There were no visual, sensory or 
cognitive complaints and she denied sphincter involvement. Examination revealed 




down. There were signs of upper and lower motor neuron involvement in all limbs and 
the cranial nerves. Elecromyography (EMG) confirmed the presence of LMN involvement 
in upper and lower limbs. Respiratory muscle weakness was confirmed by spirometry. 
Her condition continued to deteriorate, she declined assisted ventilation and died six 
months following diagnosis.  
The family reported that one brother (IV-2) had recently died after suffering a similar 
illness, and a second brother (IV-3) had just been diagnosed as having a neuromuscular 
condition, which was later confirmed to be ALS. Although there was no indication of 
visual impairment in the proband, the wife of IV-2 reported that in the months before his 
death he became blind, however no ophthalmological exam was performed. 
Furthermore, another sibling (IV-7) has also recently reported similar motor symptoms.  
4.4.2 Exome sequencing of two affected individuals reveals a novel OPTN 
mutation  
Studying consanguineous families, or isolated populations, has been proven to be an 
effective methodology to discover novel ALS-linked variants (Yang et al., 2001; 
Laaksovirta et al., 2010; Maruyama et al., 2010; Smith et al., 2013). As described above, 
the Japanese study that identified the first ALS-linked mutations in OPTN has been an 
important advance in gene discovery, as the mutations found in their population have 
also been identified in populations of different ethnicity (Maruyama et al., 2010).  
Through a collaboration with Dr Marc Gotkine at Hadassah University Hospital in Israel, 
we were able to obtain DNA and perform exome sequencing on two members (IV-1 and 
IV-3, Figure 4.2) of this consanguineous family presenting an adult onset fast 
progressive form of ALS. Exome capture and exome sequencing were outsourced at the 
Centre for Genomic Research in Liverpool and at the Biomedical Research Centre at 
Guy’s and St Thomas’ NHS Foundation Trust, King’s College London, respectively. The 
rationale behind this approach is that consanguineous families have a higher risk of 




discovery more efficient and cost effective in these families. Around 95% of the protein 
coding region of the genome were captured and sequenced to a depth higher than 10 
reads in both patients, making it unlikely that a shared pathogenic variant will have been 
excluded from this analysis. The data obtained was further analysed by Simon Topp 
through a rigorous filtering strategy using public and private databases, illustrated in 
Table 4.1. 
Filtering rationale Number of variant 
Total Unfiltered variants 1,569,097 
Within probes and overhang 50,456 
Homozygous 19,335 
Protein changing 4,822 
Not present in KCL controls as 
homozygous variant 
100 
Not present in EVS as homozygous 
variant 
62 
Not present in ExAC as a homozygous 
variant 
27 
Exac Coverage >50% 15 
Shared in the two affected 2 
Table 4.1 – Filtering strategy used to analyse the exome sequencing data from IV-1 and IV-3. 
Two homozygous variants were identified as being novel and present in both individuals. 
The first one was p.A94T in Lipase E (LIPE) found 294 times in ExAC as a heterozygous 
variant. The second was a novel OPTN variant (p.S174X), which causes a premature 
stop codon that eliminates both the UBAN domain and TBK1 phosphorylation site, as 
well as other important protein interaction sites (Figure 4.1). This variant was also found 
to be absent, even as a heterozygote, from over 70,000 controls as well as 1000 
ethnically matched controls screened by Dr Gotkine’s collaborators in Bethlem 
University. Considering that OPTN had already been acknowledged as an ALS causing 
gene and that the variant p.S174X was completely novel, it was chosen as the candidate 




All of the available DNA samples from the same family were Sanger sequenced in house 
by my fellow PhD student Chun Hao Wong. This confirmed that the mother (III-1) was a 
heterozygous carrier for p.S174X and that individuals IV-1 and IV-3 as well as IV-5 were 
homozygous carriers for the p.S174X variant, whereas individual IV-6 showed wild type 
genotype (Figure 4.2). Interestingly, IV-5 has not reported any motor neuron symptoms 
and has now reached the age of 54. The mean age of onset of the family is 48.5.  
The sibling IV-7 has recently presented with progressive gait difficulty and limb 
weakness with combined UMN and LMN features suggestive of ALS. DNA was obtained 
and sequenced by PhD student Nada Alahmady, confirming the presence of 
homozygous OPTN variant p.S174X. 
RoH analysis of the Illumina chip genotyping data confirmed that both affected siblings 
IV-1 and IV-3 had a block of homozygosity approximately 10Mb in size overlapping the 
OPTN gene, and that this homozygous block was not present in the heterozygous 
mother III-1. 
4.4.3 All fibroblast lines carry the expected genotype 
Primary fibroblast lines were obtained from three healthy siblings (IV-5, IV-8, IV-9) and 
one healthy parent (III-1, all marked with * in the pedigree in Figure 4.2 by our 
collaborators in the Shaare Zedek medical centre as described in section 2.5.4. Three 
commercially available human fibroblast control lines (described in section 2.5.4) were 
kindly donated to us by Professor Fiona Watt’s laboratory. The OPTN genotype of each 





Figure 4.3 – All fibroblast lines carry the expected genotype. On the left, the genotyping for the locus of 
the c.521C>A, p.S174X in controls showing a wild type genotype. On the right, genotyping of the 
heterozygous individual derived lines. III-1, IV-8 and IV-9 show a double peak (cytosine and adenine) 
whereas IV-5 shows a green peak (adenine) indicating that the line carries the homozygous p.S174X 
change. Blue peaks indicate cytosine, red peaks indicate thymine, green peaks indicate adenine and black 
peaks indicate guanine. 
4.4.4 OPTN mRNA expression is significantly reduced in p.S174X fibroblasts 
In order to understand whether the expression of OPTN varied when individuals carried 
the heterozygous or homozygous p.S174X variant, quantitative PCR was carried out on 
cDNA derived from control and mutant fibroblast lines. OPTN mRNA levels were 
analysed across three biological replicates and normalised to GAPDH, Ribosomal 
Protein L13a (RPL13A) and Succinate Dehydrogenase Complex Flavoprotein Subunit A 
(SDHA). When grouped by genotype, there was a significant difference between the 
expression of OPTN in controls compared to heterozygous carriers (p=0.0419, Figure 
4.4). Furthermore, the expression of OPTN transcript in the mutant homozygous 
fibroblast cell line is significantly lower when compared to any other wild type or 





Figure 4.4 – OPTN expression is reduced in fibroblast harbouring the p.S174X mutation. On the left, 
data grouped by genotype and analysed by unpaired t-test (WT/WT vs WT/MUT two tailed p=0.0419). Error 
bars represent standard error of the mean (SEM). On the right, the level of OPTN expression per sample: 
controls are blue, heterozygous carriers are green and the homozygous carrier is pink. The pink stars 
indicate the p value derived from the comparison of IV-5 with every other individual (one way ANOVA 
followed by Dunnett’s correction **** is ≤ 0.0001, *** is ≤ 0.001, ** ≤ 0.01, * ≤ 0.05, error bars represent SEM, 
n=3). Error bars represent the standard error of the mean (SEM). 
4.4.5 OPTN variant p.S174X mRNA is degraded by nonsense mediated decay 
Nonsense mediated mRNA decay (NMD) is an evolutionarily conserved mechanism that 
degrades mRNA containing premature stop codons (Brogna and Wen, 2009). Given that 
the OPTN transcript is harbouring the p.S174X we sought to determine whether its RNA 
might be degraded by NMD. When sequenced, the cDNA derived from the heterozygous 
fibroblast lines showed only a wild type genotyped, indicating that the mutated allele was 
not expressed at sufficient level to be detected in these cell lines (Figure 4.5). When the 
fibroblast lines were treated for 16 hours with 100 µg/ml cyclohexamide (CHX), an 
inhibitor of NMD and protein synthesis (Nickless, Bailis and You, 2017), cDNA sequence 
from the heterozygous lines revealed both the wild type and mutated allele, 
demonstrating that, the OPTN variant p.S174X is largely degraded through NMD. 
Interestingly mRNA from the homozygous mutant was detected with and without CHX, 





Figure 4.5 – The OPTN variant p.S174X is degraded by nonsense mediated decay. On the left, 
sequencing of cDNA derived by control, heterozygous and homozygous fibroblast lines, showing that the 
homozygous lines only present the wild type allele. On the right, sequencing of cDNA derived by control, 
heterozygous and homozygous fibroblast lines after treatment with 100 µg/ml CHX for 16 hours, showing a 
double peak in the heterozygous samples.  
4.4.6 No truncated OPTN protein is detectable in OPTN p.S174X fibroblasts 
All fibroblast cell lines were harvested and processed for western blotting as described in 
section 2.6.2. The membrane was probed for an antibody raised against the OPTN N-
terminal fragment (1-14 aa) in order to determine whether any protein was translated 
from the OPTN p.S174X variant (expected molecular weight ~20 kDa). No OPTN protein 






Figure 4.6 - OPTN N-terminal fragment is not expressed in IV-5. Western blot showing the presence of 
N-terminal OPTN (~75 kDa) in all individuals with the exception of IV-5 (MUT/MUT). p.S174X expected 
molecular weight ~20kDa. GAPDH shows an equal amount of protein loaded for each sample. n=3. 
C=Control. 
4.4.7 N-terminal OPTN expression is not rescued by treatment with MG132 
MG132 is a proteasome inhibitor that drastically reduces the degradation of ubiquitinated 
proteins (Lee and Goldberg, 1998). The OPTN p.S174X variant, if translated at all, is 
likely to misfold, be ubiquitin tagged and degraded by the proteasome. Therefore, if the 
p.S174X is translated in homozygous and heterozygous fibroblasts the truncated protein 
(~20 kDa) should be visible by western blot in cells treated with MG132. All fibroblast 
lines were, therefore, treated with 5µM MG132 or DMSO only control for 24 hours and 
processed for western blot as described in section 2.6.2. Immunoblot analysis showed 
no truncated protein for the homozygous or heterozygous samples, when treated with 
MG132 (Figure 4.7). Quantification of OPTN, normalised by GAPDH, revealed a 




control derived fibroblast lines, in both MG132 treated (p=0.007) and DMSO treated 
(p=0.0083) samples (Figure 4.7). Since a truncated protein could not be detected even 
following proteasome inhibition, we concluded that the OPTN p.S174X transcript is 
largely degraded by NMD. We were able to confirm that proteasome inhibition had 
occurred as the same blot was probed for p62 which was increased in all samples 
treated with MG132 (Figure 4.7)(Kuusisto, Suuronen and Salminen, 2001). However, we 
were surprised that OPTN protein did not appear to accumulate following proteasome 






Figure 4.7 - Expression of the OPTN variant p.S174X is not rescued by treatment with MG132. On the 
top, western blot showing the expression of OPTN in all available fibroblast lines treated with DMSO or 5µM 
MG132. The expression of p.S174X is not rescued by the MG132 treatment as no truncated fragment of 
OPTN was detected in any of the samples. GAPDH was used as loading control and p62 was used to verify 
the effectiveness of the MG132 treatment. On the bottom, quantification of the amount of OPTN present in 
each sample normalised by GAPDH (n=4). The graph shows a significant difference between the expression 
level of OPTN in controls when compared to heterozygous samples (multiple t-test using Holm-Sidak method 
DMSOp=0.0083, MG132p=0.0072). No significant difference is observed between the expression of OPTN 
in cells treated with DMSO or MG132 (two way ANOVA followed by Sidak correction p=ns). Controls 
(WT/WT) are blue, heterozygous carriers (WT/p.S174X) are green and the homozygous carrier 




4.4.8 Heterozygous OPTN p.S174X, but not homozygous, fibroblasts show a 
modest increase in mitochondria markers  
OPTN is involved in a particular subtype of selective autophagy called mitophagy 
(described in section 1.6.6). Impaired mitophagy causes the accumulation of defective 
mitochondria (Corti, Lesage and Brice, 2011), which would result in a higher expression 
of mitochondria markers. All primary fibroblast lines were therefore analysed by western 
blot and probed for the mitochondria markers TOM20 and COXIV, described in section 
3.4.10. Following quantification, p.S174X heterozygous lines show a modest increase in 
both COXIV (unpaired t test, two tailed p=0.034) and TOM20 (unpaired t test, two tailed 
p=0. 026) levels when grouped by genotype and compared to controls, however no 
increase was detected in the homozygous line when compared individually to each other 
sample by one way ANOVA (Figure 4.8).  
 
Figure 4.8 – p.S174X heterozygous fibroblast lines show a mild increase in mitochondria markers. On 
the left, western blot showing TOM20 expression levels in all available fibroblast lines and its quantification, 
normalised against GAPDH (n=3). Control and heterozygous samples were grouped by genotype and 




individual control and homozygous sample by one way ANOVA followed by Dunnett’s correction and shows 
no significant difference in the expression of TOM20 (p=ns). On the right, western blot showing COXIV 
expression levels in all available fibroblast lines and its quantification, normalised against GAPDH (n=3). 
Control and heterozygous samples were grouped by genotype and analysed by unpaired t-test (two tailed 
p=0.0339). The homozygous sample was compared with each individual control and heterozygous line by 
one way ANOVA followed by Dunnett’s correction and shows no significant difference in the expression of 
COXIV (p=ns). Error bars represent SEM. C=Control. Controls (WT/WT) are blue, heterozygous carriers 
(WT/p.S174X) are green and the homozygous carrier (p.S174X/p.S174X) is pink. 
4.4.9 Mitochondria morphology was unchanged in p.S174X fibroblasts 
In order to understand whether there were any morphological abnormalities in the 
fibroblast lines harbouring the p.S174X change, cells were treated with MitoTracker, 
fixed and stained for DAPI as described in section 2.6.1.1. The fibroblasts were then 
imaged (~15 cells per line, per replicate, Figure 4.9) and analysed using the ImageJ 
Mito-Morphology Macro as explained in section 2.6.1.1.1 (n=3). No difference was 
observed in the morphology of mitochondria among control, heterozygous and 





Figure 4.9 – Mitochondria in the control, heterozygous and homozygous fibroblast lines show similar 
morphology. Fibroblast lines were treated with MitoTracker, fixed and stained for DAPI. This figure shows 
one representative picture for each control, heterozygous and homozygous fibroblast lines. In red is the 
MitoTracker which permeated in mitochondria of the live cells. In blue is DAPI which stains the nucleus. 





Figure 4.10 – Mitochondria morphology is similar across all fibroblast lines. Quantitative analysis of 
Figure 4.9 using the ImageJ Mito-Morphology Macro (Ruben, 2014). 15 cells were analysed per line and the 
data from three replicates quantified. No difference was detected among the different samples (analysed by 
one way ANOVA followed by Tukey correction, p=ns, n=3). Error bars represent SEM. C=Control. Controls 
(WT/WT, blue), heterozygous carriers (WT/p.S174X, green) and homozygous carrier (p.S174X/p.S174X, 
pink). 
4.4.10 Mitochondrial membrane potential is unaffected by OPTN p.S174X 
The mitochondrial membrane potential is fundamental for these organelles to be able to 
produce Adenosine triphosphate (ATP), the major energy source of the cell. For this 
reason, measuring mitochondrial membrane potential assay is a good index of the health 
of mitochondria and of the whole cell (Perry et al., 2011). With this in mind, control, 
heterozygous and homozygous fibroblast lines were analysed using the NucleoCounter 
NC-3000 mitochondrial potential assay, as explained in section 2.6.8. Carbonyl cyanide-
p-trifluoromethoxyphenylhydrazone (FCCP) treated cells were used as a positive control. 




mitochondrial membrane potential. As shown in Figure 4.11, no significant difference 
was found in the percentage of cells showing a collapsed mitochondrial membrane 
potential among control, heterozygous and homozygous derived fibroblasts.   
 
 
Figure 4.11 – Control, heterozygous and homozygous derived fibroblast lines do not show evidence 
of mitochondria membrane potential collapse. Cells were analysed using the mitochondrial potential 
assay for the NucleoCounter NC-3000 as decribed in section 2.6.8. On the top, an example of four two-




Red JC-1 intensity represents cells with physiological mitochondrial membrane potential, whereas Green JC-
1 intensity represents cells with collapsed mitochondrial membrane potential. At the bottom, quantification of 
three biological replicates including the positive control. No significant difference was observed among 
control, heterozygous and homozygous fibroblasts (one way ANOVA followed by Tukey correction, 
p=0.6689, n=3). Controls (WT/WT) are blue, heterozygous carriers (WT/p.S174X) are green and the 
homozygous carrier (p.S174X/p.S174X) is pink, FCCP treated fibroblast line is in yellow. Error bars 
represent SEM.  
4.4.11 OPTN p.S174X fibroblasts show a modest increase in cellular respiration 
Further functional mitochondria characterisation was conducted using the Agilent 
Seahorse XF Cell Mito Stress Test as described in section 2.6.9. This is an automated 
test that records the level of mitochondria activity following the sequential application of 
three different drug challenges. The test initially measures the level of basal oxygen 
consumption (basal respiration), the cells are then treated with oligomycin, which blocks 
the respiration chain. The difference in the oxygen consumption between the initial 
phase and treatment with olygomycin, indicates the level of ATP production (Figure 
4.12). Cells are then treated with FCCP which allows protons to enter mitochondria 
membrane unregulated and causes a peak in the mitochondrial production of oxygen, 
which represents the maximum respiration rate that the cell can achieve (maximal 
respiration, Figure 4.12). When cells are treated with antimycin A and rotenone, which 
block the respiration chain, cellular respiration is inhibited and cells only consume 
oxygen through non-mitochondrial respiration (Figure 4.12).  
Our data analysis revealed that fibroblast lines heterozygous for p.S174X OPTN have a 
higher basal level of respiration (two-tailed p=0.0156), higher non-mitochondrial 
respiration (two-tailed p=0.0245) as well as higher ATP production (two-tailed p=0.0310), 
when compared to the controls (Figure 4.13). However, the heterozygous lines did not 
show any significant difference in their maximal respiration or spare respiratory capacity 
(ability of the cell to respond to an energetic need) (Figure 4.12). There was no 
difference in their coupling efficiency (correlation between the protons entering the 




respiration by the ATP production) when compared to controls (Figure 4.13). The 
fibroblast line homozygous for the OPTN p.S174X variant, shows a trend for defective 
mitochondrial function in all parameters, with the exception of the relative coupling 
efficiency, however this did not reach statistical significance (Figure 4.13).  
 
Figure 4.12 – Oxygen consumption rate (OCR) measured by the Agilent Seahorse XF Cell Mito Stress 
Test. On the left, an example of the OCR measurement and how it should change with the oligomycin, 
FCCP and antimicin A/rotenone treatments. In the initial stage, the base level of oxygen consumption is 
measured (basal respiration) then the oligomycin is added, which inhibits ATP synthase and blocks the 
respiration chains. When FCCP is added protons are free to enter the mitochondria membrane pushing the 
cells to their maximal respiration rate. Antimycin A and Rotenone inhibit complex I and complex III in 
respiration chain, shutting down mitochondria respiration. On the right, a representative example of the 








Figure 4.13 – Agilent Seahorse XF Cell Mito Stress Test analysis shows a minor increase in cell 
respiration in the heterozygous fibroblast lines. (a) A significantly higher basal respiration is observed in 
heterozygous samples when compared to controls (unpaired t-test, two tailed p=0.0156), no significant 
difference was detected when comparing the homozygous line to any other line (one way ANOVA followed 
by Dunnett’s correction, p=0.2032). (b) A significantly higher non mitochondria respiration is observed in 
heterozygous samples when compared to controls (unpaired t-test, two tailed p=0.0245), no significant 
difference was detected when comparing the homozygous line to any other line (one way ANOVA followed 
by Dunnett’s correction, p=0.0755). (c) A significantly higher level of ATP production is observed in 
heterozygous samples when compared to controls (unpaired t-test, two tailed p=0.0310), no significant 
difference was detected when comparing the homozygous line to any other line (one way ANOVA followed 
by Dunnett’s correction, p=0.1364). (d) No difference is observed in the control and heterozygous maximal 
respiration (unpaired t-test, two tailed p=0.0778) or when comparing the homozygous line to any other line 
(one way ANOVA followed by Dunnett’s correction, p=0.1711). (e) No difference is observed in the control 
and heterozygous spare respiratory capacity (unpaired t-test, two tailed p=0.1766) or when comparing the 
homozygous line to any other line (one way ANOVA followed by Dunnett’s correction, p=0.1979). (f) No 
difference is observed in the control and heterozygous coupling efficiency (unpaired t-test, two tailed 
p=0.5675) or when comparing the homozygous line to any other line (one way ANOVA followed by Dunnett’s 





4.4.12 The autophagy marker LC3-II is not affected by OPTN p.S174X mutation 
The comparison of LC3-II expression levels has been accepted as a good indicator of 
autophagy (Mizushima and Yoshimori, 2007). LC3 is synthesised in the form of proLC3, 
which is quickly processed by Atg4 into LC3-I (Kabeya, 2000). LC3-I is then converted in 
LC3-II through a mechanism regulated by Atg4 itself and activated by autophagy leading 
events such as the accumulation of reactive oxygen species during starvation (Scherz-
Shouval et al., 2007). This cleavage stimulates the generation of the autophagosome, 
which is important for the completion of the autophagy process (Klionsky, 2007; 
Mizushima, 2007). Because LC3-II expression is closely correlated with the number of 
autophagosomes present in a cell (Kabeya, 2000), an accumulation of LC3-II implies an 
accumulation of autophagosomes and, therefore, an impairment of autophagy 
(Mizushima and Yoshimori, 2007). Since OPTN is involved in the delivery of 
ubiquitinated cargoes to the autophagosome through LC3 binding (described in section 
4.1.1.2 and 4.1.3), we measured LC3-II levels by immunoblotting in control, 
heterozygous and homozygous derived fibroblast lines. No difference was observed 
between control and p.S174X heterozygous fibroblast lines (p=0.4277) or by comparing 
p.S174X homozygous fibroblast line with any other line (p=0.1975), indicating no major 





Figure 4.14 – LC3-II maintains similar expression level among control heterozygous and 
homozygous primary fibroblast lines. At the top, western blot showing the presence of LC3-I (~16 kDa) 
and LC3-II (~14 kDa) in all individuals. GAPDH shows an equal amount of protein loaded for each sample 
(C=Control). At the bottom, the quantification of LC3-II showing no significant difference between the control 
and the heterozygous group (compared by unpaired t-test, two tailed p=0.4277, n=3) or among any of the 
individual samples (one way ANOVA, followed by Tukey correction p=0.1795). 
4.4.13 Ubiquitin K63 shows no difference in ubiquitination in OPTN p.S174X cells.  
Ubiquitination of proteins is an important post transcriptional modification, which is 
regulated by a string of enzymatic reactions that involves ubiquitin activating enzyme 
(E1), ubiquitin conjugating enzyme (E2) and ubiquitin ligase (E3) (Glickman and 
Ciechanover, 2002). Polyubiquitination is the addition of poly-ubiquitin (poly-Ub) chains 
to a substrate, which are interconnected through one of the seven Lysine (K) residue of 
Ub. The most common types of polyubiquitinatons are the ones linked through K-48 or 
K-63 (Weissman, 2001). K-48 associated proteins are thought to be transported and 




are recognised by p62 and are directed towards degradation by autophagy (Seibenhener 
and Babu, 2004). Furthermore, OPTN has been shown to preferably recognise K63 
ubiquitin chain through its UBAN domain (Rahighi et al., 2009; Gleason et al., 2011). In 
order to determine whether OPTN deficiency would cause impaired autophagy, we 
probed heterozygous and homozygous OPTN p.S174X fibroblasts for K63 ubiquitin 
labelled proteins by immunocytochemistry, however, no striking differences were 





Figure 4.15 – K63 staining maintains a similar pattern across control, heterozygous and homozygous 
primary fibroblast lines. Representative confocal images (63x) of controls (Cntrl1-WT/WT, Cntrl2 – 
WT/WT, Cntrl3 – WT/W), heterozygous (III-1 – WT/MUT, IV-9 – WT/MUT, IV-8 – WT/MUT) or the 
homozygous (IV-5 – MUT/MUT) fibroblast line stained for K63 ubiquitin (green) and DAPI (blue). Scale bars 





Figure 4.16 – K63 staining maintains a similar pattern across control, heterozygous and homozygous 
primary fibroblast lines (magnified). Higher magnification of images of controls (Cntrl1-WT/WT, Cntrl2 – 
WT/WT, Cntrl3 – WT/W), heterozygous (III-1 – WT/MUT, IV-9 – WT/MUT, IV-8 – WT/MUT) and the 
homozygous (IV-5 – MUT/MUT) fibroblast line stained for K63 ubiquitin (green) and DAPI (blue). Scale bars 




4.4.14 p.S174X fibroblasts do not show evidence of TDP-43 aggregation 
TDP-43 aggregation is a hallmark of ALS in over 95% of the ALS cases (Peters, 
Ghasemi and Brown, 2015) including those carrying OPTN mutations (Maruyama et al., 
2010; Ito et al., 2011; Pottier et al., 2015). The TDP-43 aggregates are labelled with K63 
and K48 ubiquitin chains and recognised by ubiquilin-1 and -2 (Neumann et al., 2006; 
Deng et al., 2011) and SQSTM1/p62 (Arai et al., 2003), which will promote aggregate 
degradation through UPS or aggrephagy (Scotter et al., 2014). In order to verify whether 
OPTN p.S174X fibroblasts showed evidence of defective proteostasis we performed 
immunocytochemistry for TDP-43 and p62. Occasional TDP-43 immunoreactive 
inclusions appeared in all fibroblast lines (red arrows) with no striking differences in their 
number and distribution and few appeared to colocalise with p62 (green arrows) again 





Figure 4.17 – TDP-43 staining shows mild aggregation in all fibroblast lines. Representative confocal 
images (40x) of controls (Cntrl1-WT/WT, Cntrl2 – WT/WT, Cntrl3 – WT/W), heterozygous (III-1 – WT/MUT, 
IV-9 – WT/MUT, IV-8 – WT/MUT) or the homozygous (IV-5 – MUT/MUT) fibroblast line stained for DAPI 
(blue), TDP-43 (red), which revealed occasional cytoplasmic inclusions (red arrows) and p62 (green) 





Figure 4.18 – TDP-43 staining shows mild aggregation in all fibroblast lines (magnified). Higher 
magnification of images of controls (Cntrl1-WT/WT, Cntrl2 – WT/WT, Cntrl3 – WT/W), heterozygous (III-1 – 
WT/MUT, IV-9 – WT/MUT, IV-8 – WT/MUT) or the homozygous (IV-5 – MUT/MUT) fibroblast line stained for 
DAPI (blue), TDP-43 (red), which revealed occasional cytoplasmic inclusions (red arrows) and p62 (green) 





This study shows the genetic and functional characterisation of a novel OPTN variant 
(p.S174X) found by shared region of homozygosity and exome sequencing of a 
consanguineous Palestinian family affected by an aggressive ALS phenotype (Figure 
4.2). All four affected siblings carried the OPTN p.S174X non-sense mutation and their 
heterozygous parents and siblings were unaffected. This variant was absent from 
>70,000 individuals of European ancestry and 1000 ethnically matched Palestinian 
controls, showing that this variant is rare if not absent in these two populations.  
Investigating consanguineous families is an efficient technique to discover novel 
recessive mutations that can occur as homozygous variants and therefore be easier to 
identify. This method has been successfully used in ALS gene discovery and 
investigation (Yang et al., 2001; Maruyama et al., 2010). 
Through an international collaboration with Dr Marc Gotkine at The Hebrew University 
Hadassah Medical School in Jerusalem, we obtained fibroblast lines from four members 
of a consanguineous Palestinian family (Figure 4.2). Three healthy individuals carried the 
OPTN p.S174X variant as heterozygotes and one unaffected individual was 
homozygous. In order to verify whether these fibroblast lines showed any phenotypic 
abnormalities, they were compared to three commercially available Caucasian controls 
carrying the WT OPTN allele (Figure 4.3). One limitation of this study is the different 
ethnic origin of the members of the family and controls. Indeed, it is possible that some 
of the differences here observed could be due to a different genetic background. It would 
be, therefore, interesting to repeat some of the assays presented here using ethnically 
matched controls.  
Quantitative PCR of these lines showed a significant decrease of OPTN mRNA in the 
heterozygous when compared to control fibroblasts and a severe loss of OPTN 
transcripts in the homozygous cells (Figure 4.4). I demonstrated that the decrease in 




mediated decay (NMD) as cDNA sequencing from heterozygous fibroblast lines detected 
only a WT genotype and treatment with CHX (an NMD inhibitor) rescued the 
heterozygous genotype (Figure 4.5). This finding has previously been observed by 
Maruyama and colleagues who showed that the level of OPTN expression in patients 
homozygous for the p.Q398X variant was dramatically diminished and was rescued by 
CHX treatment (Maruyama et al., 2010).  
The absence of a truncated OPTN protein derived from the p.S174X allele was 
confirmed by western blot analysis (Figure 4.6). A similar result was also reported by 
Maruyama and colleagues who observed loss of OPTN expression in lymphocyte cell 
lines derived from patients homozygous for the OPTN p.Q398X variant (Maruyama et al., 
2010). Here we report that heterozygous p.S174X individuals also have a reduced 
expression of OPTN when compared to controls. Furthermore, when the proteasome 
was inhibited, the expression of the truncated form of OPTN was not detected confirming 
NMD of the mutant transcript (Figure 4.7). When treated with MG132 control, 
heterozygous and homozygous fibroblast lines show an accumulation of p62, however, 
no difference was found in the levels of OPTN between DMSO and MG132 treated cells. 
This result is consistent with what was observed in neuroblastoma cells (Shen et al., 
2015) however, it is not consistent with what was shown in HEK293 cells (Mao et al., 
2017).  
OPTN has an important role in the mitophagy pathway and the lack of OPTN has been 
previously correlated with higher expression of mitochondria markers such as TOM20 
(Wong and Holzbaur, 2014). For this reason, mitochondria abundance, function and 
morphology were analysed in the fibroblast lines. Although the expression of 
mitochondria markers COXIV and TOM20 was found to be marginally higher in 
heterozygous samples compared to controls (Figure 4.8), there does not seem to be any 
morphological difference in their mitochondria using mitotracker stain (Figure 4.10). 
Heterozygous fibroblast lines also showed a higher rate of ATP production, as well as 




did not show a difference in the maximal respiration, spare respiratory capacity and 
coupling efficiency and the mitochondria membrane potential was unchanged (Figure 
4.11 and Figure 4.13). One explanation is that damaged mitochondria might be degraded 
more slowly in these cells compared to controls, which would explain why mitochondria 
were more abundant, as measured by TOM20 or COXIV blots (Figure 4.8). These 
mitochondria might retain some of their functions boosting the ATP production but might 
not be able to perform to their maximum respiratory function when challenged in the 
Seahorse assay, which would explain why there was no difference in the maximal 
respiration parameters (Figure 4.13). These cells also show higher non-mitochondrial 
respiration, which may imply a compensatory mechanism to support the fully functional 
mitochondria.  
Curiously, I observed no difference in mitophagy and autophagy markers when 
comparing the p.S174X homozygous fibroblasts to controls. This could be because only 
one homozygous p.S174X individual was available, which limited the power of the study 
and it is indeed possible a larger number of homozygous individuals would have shown a 
difference. Another possible explanation is that homozygous p.S174X fibroblasts have 
developed without any OPTN and may have generated a compensatory mitophagy 
mechanism that might fail with age. Lastly, it is also possible that given that individual IV-
5 was 54 at the time of the study and has not manifested symptoms of ALS that she 
individual has an unknown protective mechanism not shared by her affected siblings.  
It has been previously reported that OPTN silencing as well as the expression of 
p.Q398X or p.E478G in neuroblastoma cell lines is sufficient to create a disruption of the 
autophagosome-lysosome fusion, leading to an accumulation of LC3-II (Shen et al., 
2015; Sundaramoorthy et al., 2015). However, in this study LC3-II quantification in 
mutant lines showed no expression difference from controls (Figure 4.14), providing no 
evidence of major disruption of the autophagosome-lysosome fusion. A qualitative 
staining of ubiquitin K63 has also shown no striking differences in the distribution of K63 




ubiquitinated material in these cells. These observations suggest that the lack of OPTN 
in fibroblasts does not significantly disrupt the autophagy machinery. However, these 
data were collected in mitotically active culture fibroblasts growing in optimal conditions. 
It is possible that homozygous and heterozygous fibroblast lines would show a disruption 
of the autophagy pathway when stressed with inhibitors of autophagy or other cellular 
stressors. It is also possible that defects in autophagy are most marked in post-mitotic 
motor neurons which may be more susceptible to autophagic defects as they are the 
cells that degenerate in ALS and skin fibroblasts are not know to be affected in OPTN 
deficient patients.  
As ALS patients harbouring mutations in OPTN have previously been shown to 
accumulate neuronal cytoplasmic TDP-43 inclusions on pathological examination 
(Maruyama et al., 2010; Pottier et al., 2015), I stained the fibroblast lines for TDP-43 and 
p62, in order to determine whether they showed any pathological changes. TDP-43 
aggregates were occasionally found in all of the cell lines and no striking difference were 
observed. Furthermore, no difference was observed in the colocaliation of p62 and TDP-
43 inclusions in any of the analysed cells. Once again, stressing the cells could reveal a 
phenotype that appears only subtle when cells are growing in a physiological-like state. 
Unfortunately, due to time constrains, this study only shows a qualitative analysis of 
these aggregates in one replicate. It would be worthwhile analysing these data 
quantitatively across three biological replicates to determine whether there is a 
statistically significance difference.  
4.6 Conclusions 
In summary, this study identified a novel OPTN truncation mutation (p.S174X) that 
causes an aggressive form of ALS which is inherited in an autosomal recessive fashion. 
The expression of this variant is inhibited by nonsense mediated decay, therefore, 
individuals homozygous for the p.S174X mutation completely lose OPTN protein 




and mitophagy function has been hypothesised as the likely neurodegenerative 
mechanism (Maruyama et al., 2010). Interestingly, this study did not present any striking 
mitophagy or autophagy phenotype, which have been shown to be altered in OPTN 
knock out cellular models before (Wong and Holzbaur, 2014; Shen et al., 2015; 
Sundaramoorthy et al., 2015). However, these studies have been conducted in HeLa 
cells, cervical cancer derived cell line, Neuro2A cells, a mouse neuroblastoma cell line, 
and NSC-34, a hybrid cell line obtained from the fusion of embryonic murine spinal cord 
and mouse neuroblastoma cells. These are all immortalised cell lines with a high 
replication rate, which are very different from patient primary fibroblasts used in our 
study. Indeed, primary fibroblasts have a very slow replication rate and a slow 
metabolism, which may make any subtle phenotype difficult to detect. ALS is a motor 
neuron disease that does not show any manifestation in the skin, however, it is valuable 
to study patient derived cells which carry their genetic information in the correct genomic 
and epigenetic context. iPSCs have recently been developed from the homozygous 
fibroblast line, which will be differentiated in motor neurons and investigated further in 





 – Genetic and functional characterisation of MATR3 
ALS-linked variants 
5.1 Background 
Matrin 3 (encoded by MATR3) was associated with ALS in 2014 when an exome 
sequencing study identified four candidate heterozygous variants in a cohort of 205 fALS 
cases, three of which segregated with disease (Johnson et al., 2014). Mutations in 
MATR3 have also been associated with autosomal dominant, distal, asymmetrical 
myopathy with vocal cord paralysis (Feit et al., 1998; Senderek et al., 2009). 
Interestingly, one of the family identified by Johnson and colleagues that carries the 
p.S85C MATR3 mutation, was initially diagnosed with distal myopathy and lately with 
ALS (Johnson et al., 2014), other studies have also reported distal myopathy in patients 
harbouring the p.S85C MATR3 variant (Müller et al., 2014; Palmio et al., 2015). Since 
2014, 15 different MATR3 variants (Table 5.1) have been published in screening of 
~2000 ALS patients from 7 different countries (US, Australia, France, Italy, Taiwan, 
French Canada and China), with a mutation frequency of 0.8% in ALS cases (Fifita et al., 
2014; Millecamps et al., 2014; Lin et al., 2015; Origone et al., 2015; Leblond et al., 2016; 
Xu et al., 2016; Marangi et al., 2017). These patients present with a mean age of onset 
of ~57 and show a large range of survival (2-12 years), most had sporadic disease and 
interestingly very few had features of dementia (Johnson et al., 2014; Lin et al., 2015; 
Origone et al., 2015; Leblond et al., 2016; Marangi et al., 2017) (Table 5.1).  
In the original publication by Johnson and colleagues, post mortem human tissue from 
spinal cord of MATR3-ALS patients carrying the p.F115C variant, showed intense 
MATR3 nuclear staining compared to lighter MATR3 staining in neurologically normal 
controls (Johnson et al., 2014). Furthermore, analysis of skeletal muscle tissue in these 
patients, revealed that TDP43 and MATR3 mislocalise to the sarcoplasm, the cytoplasm 
of skeletal muscle cells, aggregating to form small cytosolic inclusions. Interestingly, a 




different MATR3 variant (p.Q66K), has shown no significant difference in the localisation 











Gender Phenotype Site of onset Age of onset Survival  (years) Origin Familial Reference 
c.48+1G>T 5 - 1 - 1 M - DUL 63 1.8 Canada N 
(Leblond et 
al., 2016) 
c.196C>A 5 p.Gln66Lys 1 - 0 M LMN R 51 2 Italy N 
(Marangi et 
al., 2017) 
c.214G>A 5 p.Ala72Thr 1 - 0 M Classic L 43 11 China N 
(Lin et al., 
2015) 
c.254C<G 5 p.Ser85Cys 
6 affected 
relatives 
- 0 - Classic 3LL,2B,1UL 44,42,33,47,44,49 
21,15,32,16,16,1all 




c.344T>G 5 p.Phe115Cys 
5 affected 
relatives 
- 1 2M,2F,1- - 3UL,2LL 50,52,57,63,70 - - Y 
(Johnson et 
al., 2014) 
c.-339+2T>A 5 - 1 - 0 M - B 79 - Canada N 
(Leblond et 
al., 2016) 
C439A>T 5 p.Arg147Trp 1 - 0 M Classic L 43 9 Italy N 
(Origone et 
al., 2015) 
c.457G>T 5 p.Gly153Cys 2 - 0 M,M UMN-D LL,UL 48,55 15,7 Italy Y,N 
(Marangi et 
al., 2017) 
c.460A>G 5 p.Pro154Ser 1 - 0 - - UL 59 - Asia N 
(Johnson et 
al., 2014) 
c.1180G>A 9 p.Val394Met 1 RRM1 0 M - B 58 - Canada N 
(Leblond et 
al., 2016) 
c.1829C>T 15 p.Ser610Phe 1 - 0 F - UL 48 - China N 
(Xu et al., 
2016) 
c.1864A>G 15 p.Thr622Ala 2 first cousins - 0 F,F Classic, - UL,L 60,62 2.75, - Italian Y 
(Johnson et 
al., 2014) 
c.1991A>C 15 p.Glu664Ala 1 - 36 F Classic B 64 2 Italy N 
(Marangi et 
al., 2017) 
c.2120C>T 15 p.S707L 1 NLS 0 M UMN-D/FTD B 57 12 Italian - 
(Marangi et 
al., 2017) 
c.2360A>G 16 p.N787S 1 - 46 M Classic LL 51 2 Italian N 
(Marangi et 
al., 2017) 
Table 5.1 – All reported MATR3 associated ALS variants and their clinical characteristics. a Mutation nomenclature as recommended by the Human Genome Variation society 
www.hgvs.org, utilising +1 as the A of the initiator Met codon, translation start site. DUL=Distal upper limb, R=respiratory, L=limbs, LL=lower limbs, UL=upper limbs. UMN-D=upper 




MATR3 encodes for a highly conserved protein, Matrin 3 (MATR3), involved in RNA 
processing. It localises to the nucleus and is part of the nuclear matrix, a system that 
supports the nucleus structurally and functionally. MATR3 contains a nuclear export 
signal (NES), two zinc finger domains (ZF), two tandem RNA recognition motifs (RRM1, 
RRM2), a nuclear localisation signal (NLS) and a membrane retention signal (MRS) as 
shown in Figure 5.1 (Hibino et al., 2006). MATR3 has been reported to be involved in 
hyper edited mRNA retention to the nucleus, preventing its translation (Xu et al., 2011), 
DNA repair (Rowland, Hneider and Shneider, 2001), alternative splicing (Coelho et al., 
2015) and NMDA-mediated neurotoxicity (Giordano et al., 2005). MATR3 is also found to 
be phosphorylated by the nuclear protein kinase Ataxia Telangiectasia Mutated (ATM) in 
response to double strand break in DNA, and to cooperate with SFPQ and NONO in 
DNA damage repair (Salton et al., 2010). Furthermore, MATR3 expression has been 
found to be reduced in the CNS in foetal Down’s Syndrome (Bimpaki et al., 2010). A 
recent study has highlighted that MATR3 is expressed at low levels in the muscle and 
spinal cord of mice, and in patients with ALS and distal myopathy, compared to the rest 
of the CNS and other tissues (Rayaprolu et al., 2016). Furthermore, overexpression of 
human wild type MATR3 in mice causes a motor phenotype which shows incomplete 
penetrance as well as clear evidence of pathology in muscle tissue (Moloney et al., 
2016).  
Little functional characterisation has been carried out on ALS-linked MATR3 variants. 
Johnson and colleagues have shown that MATR3 associated with TDP43 in an RNA-
dependent manner and that the p.S85C MATR3 mutant binding to TDP-43 is stronger 
than WT (p<0.01). A different study reported that overexpression of wild type and mutant 
MATR3 (p.S85C, p.F115C, p.P154S and p.T622A) does not alter its cellular localisation 
in Chinese hamster ovary (CHO) and human neuroglioma cells (Gallego-Iradi et al., 
2015). Further investigation of MATR3 mechanism of pathogenicity is necessary in order 





Figure 5.1 – Matrin 3 protein structure (according to Hibino et al. 2006). The figure shows all the mutations annotated in ALSdb (found ≤ 13 times in ExAC) and reported in literature 
to date (in light blue) as well as mutations found by our exome sequencing project (in maroon). NES=nuclear export signal, ZF=zinc finger, RRM=RNA recognition domain, NLS= 




5.1.1 Exome sequencing study  
WES was performed on a cohort of 932 patient samples primarily of European ancestry 
of which 757 were index cases and 175 were affected relatives. Any sample positive for 
mutations in known ALS genes (eg. SOD1, TARDBP, FUS, PFN1, UBQLN2, OPTN, 
VCP, and ANG) or for the C9ORF72 hexanucleotide expansion (Dejesus-hernandez et 
al., 2011) were excluded from further analysis, resulting in a cohort of 699 index samples 
from eleven countries (UK, USA, Italy, Spain, Canada, Germany, Netherlands, Belgium, 
New Zealand, Israel and Ireland, Table 2.1). The DNA extraction and exome capture 
were performed by previous lab members Athina Soraya Gkazi and Jack Miller and 
sequencing was outsourced mainly to the Genomic Core Facility at Guy’s Hospital. The 
data analysis was performed by my colleague bioinformatician Simon Topp.  
Five novel and/or potentially damaging protein changing variants were identified in 
MATR3 (Table 5.3). When this project was initiated, the ExAC 
(http://exac.broadinstitute.org) and GnomAD (http://gnomad.broadinstitute.org/) 
databases had not yet been made available. Variants were, therefore, filtered, as 
explained in section 2.2, against neurologically normal controls in the ESP 
(http://evs.gs.washington.edu/EVS), UK10K (www.uk10k.org) and a 1000 genomes 
(http://www.internationalgenome.org/) cohort accounting for a total of 12,584 control 
samples. When the ExAC and GnomAD genomes data was released the analysis was 
adjusted to include the data from ~60,000 and ~15,000 additional control samples 
respectively, reaching a control number > 80,000 for most loci. Although some variants 
were no longer novel they remained extremely rare (i.e. p.R317C and p.R841C). 
All of the rare candidate variants found in this study are missense heterozygous variants. 
This is in accordance with the literature as no nonsense or homozygous MATR3 variants 
have been associated with ALS to date. Four of the five variants have been found at 




novelty after the addition of the ExAC and GenomAD data and it has also been recently 
described in two unrelated ALS cases (Marangi et al., 2017).  
5.2 Aims of the project  
The aim of this project was to functionally investigate a subset of variants likely to be 
damaging as well as to determine MATR3 variant frequency in a cohort of 174 
apparently sporadic ALS cases. This project ultimately aimed to determine the 
contribution of MATR3 variants to motor neuron degeneration in ALS. 
5.3 Materials and methods   
Most of the materials and methods used in this section have been previously described 
in Chapter 2. Techniques specific to this chapter are explained below.  
5.3.1 Genotyping of patients carrying the MATR3 p.R841C variant 
Patient DNA was amplified and sequenced as described in section 2.3 using the primers 
below (Table 5.2). 
 Forward Reverse 
Amplification and sequencing TGCTGCATTTCTCTTAGGTGAC CCAAAACGGGTTCAAACTCCA 
Table 5.2 –Primers used genotyping of MATR3 p.R841C variant. Primers were designed using Primer 3 
as described in section 2.3.1. Sequences are represented 5’ – 3’. 
5.4 Results 
5.4.1 Genetic screening for MATR3 variants 
In order to determine MATR3 variant frequency in our sporadic cohort, I performed 
Sanger sequencing on six out of the fourteen coding exons of MATR3 in 174 apparently 
sporadic ALS cases and eight exons were sequenced by an MSc student Tegan Fletcher 




and 15 was not possible. No MATR3 variants were identified in DNA from the 174 sALS 
cases.  
5.4.2 Selection of subset of variants 
Five MATR3 variants were identified in our cohort of 699 familial ALS cases (0.7%). 
When this study was initiated we had access to a restricted subset of exomes from 1000 
genomes, EVS and UK10K databases (n=12,584). Three of our variants (p.G153C, 
p.R317C and p.R841C) were considered novel and consistently predicted to be 
damaging by the algorithms SIFT, Polyphen2-hdiv and Polyphen2-hvar. p.R841C was 
found to be present in samples from two unrelated cases. However, the genomic locus 
chr5:139329372, which corresponds to the c.2521 nucleotide on exon 18 of MATR3 that 
is mutated in the p.R841C variant, had no coverage in EVS database decreasing the 
number of individuals sequenced for this region to ~6,000. Our collaborator Dr Nicola 
Ticozzi sequenced exon 18 in 3,596 controls and none carried the p.R841C variant. 
p.R841C was later found in a larger cohort of exomes in ExAC database, an up to date 
































c.457G>T 5 p.Gly153Cys 1 - 0 Damaging M ALS 
Upper 
Limb 




c.949C>T 6 p.Arg317Cys 1 ZF 1 Damaging M ALS Spinal 44 72 Italy - 
c.1102C>A 8 p.Pro368Thr 1 - 2 Damaging F ALS - 49 12 UK - 







2 - 19 Damaging M,F ALS - - - UK ALSdb 
Table 5.3 – Description of the nonsynonymous variants identified in MATR3 and their clinical characteristics. Damage prediction was verified using the cumulative score of 20 
pathogenicity prediction algorithms (2.2.3). a Mutation nomenclature as recommended by the Human Genome Variation society www.hgvs.org, utlizing +1 as the A of the initiator Met 




DNA samples from the two unrelated British patients carrying p.R841C were Sanger 
sequenced in house and this detected the variant to be heterozygous in both cases 
(double peak where red stands for thymine and blue for cytosine) and absent from the 
control sample (Figure 5.2). Unfortunately, we did not have access to any other DNA 
sample from the other individuals harbouring MATR3 nonsynonymous variants in our 
cohort, as they were initially exome sequenced by our international collaborators.   
 
Figure 5.2 – Sequencing of p.R841C samples. Sanger sequencing of one control sample and two affected 
unrelated patients carrying the heterozygous MATR3 p.R841C variant. Blue peaks represent C bases, red 
peaks T bases, black peaks G bases and green peaks A bases.  
The remaining two variants (p.P368T and p.S748P) were either found at least once in 
the exome databases, predicted to be benign or to affect splicing (Table 5.3), and were 
not prioritised for further investigation. N-terminal HA tagged clones of mutants p.R841C, 
p.R317C, p.G153C, p.F115C and p.S85C were made in a Gateway pDEST-30 vector 
(see section 2.4.1) however, due to technical complications and multiple attempts, the 
p.R317C mutant could not be made and therefore was excluded from the study.  
Constructs carrying two of the mutations published by Johnson and colleagues in 2014, 




mechanism further. We chose to study p.S85C as it was reported to have a different 
functional phenotype compared to WT and p.F115C which was shown to mislocalise and 
aggregate in post mortem tissues.  
5.4.3 MATR3 variant p.R841C is not enriched in an ALS population of >5000 
patients 
The MATR3 variant p.R841C was observed three times in a cohort of 5,217 patients and 
19 times in 83,079 published exomes. A Chi square test followed by Yate’s correction 
was applied to determine whether the variant frequency was significantly different 
between the two populations. This analysis revealed that p.R841C is not significantly 
enriched in this ALS population (Chi square=1.178 with one degree of freedom; two 
tailed p value=0.2778).   
 Carrier Non Carrier 
ALS 3 5,214 
Exome database 19 83,060 
Table 5.4 – 2X2 contingency table illustrating the number of ALS and control cases harbouring the 
p.R841C variant and those that do not. 
When the same statistical test was applied to our other chosen variants, only p.R841C 
was significantly enriched in this ALS population compared to controls at the time. 
However, we chose to conduct functional studies on p.S85C, p.F115C, p.G153C and 
p.R841C variants as no phenotypic information is available in the exome databases and 




















5 c.254C<G p.Ser85ysC 1 0 0.566 0.1240 
(Johnson et al., 
2014) 
5 c.344T>G p.Phe115Cys 1 2 0.4142 0.1240 
(Johnson et al., 
2014) 
5 c.457G>T p.Gly153Cys 3 0 0.0001 0.1240 
(Marangi et al., 
2017) 
18 c.2521C>T p.Arg841Cys 3 19 0.2778 0.0119 ALSdb 
Table 5.5 – Enrichment of MATR3 variants in ALS vs control populations. Table showing the variants 
investigated in this study and how many times they are present in the ALS and control cohorts. The p value 
(2017), obtained with a Chi square test followed by Yate’ correction, shows whether they are enriched in the 
current ALS population compared to controls. p Value (2014) shows whether they were enriched in the ALS 
population compared to the control population available at the beginning of this study. a Mutation 
nomenclature as recommended by the Human Genome Variation society www.hgvs.org, utilising +1 as the A 
of the initiator Met codon, translation start site. 
5.4.4 ALS-linked MATR3 variants maintain similar expression in HEK293T 
HEK293T cells were transfected with HA tagged MATR3 WT, p.R841C, p.G153C, 
p.F115C and p.S85C. 48 hours later cells were harvested and processed for western 
blotting as described in section 2.6.2. The membrane was then probed for HA tag and 
GAPDH, with the aim of verifying whether the expression of MATR3 was altered in any 
of the variants compared to wild type.  
MATR3 is a 125 kDa protein, however, when expressed in HEK293T cells, the most 
abundant HA-labelled band was at ~40 kDa band (Figure 5.3). Both bands were absent 
from untransfected cells and, as the clone was from cDNA, the lower band must 
represent a cleaved N-terminal fragment. Quantification of the ~125 kDa and ~40 kDa 
bands did not show any statistically significant difference between the expression of 
MATR3 WT and any of the variants. However, MATR3 p.R841C construct shows higher 
expression of full length (125kDa) proteins compared to wild type (Figure 5.3), despite 






Figure 5.3 – MATR3 construct expression levels in HEK293T cells. Western blot showing MATR3 
expression in WT and mutants showing the predicted ~120 kDa band as well as an additional ~40 kDa band 
(UNTR= untransfected). MATR3 expression was normalised against GAPDH and no statically significant 
difference was observed (n=3, analysed by One Way ANOVA followed by Dunnett's multiple comparison 
test, MATR3 120kDa p= 0.1077 and MATR3 40 kDa p= 0.5394). Error bars represent the standard error of 
the mean (SEM).  
5.4.5 Cellular localisation remains similar among MATR3 variants  
When this project was undertaken, no study had shown whether MATR3 cellular 
localisation was altered in the presence of possibly damaging ALS associated MATR3 
variants. Mislocalisation of the RNA binding proteins TDP43 and FUS from the nucleus 
to the cytoplasm of motor neurons are a key feature of ALS pathology (Neumann et al. 
2006; Vance et al. 2009). To investigate whether the subcellular localisation of MATR3 
was affected by mutation, a fractionation nuclear/cytoplasmic assay was performed on 
HEK293T cells transiently transfected with HA tagged MATR3 WT, p.R841C, p.G153C, 




observed between WT and mutant MATR3 protein levels in the cytoplasmic or nuclear 
fraction (Figure 5.4 b and c). However, p.S85C shows a trend towards higher expression 
of MATR3 in the nucleus (p=0.2784) (Figure 5.4b). Further analysis revealed no 
significant difference in the nuclear to cytoplasmic ratio of MATR3 WT compared to any 
other mutant. However, a higher ratio of nuclear to cytosolic p.S85C MATR3 was 
observed compared WT, despite not reaching significance (p=0.1403 Figure 5.4d).  
Interestingly, the ~40 kDa band clearly observed in Figure 5.3 is weakly expressed only 
in the nuclear fraction of HEK293T transfected with MATR3 WT, p.R841C, p.G153C and 
p.S85C (Figure 5.4a, black arrow).        
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Figure 5.4 – Cellular localisation of ALS-associated MATR3 variants. (a) Representative western blot of 
a nuclear/cytoplasmic fractionation on HEK293T cells transiently transfected with MATR WT, p.R841C, 
p.G153C, p.F115C, p.S85C (black arrow pointing at the ~40 kDa cleaved MATR3) and its quantification 
showing the amount of nuclear (b) and cytoplasmic (c) MATR3 per sample. No significant difference was 
observed among samples (n=3, analysed by One Way ANOVA followed by Dunnett’s multiple comparison 
test, (b) p=0.2586 (c) p=0.3068). (d) Graph showing the percentage of nuclear and cytoplasmic MATR3 per 
sample. (e) Graph showing the ratio of nuclear divided by cytoplasmic MATR3. No significant difference was 
observed among fractions (n=3, analysed by One Way ANOVA followed by Dunnett’s multiple comparison 
test, p=0.0964). Error bars represent the standard error of the mean (SEM). 
5.4.6 MATR3 mutants form cytosolic inclusions when expressed in HEK293T 
cells 
We further investigated MATR3 subcellular localisation in transfected HEK293T cells 
using immunocytochemistry. Cells were fixed and probed with a HA tag antibody and 
DAPI, which revealed WT MATR3 was almost exclusively nuclear, however cytoplasmic 
inclusions were occasionally observed in cells expressing MATR3 p.R841C, p.G153C 
and p.F115C mutant constructs (Figure 5.5). Quantification revealed that all MATR3 






Figure 5.5 – HA staining in HEK293T cells transfected with MATR3 WT, p.R841C, p.G153C, p.F115C, p.S85C. These were probed for HA tag and DAPI staining. Transfected cells 






Figure 5.6 – Inclusion quantification. Quantification of the number of transfected cells containing 
aggregates per genotype (~600 cells counted per sample per replicate, n=2). Error bars represent the 
standard error of the mean (SEM). 
5.4.7 MATR3 p.S85C variant shows increased insolubility in HEK293T 
The presence of insoluble aggregates in cells expressing pathogenic mutations is a 
feature common to most neurodegenerative disorders. To determine if the aggregates 
visualised by immunocytochemistry (Figure 5.5) were insoluble, I conducted a 
complementary RIPA solubility assay with quantification analysis of MATR3 and TDP-43 
in the insoluble fractions by western blot (see section 2.6.3).  
Transiently transfected HEK293T cells, expressing HA tagged MATR3 WT, p.R841C, 
p.G153C, p.F115C and p.S85C constructs, were harvested, processed and analysed by 
western blotting as described in section 2.6.2. Quantification of the insoluble fraction, 
normalised against the amount of MATR3 present in the lysate, revealed a four-fold 
increase of the insoluble fraction in cells expressing p.S85C (*p = 0.0223). The amount 
of soluble MATR3 p.S85C was found to be reduced when compared to the wild type but 






Figure 5.7 – ALS assoicated MATR3 variant solubility analysis in HEK293T. Representative western 
blot of solubility assay of HEK293T cells transiently transfected with MATR3 WT, p.R841C, p.G153C, 
p.F115C, p.S85C (L=lysate, S=soluble fraction, I=insoluble fraction, UNTR=untransfected). (b) Quantification 
showing the amount of soluble MATR3 per sample normalised against MATR3 lysate (n=4, analysed by One 
Way ANOVA followed by Dunnett’s multiple comparison test, p=0.0156). (c) Quantification showing the 
amount of insoluble MATR3 per sample normalised against MATR3 lysate (n=4, analysed by One Way 
ANOVA followed by Dunnett’s multiple comparison test, *p=0.0223). (d) Quantification showing the amount 
of soluble endogenous TDP-43 per sample normalised against TDP-43 lysate (n=3, analysed by One Way 




insoluble endogenous TDP-43 per sample normalised against TDP-43 lysate (n=3, analysed by One Way 
ANOVA followed by Dunnett’s multiple comparison test, p=0.3299). Error bars represent the standard error 
of the mean (SEM). 
It has previously been reported that MATR3 interacts with TDP-43, a protein that plays 
an important role in ALS pathology. Furthermore, Johnson and colleagues have also 
shown that MATR3 p.S85C displays a stronger interaction with TDP-43 compared to 
MATR3 WT (Johnson et al., 2014). In the context of ALS and FTD, TDP-43 often 
mislocalises to the cytoplasm and creates insoluble cytoplasmic inclusions (Abeliovich et 
al., 2012). With this in mind, we investigated the insolubility of TDP-43 in HEK293T cells 
transiently transfected with WT and mutant MATR3, to verify whether there was any 
correlation between MATR3 and TDP-43 solubility. No significant difference emerged 
from the comparison of mutant with WT MATR3 transfected cells. Interestingly, the 
amount of insoluble TDP-43 in p.S85C transfected cells is lower than the amount of 
insoluble TDP-43 in cells transfected with MATR3 WT, however, the comparison did not 
reach significance (p=0.1888, Figure 5.7e).  
In order to determine whether MATR3 mutations influenced colocalisation with 
endogenous TDP-43, HEK293T cells were transiently transfected with HA tagged 
MATR3 WT, p.R841C, p.G153C, p.F115C, p.S85C and probed for HA tag (green), TDP-
43 (red) and DAPI (blue). Both MATR3 and TDP-43 were predominantly localised in the 
nucleus showing occasional cytoplasmic aggregates as well as diffuse staining but no 






Figure 5.8 – Colocalisation of MATR3 and TDP43 in HEK293T cells transfected with HA tagged 
MATR3 WT, p.R841C, p.G153C, p.F115C, p.S85C. These were probed for HA tag (green), TDP-43 (red) 
and DAPI (blue). Transfected cells show nuclear HA tag, TDP-43 and DAPI staining. Scale bar = 10 µM 
5.4.8 ALS-linked MATR3 variant p.R841C shows aggregation in SH-SY5Y cells 
The neuroblastoma-derived cell line SH-SY5Y is recognised as a good model for the 
study of neurodegenerative mechanisms as it retains some neuronal characteristics 
which are not found in kidney-derived HEK293T cells (Krishna et al., 2014). SH-SY5Y 
cells were transiently transfected with HA tagged MATR3 WT and the mutant constructs 
and the number of cells containing inclusions quantified (Figure 5.9Figure 5.10). p.S85C 
variant showed a similar amount of inclusions compared to WT, while p.R841C, 
p.G153C, p.F115C showed an increased number of inclusions, however, only MATR3 
p.R841C reached statistical significance compared to WT (**p=0.0020,Figure 5.10), 






Figure 5.9 – SH-SY5Y cells transfected with MATR3 WT, p.R841C, p.G153C, p.F115C, p.S85C. These were probed for HA tag and DAPI staining. Transfected cells show nuclear 




Figure 5.10 – Inclusions quantification. Quantification of the number of transfected cells containing 
aggregates per genotype (~250 cells counted per sample). A significant difference is observed between the 
number of MATR3 WT and MATR3 p.R841C transfected cells containing aggregates (n=3, analysed by One 
Way ANOVA followed by Dunnett’s multiple comparison test, **p=0.0020). Error bars represent the standard 
error of the mean (SEM). 
5.5 Discussion 
The aim of this project was to genetically and functionally characterise ALS-associated 
MATR3 variants. This chapter describes five ALS-linked MATR3 variants that have been 
identified through exome sequencing project of 699 fALS cases. These mutations were 
originally filtered against ~12,600 controls and, a subset of variants (p.G153C, p.R317C 
and p.R841C) were chosen for functional investigation. This decision was made based 
on public exome databases available at the time. The variant p.R841C was initially found 
to be enriched in our ALS cohort in 2014 but was no longer significant in 2017 (Table 
5.5), as the same variant was later found to be present a total of 19 times in 83,079 
controls and 3 times in a 5,217 ALS patients. When the same analysis was applied to the 
other mutations none of these reached statistical significance in the ALS population, with 
the exception of p.G153C. It is important to note that highly powered burden analysis 
failed to identify confirmed ALS genes such as PFN1, OPTN and VAPB to as reaching 
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statistical significance for association with fALS and sALS (Kenna et al., 2016). 
Moreover, the single variant chi-square enrichment test as well as burden analysis tests 
do not take into account the segregation of the p.S85C and p.F115C MATR3 variants 
with disease in pedigrees, as illustrated by Johnson and colleagues (Johnson et al., 
2014), and the fact that we have found the p.R841C variant twice in our cohort of fALS. 
Lastly, little is known about the majority of publicly available exome controls. ALS is 
predominantly a late onset disease and invariably lowly penetrant (as evidenced by 
sALS cases), so it cannot be excluded that a proportion of these controls may develop 
ALS later in their life. Even in the absence of segregation or burden analysis our rare 
variants do merit functional studies to determine whether they might disrupt MATR3 
function and be pathogenic. 
From a clinical point of view, the patients belonging to our cohort do not seem to show 
the same characteristics (Table 5.3) as the ones reported in the literature (Table 5.1). 
More specifically, the patient from our cohort harbouring p.G153C variant does not show 
longer survival that was previously reported (Marangi et al., 2017). Interestingly, 
mutations in other ALS genes, such as VCP (Johnson et al., 2010) and ATX2 (Van 
Damme et al., 2011), have shown heterogeneous rate of survival (Li and Wu, 2016). 
However, a larger pool of MATR3 patients is needed in order to understand the clinical 
traits of MATR3-linked ALS. 
When transfected in HEK293T cells, our MATR3 variants showed similar levels of 
protein expression (Figure 5.3), which does not confirm the report by Johnson and 
colleagues, who detected a lower expression of p.S85C mutant in HEK293FT cells 
(Johnson et al., 2014). When overexpressed in HEK293T all MATR3 constructs 
consistently show a discrete ~40 kDa band, which is likely to be the result of a cleavage 
event. Since all of our MATR3 have a 3kDa N-terminal HA tag, the fragment observed 
represents the first ~37 kDa of the protein. Interestingly, a recent study reports that, in 
mice, MATR3 shows an ~80 kDa fragment that was detected using an antibody raised 
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against the C-terminal region of MATR3 (Rayaprolu et al., 2016), so the 37kDa fragment 
we observed could represent its complementary N-terminal fragment. It would be 
interesting to verify whether, if stained with an N-terminal MATR3 antibody, the same 
lysates from mouse tissue also detected a ~40 kDa band. However, the abundance of 
these bands could be due to the overexpression of MATR3 and might not be detectable 
at endogenous level.  
In the context of ALS, RNA binding proteins, which are predominantly confined to the 
nucleus, often mislocalise to the cytosol and aggregate. In our studies MATR3 remained 
predominantly in the nucleus and no shift to the cytoplasm was detected (Figure 5.4). If 
anything, the nuclear proportion of MATR3 p.S85C protein was increased although this 
did not reach statistical significance (Figure 5.4e). This is largely in accordance with the 
recent observation that the expression of MATR3 p.S85C, p.F115C, p.P154S and 
p.T622A in Chinese Hamster Ovary (CHO) cells did not affect the nuclear localisation of 
MATR3 (Gallego-Iradi et al., 2015).  
The formation of insoluble cytoplasmic aggregates in affected motor neurons is another 
common characteristic of RNA binding proteins such as TDP-43 and FUS. The solubility 
of MATR3 WT, p.R841C, p.G153C and p.F115C, was not significantly different from WT 
however p.S85C was significantly more insoluble (Figure 5.7). Johnson and colleagues 
have found that MATR3 p.S85C coaggregates with TPD-43 in skeletal muscle tissue 
(Johnson et al., 2014). Surprisingly, the level of endogenous TDP-43 was relatively 
decreased in both the soluble and insoluble fractions of cells transfected with p.F115C 
and p.S85C, although this did not reach statistical significance.  
We were unable to show any correlation between the solubility and aggregation of ALS-
linked MATR3 variants and TDP-43 in transiently transfected HEK293T cells. It would be 
interesting to replicate the immunoprecipitation study reported by Johnson’s and 
colleagues to determine whether p.R841C and p.G153C cause any impairment of the 
MATR3-TDP43 interaction. Furthermore, since MATR3 has been shown to interact with 
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TDP-43 in an RNA dependent manner (Johnson et al., 2014), an informative experiment 
would be to check whether any of the mutations in our cohort disrupted MATR3-RNA 
interactions at the RRM2 domain (Salton et al., 2011).  
The presence of insoluble MATR3 in the nucleus could cause an impairment of MATR3’s 
ability to cooperate with SFPQ and NONO. MATR3, in fact, interacts with these two 
proteins in order to perform non homologous end joining (NEHJ) and repair double 
strand DNA damage (Salton et al., 2010). Checking for MATR3 interaction with SFPQ 
and NONO, by immunoprecipitation for instance, would reveal whether our subset of 
mutations disrupts MATR3 ability to coordinate NEHJ. In this process, MATR3 is known 
to be phosphorylated by ATM. Lack of MATR3 phosphorylation has been found in 
patients with ataxia-telangiectasia (A-T) (Salton et al., 2010). Another interesting 
experiment would be to verify whether any of our variants causes lack of MATR3 
phosphorylation, resulting in an impairment of DNA double strand break repair, which 
could cause neuronal toxicity.  
Furthermore, the increased presence of p.S85C in the nucleus could also disturb MATR3 
regulation of mRNA splicing. MATR3 acts as a splicing repressor by interacting with 
PTB, an RNA binding protein that regulates mRNA splicing (Coelho et al. 2015). It would 
be interesting to determine whether any of these variants affected MATR3’s ability to 
bind PTB and disrupted alternative splicing. The impairment of these mechanisms could 
be particularly deleterious for tissues where there is a minimal cell turnover, such as 
neurons or muscles which bear the burden in mutant MATR3 cases. Interestingly, the 
MATR3 variant p.S85C has been linked to both asymmetric myopathy (Senderek et al., 
2009) and ALS (Johnson et al., 2014).  
The biggest limitations of this study is that all the experiments have been conducted in 
overexpression models using cell lines that do not reflect the physiology of neuronal 
cells. This was due to the lack of availability of patient tissue. Although, the cell lines 
used in this study are widely accepted as a good model for biochemical and molecular 
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biology studies, it would be interesting to replicate some of these assays in human iPS-
derived cells, expressing the MATR3 variants endogenously, in order to verify whether 
the same dysfunction is observed.   
5.6 Conclusions  
In summary, we have shown that the MATR3 variant p.S85C is relatively insoluble 
compared to MART3 WT and that it has a tendency to be retained in the nucleus. 
Furthermore, the MATR3 variant p.R841C forms cytoplasmic inclusions but these were 
not insoluble. These two mutations could disrupt the low complexity domain of MATR3 
and, in a similar way to TDP-43 mutations, they could increase its solubility and tendency 
to form inclusions (Coelho et al. 2015), however the MATR3 variants did not increase 
TDP-43 insolubility and MATR3 and TDP43 did not colocalise within inclusions.  
The behaviour of MATR3 p.F115C and p.G153C variants was no different from WT in 
this overexpression model and we have no evidence for their pathogenicity. As we do 
not know the mechanism of action for MATR3 mutations it may be that these mutations 
are pathogenic by a by different molecular mechanisms and further investigation is 





 - General Discussion 
The general aim of this thesis was to shed light on ALS pathogenesis by studying the 
molecular mechanisms involved in newly identified genes: MATR3, OPTN and TBK1. 
When this project was initiated, my team and their international collaborators, had just 
completed an exome sequencing project of ~700 index familial ALS patients, with the 
aim of identifying novel genes casually implicated in ALS. This project has successfully 
identified novel ALS-associated genes, including TUBA4A, ANXA11 and NEK1 (Smith et 
al., 2014, 2017; Kenna et al., 2016). Another important contribution from exome 
sequencing is the identification of more mutations in recently discovered genes, which 
presents an opportunity to study their functional effects and map mechanistic pathways. 
We believe that studying the pathogenic mechanisms for these mutant genes will provide 
further insights that may contribute towards finding novel therapies.    
Through our exome sequencing, we identified sixteen TBK1 variants four of which were 
novel. In the first result chapter of this thesis I show that two ALS associated TBK1 
variants, the missense p.G217R and the truncation p.R357X mutations both showed a 
significant loss of TBK1 kinase activity while another variant, p.C471Y, did not. Many 
ALS-linked nonsense mutations were implicated in haploinsufficiency as a primary 
disease mechanism, however relatively little focus has been directed at understanding 
how missense mutations might cause disease (Freischmidt et al., 2015; Gijselinck et al., 
2015; Kim et al., 2016; Tsai et al., 2016; Pozzi et al., 2017). The loss of TBK1’s ability to 
auto-phosphorylate has only been observed once before in an overexpression model of 
in frame deletions (van der Zee et al., 2017) and never in missense variants or patient 
material. In this study I demonstrated that patient derived lymphoblast harbouring TBK1 
missense variants show a lower level of TBK1 phosphorylation, regardless of where the 
variants map in the functional domains. Furthermore, I also showed that the missense 
mutation p.G217R, which lies in the kinase domain, disrupts the ability of TBK1 to 
homodimerise and auto-phosphorylate and, therefore, to carry out its physiological 
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function, suggesting a common mechanism for all missense and nonsense mutations. 
This would lead to a TBK1 haploinsufficiency causing a functional impairment of 
autophagy and inflammatory response, both of which have previously been implicated in 
ALS and FTD (Cirulli et al., 2015; Freischmidt et al., 2015). I demonstrated that these 
two TBK1 mutants failed to phosphorylate IRF3, as had previously been observed 
(Freischmidt et al., 2015; Kim et al., 2016; Tsai et al., 2016; Pozzi et al., 2017). This in 
turn inhibits NF-kB/IFN activation and suggests an involvement of the inflammatory 
pathway (Freischmidt et al., 2015; van der Zee et al., 2017). However, some variants 
retain the ability to regulate this pathway and therefore this is not a mechanism common 
to all TBK1 mutations. Post-mortem brain analysis of ALS and FTD patients bearing 
mutations in TBK1 have shown accumulation of TDP-43 aggregates (Gijselinck et al., 
2015; Pottier et al., 2015; Koriath et al., 2016; van der Zee et al., 2017), which implicates 
a disruption of autophagic clearance. Furthermore, ALS-associated nonsense variants, 
or those mapping in the scaffold dimerization domain (SDD) (p.L59Ffs, p.R444X, 
p.Ile472Serfs*8, p.M559R, p.E696K, p.690-713del) have been shown to affect TBK1 
binding with OPTN (Freischmidt et al. 2015; Kim et al. 2016; Pozzi et al. 2017; Richter et 
al. 2016; Tsai et al. 2016). I have shown that the mutation p.G217R, which maps in 
TBK1’s kinase domain (KD) also affects TBK1 binding to OPTN. Therefore, autophagy 
impairment remains a valuable hypothesis. However, the involvement of TBK1 in so 
many pathways makes it hard to point the finger at one singular mechanism, and it may 
well be the case that TBK1 associated pathology results from an ensemble of different 
defective cellular pathways.  
Exome sequencing and shared region of homozygosity analysis identified a novel 
nonsense OPTN mutation (p.S174X) in a consanguineous Palestinian family presenting 
with an aggressive adult-onset form of ALS in four siblings. Through our collaborators I 
obtained fibroblasts derived from four asymptomatic family members (three 
heterozygous and one homozygous for the truncation mutation) and demonstrated that 
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when harbouring the mutation p.S174X OPTN mRNA is degraded by nonsense 
mediated decay (NMD), resulting in a complete or partial loss of OPTN expression in 
homozygous and heterozygous carriers respectively. The absence of OPTN expression 
in homozygous individuals is likely to be responsible for their disease. Because OPTN 
has been involved in the mitophagy pathway together with TBK1 (Ying and Yue, 2016), I 
explored this further in the fibroblast lines. Mild mitochondria respiratory dysfunction was 
detected in the heterozygous lines but curiously not in the homozygous line derived from 
an unaffected sibling. It may be that OPTN null cells develop a compensatory 
mechanism that may fail with aging or that this individual has another protective 
mechanism absent from her siblings. Analysis of more homozygous cell lines might 
provide an explanation. Accumulation of the autophagy markers LC3-II and K-63 
ubiquitin was not observed in any of the fibroblast lines and no striking difference was 
observed in the number of TDP-43 inclusions and their colocalisation with p62 among 
fibroblast lines. Primary fibroblasts, however, have a slow metabolism and it is possible 
that the heterozygous and homozygous fibroblast lines would show defects in autophagy 
if stressed using autophagy inhibitors or other cellular stressors.   
The exome sequencing project also identified five MATR3 variants that, at the time, had 
not been described before, and one of which (p.R841C) was found in two unrelated 
patients. I carried out overexpression studies in HEK293T cells on two of these variants 
(p.G153C and p.R841C) together with two of the variants (p.S85C and p.F115C) first 
identified by Johnson and colleagues (Johnson et al., 2014). I have demonstrated that 
the p.S85C MATR3 mutant is more insoluble when compared to the wild type, or other 
mutants. Mutant protein insolubility and inclusion formation are characteristics shared by 
other RNA binding proteins linked to ALS, including TDP-43 and FUS (Kwiatkowski et 
al., 2009; Scotter et al., 2014). I have also shown that the MATR3 mutant p.R841C 
enhances aggregate formation in two cell line models, reaching significance in SH-SY5Y 
cells, a neuroblastoma-derived cell line that preserves some neuronal characteristics 
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(Kovalevich and Langford, 2013). Aggregate accumulation of RNA-binding proteins, as 
well as other proteins, is also a feature observed in the brain and spinal cord of ALS and 
FTD patients (Peters, Ghasemi and Brown, 2015). Therefore, both these findings are 
interesting and could point towards a possible MATR3-disease causing mechanism.  
I believe that, in this thesis, I have highlighted the importance of follow up functional 
studies, starting from an anonymous investigation technique such as WES. Functional 
characterisation is necessary in order to confirm the pathogenicity of a variant, even if 
this is predicted to be pathogenic. As I observe in the case of TBK1 variant p.C471Y, 
predicted to be pathogenic by 20 algorithms, this does not show any sign of 
pathogenicity according to the assays used in this study. This might mean that the 
variant is not pathogenic at all. Without the functional characterisation we would have not 
been able to come to such conclusion. It is possible that the p.C471Y variant may cause 
the disease through a different pathway, however a result similar to what we observe for 
p.C471Y, was obtained by Kim and colleagues for the variant p.I475T (Kim et al. 2016). 
This might indicate that TBK1 variants that map in that particular region of the protein do 
not have a major impact on TBK1 function. A similar case is observed in MATR3, where 
the variant p.F115C and p.G153C are predicted to be pathogenic but do not show 
evidence of pathogenicity in our as well as other published studies (Gallego-Iradi et al., 
2015; Marangi et al., 2017; Iradi et al., 2018). Overall, I believe that this thesis 
emphasises the importance of functional variant characterisation as an essential tool to 
demonstrate a variant pathogenicity in the context of ALS.  
Many of the studies presented here employ overexpression, which are robust and widely 
used models to study neurodegenerative diseases but they also represent a limitation. 
Indeed, immortalised cell lines are known to collect genetic abnormalities when cultured 
for an extended period of time. Furthermore, the ability of these cells to replicate 
continuously and the high level of protein expression induced by the transfection do not 
accurately represent physiological or disease conditions in the brain. These models are 
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relatively quick and easy to manage and have played an important role in the discovery 
of many underlying mechanisms of neurodegeneration. For these reasons, we decided 
to adopt this method as an initial investigation of how the novel mutations found by 
exome sequencing would influence cell homeostasis. 
A similar argument can be applied to my use of non-neuronal patient derived cell lines. 
Although they carry the patient genome and express the mutated proteins endogenously, 
they do not necessarily recapitulate the neuronal pathology. However, research using 
these cells is still valuable as we assume that dramatic changes observed in fibroblast or 
lymphoblast cell lines, such as the absence of OPTN or the lack of TBK1 
phosphorylation, may also be present in neurons. Furthermore, these cells can be 
reprogrammed to become induced pluripotent stem cells (iPSCs), which can then be 
differentiated into motor neurons to generate more physiological model for the study of 
this disease.  
An additional limitation of this thesis is the amount of available lines carrying the same 
ALS-associated variant. Throughout this study we often had access to only one line 
carrying each TBK1 or OPTN mutation (with the exception of the fibroblast lines carrying 
the homozygous p.S174X OPTN change). This is due to lack of available patients 
carrying the same mutations. A solution to this problem would be to artificially introduce 
the variant in iPSCs, using the CRISPR-Cas9 system (Sander and Joung, 2014) for 
instance, that can successively be differentiated into motor neurons. This would be an 
ideal approach as control and mutated lines would be genetically identical, making any 
phenotypic change attributable to the introduced mutation.  
In conclusion, from exome sequencing I have identified several novel mutations in three 
genes recently associated with ALS: TBK1, OPTN and MATR3 and explored their 
functional consequences in simple cellular model to generate new insight into disease 
pathogenesis. While acknowledging the limitations of an overexpression system I believe 
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that several findings in this thesis have made a modest contribution to our knowledge of 
the molecular mechanisms driving neurodegeneration in ALS. It is only through a greater 
understanding of fundamental disease mechanisms that we will be able to identify 
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Appendix A. Primer List  
6.1 Primers used for genotyping of TBK1, OPTN and MATR3  
Gene Exon Forward primer Reverse primer 
TBK1 
2 CATGTCAGTAACAGATAATGGGTGA CAAAGGGATCAAAATCACCAA 
3 TCCCTGTGCCTAAAAGATGC TGAAAATTAGGGTTTGTACAACCA 
5 AATGAATTTGAGACATGCACACA AGGGTGCTACAAAACTTCCAAG 
6 AAAGGGCATAAGGGAGTGCT TGGGAGGAAAGTGCTGACAA 
7 TGGATCCTGTGAGCATCAATC TTGAGTATCTGTGGTTCTAGGCA 
8 CAGTTCCTTTGATTTGCTGGT TGGGAAATGGGTACTTTTGG 
9 TGCCTCTCACTTTATCCCCA ACACAATGAGTCCAATGCTTCT 
12 TACATCAGGATCACAGAAATGCT AGCAGGCCTCAAGTCTTAGT 
18 TGCCACAAAAGCTATGACGC GGGTGGAACTGAATGTAGGC 
OPTN 6 GGTGGCCAGCCTTAGTTG TTGTTTCATCTTTCCAGGGG 
MATR3 
5 ACGGCATCTGCTTAAAGGGA TGCTTGATCAACTCAATGTCATCA 
6 ATGGGCAGGTGTTTGTACAG TGTCCATACAGTACCACTATGTGA 
7 AGGCTGTTTTGTGAAAAGGACA TGTTGAAAGTGAAACCTGAATTCCT 
8 TGTGGTCATATATTGGGGTGCT GGGCGATAAGAGCAAAACCC 
9 TGTGTTTGGAAGATGCACGT AGGACCACGATACATACTCAACT 
10 AGTCCTAATGCGTAATTGGTTTCA CGAGACTCCGACTCCCAAAA 
12 TTGCACATTTGTCCTTTTGTTGT GAATGACGCCCAGCTCCATA 
14 CCCTAAAGGACACCTTCATTGC TGGAGATTCTTTGCCATCTGGA 
16 CAGACAGAAGGGATGCTGCA AGGAGAGTGAGGAAGGTGAAGA 
17 AGGCTGTATTGGACTTCTCAAA TCAGGAGAAAGCACTGCACT 
18 TGCTGCATTTCTCTTAGGTGAC CCAAAACGGGTTCAAACTCCA 
Table 6.1 – Sequence of all the primers used for genotyping of TBK1, OPTN and MATR3. Forward and 
reverse primers were used for the amplification and sequencing of the different exons. Primers were 
designed using Primer 3 as described in section 2.3.1. Sequences are represented 5’ – 3’.  
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6.2 Mutagenesis primers 






































Table 6.2 – Primers used for mutagenesis. Primers were designed using the Agilent QuickChange® 




6.3 Primers used for cDNA sequencing  



















Table 6.3 – Primers used for the sequencing of TBK1 and MATR3 plasmids. Primers were designed 




Appendix B. TBK1 variants discovered to date.  
Type of variant Exon Varianta Predicted aa change Affected individuals Affected domain Frequency in ExAC Diagnosis Reference 
Nonsense 
2 c.4C>T p. Gln2X 1 - 0 FTD (Gijselinck et al., 2015) 
4 c.349C>T p.Arg117X 3 KD 1 2FTD,ALS 
(Cirulli et al. 2015; 
Pottier et al. 2015; van 
der Zee et al. 2016) 
5 c.379C>T p. Arg127X 1 KD 0 ALS 
(van der Zee et al., 
2017) 
6 c.555T>A p. Tyr185X 2* KD 0 2fALS 
(Freischmidt et al., 
2015) 
8 c.1069C>T p.Arg357X 2 ULD 0 2ALS (Cirulli et al. 2015) 
11 c.1340+1G>A p.Ala417X 5 SDD 0 fALS,3sALS,FTD 
(Freischmidt et al., 
2015; van der Zee et 
al., 2017) 
11 c.1318C>T p.Arg440X 3* SDD 0 fALS,ALS-FTD,ALS 
(Freischmidt et al., 
2015) 
11 c.1330C>T p.Arg444X 1 SDD 1 ALS-FTD (Tsai et al., 2016) 
11 c.1331G>A p.Arg444X 1 SDD 0 ALS-FTD 
(Borghero et al. 2015; 
Cirulli, et al. 2015) 
11 c.1335G>A p.Trp445X 1 SDD 0 FTD 
(van der Zee et al., 
2017) 
13 c.1146T>G p.Tyr482X 1 SDD 0 ALS-FTD (Le Ber et al., 2015) 
13 - p.Ser499X 1 SDD 0 ALS (Cirulli et al. 2015) 
19 c.1963C>T p. Gln655X 1 SDD 0 ALS-FTD (Le Ber et al., 2015) 
Frameshift deletions 
2 c.86delA p.Lys29ArgfsX15 1 KD 0 FTD 
(van der Zee et al., 
2017) 
3 c.176dupT p.Leu59PhefsX16 1 KD 0 sALS (Pozzi et al., 2017) 
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4 c.358+2T>C p.Thr77TrpfsX4 1 KD 0 fALS 
(Freischmidt et al., 
2015) 
4 c.288delT p. Val97PhefsX2 1 KD 1 ALS 
(van der Zee et al., 
2017) 
4 c.358+5G>A - 1 - - sALS (Pozzi et al., 2017) 
5 c.467_468delCA p. Thr156ArgfsX6 1 KD 0 ALS-FTD (Le Ber et al., 2015) 
8 - p.T278fs 1 KD 0 ALS (Cirulli et al. 2015) 
8 c. c.958delA p. Thr320GlnfsX40 1 ULD 1 fALS 
(Freischmidt et al., 
2015) 
10 c.1191delT p. Ser398ProfsX11 1 - 0 ALS (Gijselinck et al., 2015) 
10 c.1197delC p.Leu399fs 1 - 0 fALS (Williams et al., 2015) 




p.Ile450LysfsX15 3* SDD 0 3fALS 





p.Thr462LysfsX3 2 SDD 0 2ALS 
(Cirulli et al. 2015; van 
der Zee et al. 2017) 
12 c.1414delA p.Ile472Serfs*8 1 SDD 0 ALS (Kim et al., 2016) 
12 c.1434_1435delTG p.Val479GlufsX4 1 SDD 0 fALS 
(Freischmidt et al., 
2015) 
13 - p.Asp500fs 1 SDD 0 ALS (Cirulli et al. 2015) 
14 c.1551_1552insTT p.Ser518LeufsX32 1 SDD 0 ALS (Gijselinck et al., 2015) 
15 - p.Glu550fs 1 SDD 0 ALS (Cirulli et al. 2015) 
18 - p.Gln629fs 1 SDD 0 ALS (Cirulli et al. 2015) 
20 c.2070delG p.Met690fs 1 SDD 0 ALS (Borghero et al., 2015) 
In frame deletions 
3 c.228+1G>A p. Lys30_Glu76del 1 KD 0 - 
(van der Zee et al., 
2017) 
4 c.235_237delACA p. Thr79del 1 KD 0 ALS-FTD 




5 c.499_501delGAT p. Asp167del 1 KD 0 ALS (Gijselinck et al., 2015) 




p. Gly272_Thr331del 1 KD-ULD 0 FTD 









p.Glu643del 6 SDD 0 ALS-FTD,3FTD,2ALS 
(Freischmidt et al., 





p.Glu643del 11 SDD 0 
2sALS,5dementia,1ALS,2
FTD1ALS-FTD 
(Freischmidt et al., 
2015; Gijselinck et al., 
2015) 
19 c.1960-2A>G IVS18-2A>G 1 - - ALS-FTD (Le Ber et al., 2015) 
20 c.2138+2T>c p.690-713del 3* SDD 0 2fALS,1- 




2 c.10A>G p.Thr4Ala 1 - 0 FTD (Le Ber et al., 2015) 
2 c.77G>A p. Gly26Glu 1 KD 0 ALS (Le Ber et al., 2015) 
3 c.140G>A p.Arg47His 1 KD 0 fALS 
(Freischmidt et al., 
2015) 
3 c.185T>C p. Leu62Pro 1 KD 0 sALS (Shu et al., 2016) 
3 c.217A>G p.Ile73Val 1 KD 5 - (Gijselinck et al., 2015) 
4 c.281T>C p.Leu94Ser 1 KD 0 ALS 
(van der Zee et al., 
2017) 
4 c.314A>G p.Tyr105Cys 1 KD 0 sALS 
(Freischmidt et al., 
2015) 
4 c.352G>A p.Asp118Asn 1 KD 1 sALS (Pozzi et al., 2017) 
5 c.362G>A p.Gly121Asp 1 KD 0 ALS 
(Freischmidt et al., 
2015) 
5 c.427C>T p.Arg143Cys 1 KD 0 ALS (Le Ber et al., 2015) 
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6 c.687G>T p.Arg229Ser 1 KD 0 ALS 
(van der Zee et al., 
2017) 
7 c.731G>T p. Gly244Val 1 KD 0 ALS-FTD 
(van der Zee et al., 
2017) 
7 c.737T>C p. Ile246Thr 1 KD 0 ALS 
(van der Zee et al., 
2017) 
8 c.871A>G p.Lys291Glu 1 KD 21 FTD (Gijselinck et al., 2015) 
8 c.914T>C p.Ile305Thr 1 KD 5 sALS 
(Freischmidt et al., 
2015) 
8 c.916C>A p.Leu306Ile 1 KD 36 ALS-FTD (Pottier et al., 2015) 
8 c.923G>A p.Arg308Gln 1 ULD - sALS 
(Freischmidt et al., 
2015) 
8 c.959C>T p.Thr320Ile 1 ULD - ALS (Le Ber et al., 2015) 
9 c.1001T>C p.Ile334Thr 1 ULD 2 sALS (Shu et al., 2016) 
9 c.1070G>A p.Arg357Gln 2 ULD 1 fALS,sALS 
(Freischmidt et al., 
2015; Pozzi et al., 
2017) 
10 c.1201A>G p. Lys401Glu 1 SDD 1 FTD-AD (Le Ber et al., 2015) 
11 c.1252A>G p.Ile418Val 1 SDD 1 FTD 
(van der Zee et al., 
2017) 
15 c.1676T>G p.Met559Arg 1 SDD 0 fALS 
(Freischmidt et al., 
2015) 
15 c.1712C>T p.Ala571Val 1 SDD 2 sALS 
(Freischmidt et al., 
2015) 
17 c.1792A>G p.Met598Val 1 SDD 0 sALS 
(Freischmidt et al., 
2015) 
19 c.1985T>C p.Met662Thr 1 - 0 ALS-FTD (Le Ber et al., 2015) 
20 c.2086G>A p.Glu696Lys 3 CTD 2 fALS,sALS,FTD-AD 
(Freischmidt et al., 
2015; Pottier et al., 
2015) 




2 - Asn22His 1 KD 0 ALS (Cirulli et al. 2015) 
2 - Asn22Asp 1 KD 0 ALS (Cirulli et al. 2015) 
2 - Arg25His 1 KD 0 ALS (Cirulli et al. 2015) 
3 c.127A>G p.Ile43Va 1 KD 0 sALS (Tsai et al., 2016) 
3 c.188A>G p.Asn63Ser 1 KD 0 - 
(van der Zee et al., 
2017) 
5 - p.Asn129Asp 1 KD 0 ALS (Cirulli et al. 2015) 
5 - p.Val132Glu 1 KD 0 ALS (Cirulli et al. 2015) 
5 - p.Arg134His 1 KD 0 ALS (Cirulli et al. 2015) 
5 - p.Ser151Cys 1 KD 0 ALS (Cirulli et al. 2015) 
5 - p.Ser151Phe 1 KD 1 ALS (Cirulli et al. 2015) 
6 c.550A>G p.Met184Val 1 KD 2 - 
(van der Zee et al., 
2017) 
6 - p.Gly217Arg 1 KD 1 ALS (Cirulli et al. 2015) 
6 - Arg228His 1 KD 1 ALS (Cirulli et al. 2015) 
7 - Ile257Thr 1 KD 0 ALS (Cirulli et al. 2015) 
7 c.794T>C p.Val265Ala 1 KD 0 - 
(van der Zee et al., 
2017) 
7 c.812G>T p.Arg271Leu 1 KD 0 FTD (Gijselinck et al., 2015) 
8 - p.Leu277Val 1 KD 0 ALS (Cirulli et al. 2015) 
8 c.871A>G p.Lys291Glu 1 KD 21 sALS (Pozzi et al., 2017) 
8 c.881G>A p.Gly294Asp 1 KD 0 sALS (Tsai et al., 2016) 
8 c.964C>T p.His322Tyr 1 ULD 62 sALS (Gijselinck et al., 2015) 
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8 - p.Thr331Ile 1 ULD 3 ALS (Cirulli et al. 2015) 
9 - p.Thr343Ser 1 ULD 2 ALS (Cirulli et al. 2015) 
9 c.1057A>G p.Ile353Val 1 ULD 0 - 
(van der Zee et al., 
2017) 
9 c.1150C>T p.Arg384Thr 2 ULD 5 2ALS (Borghero et al., 2015) 
9 c.1179A>G p.Ile393Met 1 - 7 - 
(van der Zee et al., 
2017) 
10 - p.Tyr394Asp 1 - 0 ALS (Cirulli et al. 2015) 
10 c.1190T>C p.Ile397Thr 2 - 11 - 
(van der Zee et al., 
2017) 
10 c.1217A>G p.Tyr406Cys 1 - 0 - 
(van der Zee et al., 
2017) 
10 - p.Arg440Gln 1 SDD 1 ALS (Cirulli et al. 2015) 
10 - p.Cys471Tyr 1 SDD 0 ALS (Cirulli et al. 2015) 
12 c.1424T>C p.Ile475Thr 1 SDD 0 ALS (Kim et al., 2016) 
12 c.1426G>A p.Glu476Lys 1 SDD 1 ALS (Kim et al., 2016) 
14 c.1544T>C p.Ile515Thr 1 SDD 1 ALS (Gijselinck et al., 2015) 
14 - p.Ile522Met 1 SDD 3 ALS (Cirulli et al. 2015) 
14 c.1603G>A p.Ala535Thr 1 SDD 10 FTD (Gijselinck et al., 2015) 
14 c.1612C>T p.His538Tyr 1 SDD 0 - 
(van der Zee et al., 
2017) 
15 - p.Gln565Pro 1 SDD 0 ALS (Cirulli et al. 2015) 
15 c.1709A>G p.Lys570Arg 1 SDD 21 - 
(van der Zee et al., 
2017) 
15 c.1717C>G p.Arg573Gly 1 SDD 0 - 
(van der Zee et al., 
2017) 
16 - p.Gln581His 1 SDD 0 ALS (Cirulli et al. 2015) 
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19 c.1975G>C p.Glu653Gln 1 SDD 32 - 
(van der Zee et al., 
2017) 
20 - p.Ile710Asn 1 SDD 0 ALS (Cirulli et al. 2015) 
Table 6.4 – TBK1 variants reported in ALS and FTD. Mutation nomenclature as recommended by the Human Genome Variation society www.hgvs.org, utilising +1 as the A of the 




Appendix C. TBK1 variants functionally characterised to date.  
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Table 6.5 – TBK1 variants functionally characterised in ALS and FTD. Mutation nomenclature as recommended by the Human Genome Variation society www.hgvs.org, utilising +1 
as the A of the initiator Met codon, translation start site. Rows in darker grey represent variants characterised in this study. 
 
